RED DE INVESTIGACION COOPERATIVA DE CANCER

Article. 10.3324/haematol.2009.007872. 2009

Central Nervous System Involvement in Epstein-Barr Virus-Related Post-Transplant Lymphoproliferative Disorders after Allogeneic Hematopoietic Stem Cell Transplantation.

Balaguer-Rosello, Aitana; (...); Sanz, Jaime

Article. 10.1016/j.jtct.2020.12.019. 2021

C-FMS mutational analysis in chronic myelomonocytic leukemia (CMML)

Such, E.; (...); Sanz, G. F.

Article. 10.1016/S0145-2126(07)70147-9. 2007

CIP2A high expression is a poor prognostic factor in normal karyotype acute myeloid leukemia

Barragán E; (...); Odero MD

Letter. 10.3324/haematol.2014.118117. 2015

Circulating megakaryocyte in primary myelofibrosis. An uncommon finding in a myelofibrosis blood smear.

Cantó PA, Peris MLS, Castera EM

Editorial Material. 10.5045/br.2021.2020269. 2021

Circulating Tumor Cells for the Staging of Patients With Newly Diagnosed Transplant-Eligible Multiple Myeloma.

Garces, Juan-Jose; (...); Paiva, Bruno

Article. 10.1200/JCO.21.01365. 2022

Cis-Acting Splicing-Associated Variants Can Redefine the Molecular Signature of Genes Commonly Mutated in Acute Myeloid Leukemia

Morote-Faubel, Mireya; (...); Cervera, Jose

Meeting Abstract. 10.1182/blood-2023-177571. 2023

Classification and clinical behavior of blastic plasmacytoid dendritic cell neoplasms according to their maturation-associated immunophenotypic profile

Martín-Martín L; (...); Almeida J

Article. 10.18632/oncotarget.4146. 2015

Classification and Personalized Prognostic Assessment on the Basis of Clinical and Genomic Features in Myelodysplastic Syndromes.

Bersanelli M; (...); Della Porta MG

Article. 10.1200/JCO.20.01659. 2021

Classification, risk stratification and response assessment in myelodysplastic syndromes/neoplasms (MDS): A state-of-the-art report on behalf of the International Consortium for MDS (icMDS).

Stahl M; (...); Zeidan AM

Article. 10.1016/j.blre.2023.101128. 2023

Clinical and Biological Characterization of Low Risk MDS Patients According to Ring Sideroblasts (RS). Comparison between the 3 Subgroups in WHO2017 Classification. Study from the Spanish MDS Registry

Lopez Cadenas, Felix; (...); Diez-Campelo, Maria

Meeting Abstract. 10.1182/blood-2021-152678. 2021

Clinical and biological significance of isolated Y chromosome loss in myelodysplastic syndromes and chronic myelomonocytic leukemia. A report from the Spanish MDS Group

Nomdedeu, M; (...); Spanish MDS Group

Article. 10.1016/j.leukres.2017.10.011. 2017

Clinical and biological significance of Y chromosome loss in a series of 2,423 male patients with Myelodysplastic syndromes and Chronic Myelomonocytic Leukemia

Costa, D.; (...); Campo, E.

Meeting Abstract. 2018

Clinical and Genomic-Based Decision Support System to Define the Optimal Timing of Allogeneic Hematopoietic Stem-Cell Transplantation in Patients With Myelodysplastic Syndromes.

Tentori CA; (...); Della Porta MG

Article. 10.1200/JCO.23.02175. 2024

Clinical and molecular characterization by next generation sequencing of Spanish patients affected by congenital deficiencies of fibrinogen.

Moret, A; (...); Bonanad, S

Letter. 10.1016/j.thromres.2019.06.015. 2019

Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia

Cheson, Bruce D.; (...); Kantarjian, Hagop

Article. 10.1182/blood-2005-10-4149. 2006

CLINICAL APPLICATION OF THE MASSIVE SEQUENCING ADDRESSED IN ACUTE MYELOBLASTIC LEUKEMIA

Garcia, ML; (...); Gonzalez, EB

Meeting Abstract. 2017

Clinical Benefit of Glasdegib Plus Low-Dose Cytarabine in Patients with De Novo and Secondary Acute Myeloid Leukemia: Long-Term Analysis of a Phase 2 Randomized Trial

Heuser, M; (...); Cortes, JE

Meeting Abstract. 10.1016/j.clml.2019.07.116. 2019

Clinical benefit of glasdegib plus low-dose cytarabine in patients with de novo and secondary acute myeloid leukemia: long-term analysis of a phase II randomized trial (vol 100, pg 1181, 2021)

Heuser, Michael; (...); Cortes, Jorge E.

Article. 10.1007/s00277-021-04545-5. 2021

Clinical benefit of glasdegib plus low-dose cytarabine in patients with de novo and secondary acute myeloid leukemia: long-term analysis of a phase II randomized trial.

Heuser M; (...); Cortes JE

Article. 10.1007/s00277-021-04465-4. 2021

Clinical Characteristics and Transfusion Management of Patients Diagnosed of Multiple Myeloma Receiving Daratumumab: Experience of a Single Centre

Arnao, M; (...); Sanz, G

Meeting Abstract. 10.1016/j.clml.2019.09.254. 2019

Clinical Characteristics of Chilean Adult Patients with Acute Myeloid Leukemia (AML): Analysis within the Framework of the Epidemiological Registry of AML of the Pethema Group

Romero, Alejandra; (...); Montesinos, Pau

Meeting Abstract. 10.1182/blood-2022-163869. 2022

Clinical characteristics of patients with central nervous system relapse in BCR-ABL1-positive acute lymphoblastic leukemia: the importance of characterizing ABL1 mutations in cerebrospinal fluid

Sanchez, R; (...); Martinez-Lopez, J

Article. 10.1007/s00277-017-3002-1. 2017

Clinical Characteristics, Treatment Approach and Long-Term Outcomes of 678 Patients with Symptomatic Waldenstrom's Macroglobulinemia: Comprehensive Insights from a Spanish Registry of IgM Gammapathies

Askari, Elham; (...); Garcia-Sanz, Ramon

Meeting Abstract. 10.1182/blood-2023-189581. 2023

Clinical Effectiveness of Influenza Vaccination After Allogeneic Hematopoietic Stem Cell Transplantation: A Cross-sectional, Prospective, Observational Study

Pinana, JL; (...); Navarro, D

Article. 10.1093/cid/ciy792. 2019

Clinical Features and Treatment in Patients Diagnosed with Blastic Plasmacytoid Dendritic Cell Neoplasm: Interim Analysis from the Pethema Epidemiologic Registry (EPI-BLAS study)

Vicente, Navarro; (...); Montesinos, Pau

Meeting Abstract. 10.1182/blood-2023-190296. 2023

Clinical Impact of Next Generation Flow in Bone Marrow Vs Qip-Mass Spectrometry in Peripheral Blood to Assess Minimal Residual Disease in Newly Diagnosed Multiple Myeloma Patients Receiving Maintenance As Part of the GEM2014MAIN Trial

Puig, Noemi; (...); Mateos, Maria-Victoria

Meeting Abstract. 10.1182/blood-2022-165441. 2022

Clinical impact of the clone size in MDS cases with monosomy 7 or 7q deletion, trisomy 8, 20q deletion and loss of Y chromosome

Mallo, Mar; (...); Sole, Francesc

Article. 10.1016/j.leukres.2011.01.003. 2011

Clinical Implications of p53 Dysfunction in Patients with Myelodysplastic Syndromes

Riva, Elena; (...); Della Porta, Matteo G.

Meeting Abstract. 10.1182/blood-2022-166050. 2022

Clinical outcomes after CPX-351 in patients with high-risk acute myeloid leukemia: A comparison with a matched cohort from the Spanish PETHEMA registry.

Bernal, Teresa; (...); Montesinos, Pau

Article. 10.1002/cam4.6120. 2023

Clinical Outcomes in Patients with Relapsed/Refractory Acute Myeloid Leukemia Treated with Gilteritinib Who Received Prior Midostaurin or Sorafenib

Perl, AE; (...); Tiu, RV

Meeting Abstract. 2021

Clinical outcomes in patients with relapsed/refractory FLT3-mutated acute myeloid leukemia treated with gilteritinib who received prior midostaurin or sorafenib.

Perl, Alexander E.; (...); Altman, Jessica K.

Article. 10.1038/s41408-022-00677-7. 2022

Clinical Profile of IMGN632, a Novel CD123-Targeting Antibody-Drug Conjugate (ADC), in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Daver, Naval G.; (...); Kantarjian, Hagop M.

Meeting Abstract. 10.1182/blood-2019-128648. 2019

CLINICAL RESULTS AND TRANSFUSIONAL MANAGEMENT IN PATIENTS WITH MULTIPLE MYELOMA IN TREATMENT WITH DARATUMUMAB: EXPERIENCE OF A SINGLE CENTER

Blanco, J. A.; (...); Sanz Santillana, G.

Meeting Abstract. 2019

Clinical Significance and Transcriptional Profiling of Persistent Minimal Residual Disease (MRD) in Multiple Myeloma (MM) Patients with Standard-Risk (SR) and High-Risk (HR) Cytogenetics

Goicoechea, I; (...); Paiva, B

Meeting Abstract. 10.1182/blood-2018-99-113312. 2018

Clinical significance of CD56 expression in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline-based regimens

Article. 10.1182/blood-2010-04-277434. 2011

Clinical significance of complex karyotype at diagnosis in pediatric and adult patients with de novo acute promyelocytic leukemia treated with ATRA and chemotherapy

Labrador, J; (...); GATLA Grp

Article. 10.1080/10428194.2018.1522438. 2019

Clinical Significance of Sensitive Flow-MRD Monitoring in Elderly Multiple Myeloma Patients on the Pethema/GEM2010MAS65 Trial

Paiva, Bruno; (...); San Miguel, Jesus F.

Meeting Abstract. 2014

Clinical Utility of a Next-Generation Sequencing Panel for Acute Myeloid Leukemia Diagnostics

Alonso, CM; (...); Barragan, E

Article. 10.1016/j.jmoldx.2018.09.009. 2019

CLINICAL-BIOLOGICAL AND PROGNOSTIC CHARACTERISTICS OF LOW RISK SMD WITHOUT RING SIDEROBLASTS AND COMPARISON WITH ITS COUNTERPART WITH RING SIDEROBLASTS

Cadenas Felix, Lopez; (...); Ferreiras David, Valcarcel

Meeting Abstract. 2021

Clinician Concepts of Cure in Adult Relapsed and Refractory Philadelphia-Negative B Cell Precursor Acute Lymphoblastic Leukemia: A Delphi Study

Bassan, R; (...); Cong, Z

Article. 10.1007/s12325-019-00910-z. 2019

Clonal architecture in patients with myelodysplastic syndromes and double or minor complex abnormalities: Detailed analysis of clonal composition, involved abnormalities, and prognostic significance

Schanz, J; (...); Haase, D

Article. 10.1002/gcc.22667. 2018

Clonal composition and its prognostic significance in patients with MDS

Schanz, J; (...); Int Working Grp Prognosis MDS

Meeting Abstract. 2018

Clonal Cytopenias and Oligoblastic Myelogenous Leukemia (myelodysplasia) Have Neoplastic, not Hyperplastic, Erythropoiesis Reply

Arenillas, L; (...); Florensa, L

Letter. 10.1200/JCO.2016.71.3941. 2017

Clonal Evolution Analysis Using Next Generation Sequencing (NGS) Panel in a Cohort of 3,025 Patients With Acute Myeloid Leukemia (AML)

Colmenares, Rafael; (...); Montesinos, Pau

Meeting Abstract. 2023

Clonal genetic evolution at relapse of favorable-risk acute myeloid leukemia with NPM1 mutation is associated with phenotypic changes and worse outcomes

Martinez-Losada, C; (...); Sanchez-Garcia, J

Letter. 10.3324/haematol.2018.188433. 2018

Clonal Hematopoiesis Landscape in Patients with De Novo Acute Myeloid Leukemia By Deep Sequencing

Ibanez, Mariam; (...); Cervera, Jose

Meeting Abstract. 10.1182/blood.V128.22.598.598. 2016

CMV REACTIVATIONS IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT FROM HLA-MATCHED AND HAPLOIDENTICAL DONORS WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE.

Chorão P; (...); Sanz J

Article. 10.1016/j.jtct.2024.01.082. 2024

Co-culture of multiple myeloma cell lines and bone marrow mesenchymal stem cells in a 3D microgel environment.

Garcia-Briega, M Inmaculada; (...); Ribelles, Jose Luis Gomez

Article. 10.1016/j.bioadv.2025.214243. 2025

Cohort-Controlled Comparison of Umbilical Cord Blood Transplantation Using Carlecortemcel-L, a Single Progenitor-Enriched Cord Blood, to Double Cord Blood Unit Transplantation

Stiff, PJ; (...); Sanz, G

Article. 10.1016/j.bbmt.2018.02.012. 2018

Combining gene mutation with gene expression analysis improves outcomes prediction in acute promyelocytic leukemia.

Lucena-Araujo, Antonio R.; (...); Rego, Eduardo M.

Article. 10.1182/blood.2019000239. 2019

Comment on "Outcomes of autologous transplantation for multiple myeloma according to different induction regimens".

de la Rubia J

Article. 10.5581/1516-8484.20140020. 2014

Common seasonal respiratory virus infections in allogeneic stem cell transplant recipients during the SARS-COV-2 pandemic.

De La Puerta R; (...); Piñana JL

Article. 10.1038/s41409-021-01319-5. 2021

Community acquired respiratory virus infections in adult patients undergoing umbilical cord blood transplantation.

Montoro J; (...); Piñana JL

Article. 10.1038/s41409-020-0943-0. 2020

Community-acquired respiratory virus lower respiratory tract disease in allogeneic stem cell transplantation recipient: Risk factors and mortality from pulmonary virus-bacterial mixed infections

Pinana, JL; (...); Navarro, D

Article. 10.1111/tid.12926. 2018

Comparative genomic analysis of PML and RARA breakpoints in paired diagnosis/relapse samples of patients with acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy

Iaccarino, L; (...); Lo-Coco, F

Letter. 10.1080/10428194.2017.1369067. 2018

COMPARATIVE STUDY OF HEREDITARY SPHEROCYTOSIS USING FLOW CYTOMETRY AND OSMOTIC GLOBULAR FRAGILITY

Cordon Gallego, L.; (...); Sanz Alonso, M. A.

Meeting Abstract. 2015

Comparative Study of Post-Transplant Lymphoproliferative Disorders after Solid Organ Transplantation Versus Hematopoietic Stem Cell Transplantation

Romero, Samuel, Sr.; (...); Sanz, Miguel Angel

Article. 2015

COMPARATIVE STUDY OF THE CHARACTERISTICS OF THE DIAGNOSIS AND RESPONSE TO TREATMENT IN PATIENTS AGED=60 YEARS VS. <60 YEARS WITH ACQUIRED PURPLE THROMBOTIC THROMBOCYTOPENIC. RESULTS OF THE SPANISH REGISTRATION OF PTT (REPTT)

Aracil Eva, Frances; (...); Comos Javier, De la Rubia

Meeting Abstract. 2021

Comparison Between First-Generation 4-Color Vs. Second-Generation 8-Color Multiparameter Flow Cytometry (MFC) to Monitor Minimal Residual Disease (MRD) in Multiple Myeloma (MM)

Arana, Paula; (...); San Miguel, Jesus

Meeting Abstract. 2015

COMPARISON BETWEEN INTERMITTENT AND CONTINUOUS HAEMATOPOIETIC PROGENITOR COLLECTION OF THE SPECTRA OPTIA APHERESIS SYSTEM IN A SINGLE CENTRE

De la Puerta Paula, R.; (...); Gomez Segui, I

Meeting Abstract. 2019

Comparison between Two Protocols for Platelet Transfusion in Patients Undergoing ABO Incompatible Hematopoietic Stem Cell Transplantation

Carpio, N; (...); Sanz, M

Meeting Abstract. 2018

COMPARISON OF AZACITIDINE AND DECITABINE FOR THE TREATMENT OF NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA: SYSTEMATIC REVIEW AND META-ANALYSIS

Saiz-Rodriguez, M.; (...); Labrador, J.

Meeting Abstract. 2020

Comparison of Clinical Characteristics and Prognosis of a Series of Patients from the Spanish Registry of MDS Diagnosed with Myelodysplastic/Myeloproliferative Neoplasms According to the 2016 Reviewed Classification of the World Health Organization

Xicoy, B; (...); Tzu, HCL

Meeting Abstract. 10.1182/blood-2018-99-111883. 2018

COMPARISON OF CLINICAL CHARACTERISTICS AND PROGNOSIS OF CHRONIC MYELOMONOCYTIC LEUKEMIA WITH AND WITHOUT AUTOINMUNE DISEASE

Moreno, AT; (...); Santillana, GS

Meeting Abstract. 2018

COMPARISON OF CYTOGENETIC ABERRATIONS IN 1590 PATIENTS WITH THERAPY-RELATED MDS (T-MDS) AND 4738 PATIENTS FROM THE REVISED INTERNATIONAL PROGNOSTIC SCORING SYSTEM DATABASE WITH PRIMARY-MDS (P-MDS)

Kuendgen, A.; (...); Sanz, G.

Meeting Abstract. 2021

Comparison of intensive, pediatric-inspired therapy with non-intensive therapy in older adults aged 55-65 years with Philadelphia chromosome-negative acute lymphoblastic leukemia

Ribera, JM; (...); PETHEMA Grp

Article. 10.1016/j.leukres.2018.03.010. 2018

Comparison of outcomes after single or double cord blood transplantation in adults with acute leukemia using different types of myeloablative conditioning regimen, a retrospective study on behalf of Eurocord and the Acute Leukemia Working Party of EBMT

Ruggeri, A; (...); Eurocord & Acute Leukemia Working

Article. 10.1038/leu.2013.259. 2014

Comparison of outcomes after unrelated cord blood and unmanipulated haploidentical stem cell transplantation in adults with acute leukemia

Ruggeri A; (...); ALWP-EBMT study

Article. 10.1038/leu.2015.98. 2015

Comparison of the 2022 and 2017 European LeukemiaNet risk classifications in a real-life cohort of the PETHEMA group

Sargas, Claudia; (...); Montesinos, Pau

Article. 10.1038/s41408-023-00835-5. 2023

COMPARISON OF THREE PANELS OF NGS APPLICATION IN ONCOHEMATOLOGY TO DISCARD SOMATIC AND/OR GERMINAL VARIANTS

Guzman-Gimenez, C.; (...); Such, E.

Meeting Abstract. 2021

Comparison of transfusion requirements in adult patients undergoing Haploidentical or single-unit umbilical cord blood stem cell transplantation

Solves, P; (...); Sanz, GF

Article. 10.1111/ejh.13270. 2019

Comparison of Unrelated Cord Blood and Peripheral Blood Stem Cell Transplantation in Adults with Myelodysplastic Syndrome after Reduced-Intensity Conditioning Regimen: A Collaborative Study from Eurocord (Cord blood Committee of Cellular Therapy & Immunobiology Working Party of EBMT) and Chronic Malignancies Working Party

Robin M; (...); Kroger N

Article. 10.1016/j.bbmt.2014.11.675. 2015

Complex Karyotype with >= 3 Cytogenetic Alterations is a New Marker of Worse Prognosis in Adult T-Cell Acute Lymphoblastic Leukemia (T-ALL)

Genesca, Eulalia; (...); Maria Ribera, Josep

Meeting Abstract. 2020

Complex Variant t(9;22) Chromosome Translocations in Five Cases of Chronic Myeloid Leukemia.

Valencia A; (...); Sanz MA

Article. 10.1155/2009/187125. 2009

Complex, not monosomal, karyotype is the cytogenetic marker of poorest prognosis in patients with primary myelodysplastic syndrome.

Valcárcel D; (...); Vallespí T

Article. 10.1200/JCO.2012.41.6073. 2013

Comprehensive detection of CRLF2 alterations in acute lymphoblastic leukemia: a rapid and accurate novel approach.

Gil, Jose Vicente; (...); Barragan, Eva

Article. 10.3389/fmolb.2024.1362081. 2024

COMPREHENSIVE LONG-TERM FOLLOW-UP OF PAROXYSMAL NOCTURNAL HEMOGLOBINURIA: A REPORT FROM A SINGLE CENTRE

Sempere, A.; (...); Jarque, I.

Meeting Abstract. 2016

CONCORDANCE STUDY ON THE CATEGORIZATION OF NON-CANONICAL VARIANTS OF JAK2 GENE

Guzman-Gimenez, C.; (...); Such, E.

Meeting Abstract. 2021

CONCURRENT MUTATIONS IN ZRSR2 AND TET2 CAUSE SMD-COMPATIBLE ANOMALIES IN A MOUSE MODEL

Cristian, Garcia-Ruiz; (...); Alejandra, Sanjuan-Pla

Meeting Abstract. 2021

Concurrent Zrsr2 mutation and Tet2 loss promote myelodysplastic neoplasm in mice

Garcia-Ruiz C; (...); Sanjuan-Pla A

Article. 10.1038/s41375-022-01674-2. 2022

Consensus proposal for revised International Working Group response criteria for higher risk myelodysplastic syndromes.

Zeidan, Amer M.; (...); Fenaux, Pierre

Article. 10.1182/blood.2022018604. 2023

Considering Bone Marrow Blasts from Nonerythroid Cellularity Improves the Prognostic Evaluation of MDS in the Context of IPSS-R and Permits a Better Risk Assessment of MDS Patients Classified into the Intermediate Risk Category

Calvo, Xavier; (...); Florensa, Lourdes

Meeting Abstract. 10.1182/blood.V128.22.3185.3185. 2016

Considering Bone Marrow Blasts From Nonerythroid Cellularity Improves the Prognostic Evaluation of Myelodysplastic Syndromes

Arenillas L; (...); Florensa L

Article. 10.1200/JCO.2016.66.9705. 2016

Contemporary Approach to The Diagnosis and Classification of Myelodysplastic Neoplasms/Syndromes- Recommendations from The International Consortium for MDS (icMDS).

Aakash, Fnu; (...); Loghavi, Sanam

Article. 10.1016/j.modpat.2024.100615. 2024

Continued Azacitidine Therapy Beyond Time of First Response Improves Quality of Response in Patients With Higher-Risk Myelodysplastic Syndromes

Silverman, Lewis R.; (...); Seymour, John F.

Article. 10.1002/cncr.25774. 2011

Continuous ambulatory peritoneal dialysis, ascitic and pleural body fluids evaluation with the Mindray BC-6800 hematology analyzer

Fuster, O; (...); Laiz, B

Article. 10.1002/jcla.22240. 2018

Contribution of copy number to improve risk stratification of adult T-cell acute lymphoblastic leukemia patients enrolled in measurable residual disease-oriented trials.

Gonzalez-Gil C; (...); Genesca E

Article. 10.3324/haematol.2024.285416. 2024

Conventional induction and post-remission therapy in APL: Have we arrived?

Sanz MA, Iacoboni G, Montesinos P

Article. 10.1016/j.beha.2014.04.004. 2014

Conventional PCR Versus Next Generation Sequencing for Diagnosis of FLT3, IDH and NPM1 Mutations in Acute Myeloid Leukemia: Interim Analysis of the PCR-LMA Protocol of the Pethema Group

Boluda, Blanca; (...); Montesinos, Pau

Meeting Abstract. 10.1182/blood-2022-160136. 2022

CO-OCCURRENCE PROFILES OF GERMLINE AND ACQUIRED VARIANTS IN MYELODYSPLASTIC SYNDROMES IN YOUNG ADULTS WITHOUT PRIOR ORGAN DYSFUNCTION

Hua, Chen-Liang Tzu; (...); Andres, Jerez

Meeting Abstract. 2021

Copper deficiency: a cause of misdiagnosis of myelodysplastic syndrome

Villalba, A; (...); Senent, L

Letter. 10.1007/s00277-018-3334-5. 2018

Cord blood transplantation from unrelated donors in adults with high-risk acute myeloid leukemia.

Sanz J; (...); Sanz GF

Article. 10.1016/j.bbmt.2009.09.001. 2010

Correction to: A phase I-II study of plerixafor in combination with fludarabine, idarubicin, cytarabine, and G-CSF (PLERIFLAG regimen) for the treatment of patients with the first early-relapsed or refractory acute myeloid leukemia.

Martínez-Cuadrón D; (...); CETLAM and PETHEMA groups

Article. 10.1007/s00277-018-3277-x. 2018

Correction to: Spanish registry of hemoglobinopathies and rare anemias (REHem- AR): demographics, complications, and management of patients with ß-thalassemia.

Bardón-Cancho EJ; (...); Cela E

Correction. 10.1007/s00277-024-05838-1. 2024

Correction to: Update on management and progress of novel therapeutics for R/R AML: an Iberian expert panel consensus.

Montesinos P; (...); Sanz MÁ

Correction. 10.1007/s00277-020-03933-7. 2020

Correction: Vitamin C and folate status in hereditary fructose intolerance.

Cano A; (...); de Las Heras J

Correction. 10.1038/s41430-023-01334-3. 2023

Correlation of myelodysplastic syndromes with i(17)(q10) and TP53 and SETBP1 mutations

Adema V; (...); Solé F

Letter. 10.1111/bjh.13355. 2015

Corrigendum to "Performance of prognostic scoring systems in elderly patients with acute myeloid leukaemia on intensive chemotherapy: A PETHEMA registry study" [Leuk. Res. 92 (March) (2020) 106352].

Rodríguez-Medina C; (...); Montesinos P

Correction. 10.1016/j.leukres.2020.106388. 2020

Corrigendum: Evaluation of the Stellae-123 prognostic gene expression signature in acute myeloid leukemia (vol 13, 1302993, 2023)

Orgueira, Adrian Mosquera; (...); Encinas, Manuel Mateo Perez

Correction. 10.3389/fonc.2023.1302993. 2023

Cost analysis of voriconazole versus liposomal amphotericin B for primary therapy of invasive aspergillosis among patients with haematological disorders in Germany and Spain

Ostermann, H; (...); Charbonneau, C

Article. 10.1186/2050-6511-15-52. 2014

COST MINIMIZATION ANALYSIS OF RITUXIMAB BIOSIMILAR VERSUS REFERENCE RITUXIMAB IN THE TREATMENT OF FOLLICULAR LYMPHOMA

Gironella, M.; (...); Oyaguez, I

Meeting Abstract. 2019

Cost-Effectiveness Analysis of Gemtuzumab Ozogamicin for First-Line Treatment of Patients with Cd-33 Positive Acute Myeloid Leukaemia in Spain

Mareque, M; (...); Sierra, J

Article. 10.2147/CEOR.S302097. 2021

COST-EFFECTIVENESS OF GEMTUZUMAB OZOGAMICIN IN COMBINATION WITH STANDARD CHEMOTHERAPY IN FIRST-LINE TREATMENT IN PATIENTS WITH CD-33-POSITIVE ACUTE MYELOID LEUKEMIA IN SPAIN

Montesinos, P.; (...); Guinea, J. M.

Meeting Abstract. 2020

Cost-Effectiveness Of Midostaurin In The Treatment Of Acute Myeloid Leukemia With The FLT3 Mutation In Spain

Arenaza, A; (...); Vinent, JL

Article. 10.2147/CEOR.S222879. 2019

Cost-effectiveness of posaconazole versus fluconazole or itraconazole in the prevention of invasive fungal infections among high-risk neutropenic patients in Spain.

Grau S; (...); Sanz MA

Article. 10.1186/1471-2334-12-83. 2012

Cost-utility analysis of idelalisib in combination with rituximab in relapsed or refractory chronic lymphocytic leukaemia

Casado, LF; (...); Castro, A

Article. 10.1111/ejh.13007. 2018

COST-UTILITY OF IDELALISIB IN COMBINATION WITH RITUXIMAB IN RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA

Casado, LF; (...); Castro-Gomez, A

Meeting Abstract. 10.1016/j.jval.2017.08.898. 2017

Covalent Menin Inhibitor Bmf-219 in Patients with Relapsed or Refractory (R/R) Acute Leukemia (AL): Preliminary Phase 1 Data from the Covalent-101 Study

Lancet, Jeffrey; (...); Carraway, Hetty E.

Meeting Abstract. 10.1182/blood-2023-173149. 2023

COVALENT-101: phase I study of BMF-219, a covalent menin inhibitor, in adult patients with AML, ALL (with KMT2A/ MLL1r, NPM1 mutations), DLBCL, MM, and CLL/SLL (NCT05153330)

Rosenberg, Aaron; (...); Khouri, Jack

Meeting Abstract. 2023

CRISPR to fix bad blood: a new tool in basic and clinical hematology

Gonzalez-Romero, E; (...); Sanjuan-Pla, A

Review. 10.3324/haematol.2018.211359. 2019

Critical analysis of the stringent complete response in multiple myeloma: contribution of sFLC and bone marrow clonality

Martínez-López J; (...); Lahuerta JJ

Article. 10.1182/blood-2015-04-638742. 2015

Critical evaluation of ASO RQ-PCR for minimal residual disease evaluation in multiple myeloma. A comparative analysis with flow cytometry

Puig N; (...); García-Sanz R

Article. 10.1038/leu.2013.217. 2014

CRITICAL REVIEW OF THE DOUBLE NEGATIVITY IN THE SERUM AND URINE IMMUNOFIXATION (IF) TO ESTABLISH THE CATEGORY OF COMPLETE REMISSION IN MULTIPLE MYELOMA (MM)

Anglada, LL; (...); Lahuerta, J. J.

Meeting Abstract. 2017

Cross-Sectional Comparative Study of PK-Guided Switch between Standard Half-Life and Extended Half-Life Factor VIII Products

Eduardo Megias, Juan; (...); Iorio, Alfonso

Meeting Abstract. 10.1182/blood-2019-127946. 2019

Cross-sectional validation study of patient-reported outcomes in patients with paroxysmal nocturnal haemoglobinuria.

Weitz I; (...); Hill A

Article. 10.1111/j.1445-5994.2012.02924.x. 2013

Cryopreservation of Allogeneic Hematopoietic Progenitor Cells in The Current SARS-Cov-2 Pandemic: Experience of A Single Centre

Moreno, D; (...); Carpio, N

Meeting Abstract. 2021

Curative Strategy (GEM- CESAR) for High-Risk Smoldering Myeloma (SMM): Carfilzomib, Lenalidomide and Dexamethasone (KRd) As Induction Followed By HDT-ASCT, Consolidation with Krd and Maintenance with Rd

Mateos, Maria-Victoria; (...); San-Miguel, Jesus F.

Meeting Abstract. 10.1182/blood-2021-148423. 2021

Curative Strategy (GEM-CESAR) for High-Risk Smoldering Myeloma (SMM): Post-Hoc Analysis of Sustained Undetectable Measurable Residual Disease (MRD)

Mateos, Maria-Victoria; (...); Paiva, Bruno

Meeting Abstract. 10.1182/blood-2022-159606. 2022

Curative Strategy for High-Risk Smoldering Myeloma: Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Followed by Transplant, KRd Consolidation, and Rd Maintenance.

Mateos, Maria-Victoria; (...); San-Miguel, Jesus F

Article. 10.1200/JCO.23.02771. 2024

Current landscape of translational and clinical research in myelodysplastic syndromes/neoplasms (MDS): Proceedings from the 1st International Workshop on MDS (iwMDS) Of the International Consortium for MDS (icMDS).

Bewersdorf, Jan Philipp; (...); Zeidan, Amer M.

Article. 10.1016/j.blre.2023.101072. 2023

Current management of patients with chronic myelomonocytic leukemia

Mora, E, Sanz, GF

Review. 10.1097/CCO.0000000000000486. 2018

Current Results on Overall Survival with oral Azacitidine Therapy in Patients with acute Myeloid Leukemia in first Remission after intensive Chemotherapy in the Phase 3 QUAZAR Study

Pfeilstoecker, M.; (...); Roboz, G. J.

Meeting Abstract. 2022

CURRENT STATE OF ACUTE MYELOID LEUKEMIA IN SPAIN: RESULTS FROM A DELPHI STUDY ON EPIDEMIOLOGY, DISEASE MANAGEMENT AND UNMET NEEDS

Montesinos, P; (...); Sierra, J

Meeting Abstract. 2018

Current status of acute myeloid leukaemia in Spain: Results from a Delphi study on its epidemiology, disease management and unmet clinical needs.

Montesinos P, Gil A, Sierra J

Letter. 10.1016/j.medcli.2020.04.032. 2020

Current status of haematopoietic autologous stem cell transplantation in lymphoid malignancies: a European perspective

Hubel, K; (...); Corradini, P

Review. 10.1111/ejh.12362. 2015

Current treatment of acute promyelocytic leukemia

Sanz, MA

Meeting Abstract. 2019

CYP2C8 gene polymorphism and bisphosphonate-related osteonecrosis of the jaw in patients with multiple myeloma.

Such E; (...); de la Rubia J

Article. 10.3324/haematol.2011.042572. 2011

CYTOGENETIC ANALYSIS IN REAL LIFE IN PATIENTS WITH MULTIPLE MYELOMA NEW DIAGNOSIS Results: FROM THE MULTIPLE MYELOMA STUDY GROUP OF THE VALENCIAN COMMUNITY (GREMI)

Gomez, Beltran Elena; (...); De la Rubia, Comos Javier

Meeting Abstract. 2020

Cytogenetic Assessment and Risk Stratification in Myelofibrosis with Optical Genome Mapping.

Diaz-Gonzalez, Alvaro; (...); Such, Esperanza

Article. 10.3390/cancers15113039. 2023

Cytogenetic risk stratification in chronic myelomonocytic leukemia.

Such E; (...); Sanz GF

Article. 10.3324/haematol.2010.030957. 2011

Cytokine response as a biomarker for early diagnosis and outcome prediction of stem cell transplant recipients and acute leukemia patients with invasive aspergillosis.

Puerta-Alcalde, Pedro; (...); Garcia-Vidal, Carolina

Article. 10.1093/mmy/myac038. 2022

Cytopenia levels for aiding establishment of the diagnosis of myelodysplastic syndromes

Greenberg, PL; (...); Haase, D

Letter. 10.1182/blood-2016-07-728766. 2016

Challenges in Clinical Metaproteomics Highlighted by the Analysis of Acute Leukemia Patients with Gut Colonization by Multidrug-Resistant Enterobacteriaceae

Rechenberger, J; (...); Kuster, B

Article. 10.3390/proteomes7010002. 2019

Challenges in the diagnosis and treatment of secondary acute myeloid leukemia

Ossenkoppele, G, Montesinos, P

Review. 10.1016/j.critrevonc.2019.03.003. 2019

Challenges of phase III trial design for novel treatments in diseases with no standard treatment: The AZA-001 myelodysplasia study model

Fenaux P; (...); Hellstrom-Lindberg E

Article. 10.1016/j.leukres.2013.10.014. 2014

Changes in health-related quality of life in patients with newly diagnosed acute myeloid leukemia receiving ivosidenib plus azacitidine or placebo plus azacitidine.

Schuh, Andre C.; (...); Montesinos, Pau

Meeting Abstract. 2022

CHANGES IN THE HEMATIC AND SERUM GROUP IN PATIENTS SUBJECTED TO TRANSPLANTATION OF HEMATOPOIETIC PROGENITORS WITH ABO MAYOR INCOMPATIBILITY

Balsera, MS; (...); Sanz, M. A.

Meeting Abstract. 2017

Characteristics and management of primary and other immune thrombocytopenias: Spanish registry study

JUAN PALAU BARGUES; (...); Sanz MA

Article. 10.1080/10245332.2017.1311442. 2017

Characteristics and outcome of acute myeloid leukemia with uncommon retinoic acid receptor-alpha (RARA) fusion variants.

Cicconi, L; (...); Abla, O

Article. 10.1038/s41408-021-00561-w. 2021

Characteristics and outcome of adult patients with acute promyelocytic leukemia and increased body mass index treated with the PETHEMA Protocols.

Sobas M; (...); PETHEMA, HOVON, PALG, GATLA cooperative groups

Article. 10.1111/ejh.13346. 2020

Characteristics and Outcome of Early T Cell Precursor ALL (ETP-ALL) Patients Treated with High-Risk Spanish Pethema Protocols

Genesca, E; (...); Ribera, JM

Meeting Abstract. 10.1182/blood-2018-99-114559. 2018

Characteristics and Outcome of Older Patients with Acute Promyelocytic Leukemia Front-Line Treated with or without Arsenic Trioxide - an International Collaborative Study

Kayser, S; (...); Montesinos, P

Meeting Abstract. 10.1182/blood-2018-99-111768. 2018

Characteristics and Outcome of Patients with Acute Myeloid Leukemia and Trisomy 4

Kayser, Sabine; (...); Schlenk, Richard F.

Meeting Abstract. 10.1182/blood-2021-150281. 2021

Characteristics and outcome of patients with acute myeloid leukemia and trisomy 4.

Kayser, Sabine; (...); Schlenk, Richard F.

Meeting Abstract. 10.3324/haematol.2022.281137. 2022

Characteristics and outcome of patients with core binding factor acute myeloid leukemia and FLT3-ITD: results from an international collaborative study.

Kayser S; (...); Levis MJ

Article. 10.3324/haematol.2021.278645. 2022

Characteristics and Outcomes of Adult Patients in the PETHEMA Registry with Relapsed or Refractory FLT3-ITD Mutation-Positive Acute Myeloid Leukemia.

Martinez-Cuadron, David; (...); On Behalf Of The Pethema Group

Article. 10.3390/cancers14112817. 2022

Characteristics of and risk factors for pneumonia in patients with hematological malignancies developing fever after autologous blood stem cell transplantation

Puig, Noemi; (...); Sanz, Miguel

Article. 10.1080/10428190701694178. 2007

Characteristics, clinical outcomes, and risk factors of SARS-COV-2 infection in adult acute myeloid leukemia patients: experience of the PETHEMA group

Palanques-Pastor, Tomas; (...); Montesinos, Pau

Article. 10.1080/10428194.2021.1948031. 2021

Characteristics, Treatment Patterns and Outcomes Among Newly Diagnosed Patients (pts) with Acute Myeloid Leukemia (AML) Who Present with Hyperleukocytosis: Findings from a Large International Patient Cohort

Stahl, M; (...); Zeidan, AM

Meeting Abstract. 10.1182/blood-2018-99-112974. 2018

Characterization and prognostic implication of 17 chromosome abnormalities in myelodysplastic syndrome.

Sánchez-Castro J; (...); Solé F

Article. 10.1016/j.leukres.2013.04.010. 2013

CHARACTERIZATION OF CONGENITAL THROMBOTIC THROMBOCYTOPENIC PURPURA BY MEANS OF IMMUNOLOGICAL AND MOLECULAR TECHNIQUES: RESULTS OF THE GEPTT NATIONAL COLLECTION

Liquori, A.; (...); Gomez-Segui, I

Meeting Abstract. 2019

CHARACTERIZATION OF CHARACTERISTIC MORPHOLOGICAL ALTERATIONS IN PATIENTS WITH MDS/CMML AND GENE MUTATIONS OF SPLICING DIFFERENT TO SF3B1

Marco Ayala, J.; (...); Sanz, G.

Meeting Abstract. 2019

CHARACTERIZATION OF MUTATIONS ALTERING THE PROCESS OF SPLICING IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES (MDS)

Boluda-Navarro, M.; (...); Cervera, J.

Meeting Abstract. 2018

CHARACTERIZATION OF RECURRENTLY MUTATED GENES IN ACUTE MYELOID LEUKEMIA DE NOVO WITH NORMAL KARPOTYPE BY TARGETED MASSIVE SEQUENCING

Ibanez, M.; (...); Cervera, J.

Article. 2015

CHARACTERIZATION OF THE GENOMIC AND TRANSCRIPTOMIC PROFILE OF THE ACUTE MYELOID LEUKEMIA (AML) SUBGROUP "CHROMATIN-SPLICEOSOME"

Alessandro, Liquori; (...); Zamora Jose, Cervera

Meeting Abstract. 2020

Characterization of three new HLA Class I Alleles in Spanish Caucasians, HLA-A02:620, HLA-B27:150 and HLA-B*07:05:01:02

Balas, A; (...); Vicario, JL

Article. 10.1111/iji.12317. 2017

Characterization ofFLT3-ITD(mut)acute myeloid leukemia: molecular profiling of leukemic precursor cells

Travaglini, S; (...); Ottone, T

Article. 10.1038/s41408-020-00352-9. 2020

Chemotherapy or Allogeneic Transplantation in High-Risk Philadelphia Chromosome-Negative Adult Lymphoblastic Leukemia.

Ribera JM; (...); Orfao A

Article. 10.1182/blood.2020007311. 2020

CHOOSING THE APPROPRIATE DENOMINATOR FOR COUNTING BM BLASTS

Arenillas, L; (...); Florensa, L

Meeting Abstract. 10.1016/S0145-2126(17)30121-2. 2017

CHROMOSOMAL ABERRATIONS IN THERAPY-RELATED MYELODYSPLASTIC SYNDROMES - RELATIONS TO PRIMARY DISEASE, THERAPY AND PROGNOSTIC SIGNIFICANCE

Nomdedeu, M; (...); Haase, D

Meeting Abstract. 10.1016/S0145-2126(17)30161-3. 2017

Chromosomal Abnormalities and Prognosis in NPM1 -Mutated Acute Myeloid Leukemia: A Pooled Analysis of Individual Patient Data From Nine International Cohorts.

Angenendt, L; (...); Schliemann, C

Article. 10.1200/JCO.19.00416. 2019

Chromosome 8 Abnormalities (8p Losses and 8q Gains) in Patients with Chronic Lymphocytic Leukemia (CLL) and Del(17p)

Blanco, Gonzalo; (...); Espinet, Blanca

Article. 2014

Chronic graft-versus-host disease could ameliorate the impact of adverse somatic mutations in patients with myelodysplastic syndromes and hematopoietic stem cell transplantation.

Caballero JC; (...); Díez Campelo M

Article. 10.1007/s00277-019-03751-6. 2019

Chronic liver disease-associated severe thrombocytopenia in Spain: Results from a retrospective study using machine learning and natural language processing.

Calleja-Panero, Jose Luis; (...); Gonzalez Calvo, Jose

Article. 10.1016/j.gastrohep.2023.05.010. 2023

Chronic Myelomonocytic Leukemia ( CMML) with AML Typical Mutations ( NPM1, FLT3 or CEBPA) Identify a High-Risk CMML Group Independent of Molecular-Cpss

Castano-Diez, Panelsandra; (...); Diaz-Beya, Marina

Meeting Abstract. 10.1182/blood-2023-173311. 2023

Chronic Myelomonocytic Leukemia (CMML) with More Than 15% of Ring Sideroblasts in Bone Marrow: An Overlapping Disorder Between CMML and Refractory Anemia with Ring Sideroblasts

Such, Esperanza; (...); Sanz, Guillermo

Article. 2009

CHRONOLOGICAL AGE AS A PROGNOSTIC FACTOR IN PATIENTS WITH MULTIPLE MYELOMA NEW DIAGNOSIS NOT CANDIDATED FOR TRANSPLANTATION

Martinez Elena, Meseguer; (...); Comos Javier, De la Rubia

Meeting Abstract. 2021

Chronological age as a prognostic factor in transplant-ineligible patients with newly diagnosed Multiple Myeloma

Garcia Ruiz, Raquel; (...); de la Rubia, Javier

Meeting Abstract. 2021

Daratumumab, carfilzomib, and dexamethasone in relapsed or refractory myeloma: final analysis of PLEIADES and EQUULEUS.

Moreau, Philippe; (...); Goldschmidt, Hartmut

Letter. 10.1038/s41408-023-00805-x. 2023

Data-Driven Multiparameter Flow Cytometry (MFC) Classification of Blast Differentiation in Elderly Patients with Acute Myeloid Leukemia (AML)

Gonzalez, Carmen; (...); Paiva, Bruno

Meeting Abstract. 10.1182/blood-2023-180646. 2023

Data-driven, harmonised classification system for myelodysplastic syndromes: a consensus paper from the International Consortium for Myelodysplastic Syndromes.

Komrokji RS; (...); Della Porta MG

Article. 10.1016/S2352-3026(24)00251-5. 2024

Daunorubicin and cytarabine for certain types of poor-prognosis acute myeloid leukemia: a systematic literature review

Review. 10.1080/17512433.2019.1573668. 2019

Deciphering predictive factors for choice of thrombopoietin receptor agonist, treatment free responses, and thrombotic events in immune thrombocytopenia (vol 11, 16867, 2021)

Lozano, Maria L.; (...); Vicente, Vicente

Article. 10.1038/s41598-021-95732-x. 2021

Deciphering predictive factors for choice of thrombopoietin receptor agonist, treatment free responses, and thrombotic events in immune thrombocytopenia.

Lozano ML; (...); Vicente V

Article. 10.1038/s41598-019-53209-y. 2019

Decitabine as Salvage Therapy after Azacitidine in AML

De La Fuente, A; (...); Montesinos, P

Meeting Abstract. 2019

Decitabine versus intensive chemotherapy induction for older patients with acute myeloid leukaemia: a futile but successful trial.

Montesinos, Pau, Sossa-Melo, Claudia

Article. 10.1016/S2352-3026(23)00308-3. 2023

DEEP INTRONIC MUTATIONS IN THE RUNX1 AND FLT3 GENES PRODUCE OPENING SPLICING IN PATIENTS WITH MYELODYSPLASIC SYNDROMES

Mireia, Boluda-Navarro; (...); Jose, Cervera

Meeting Abstract. 2021

Deep MRD profiling defines outcome and unveils different modes of treatment resistance in standard and high risk myeloma.

Goicoechea I; (...); Paiva B

Article. 10.1182/blood.2020006731. 2020

DEEP SEQUENCING OF 23 GENES DESIGNATED BY TCGA STUDY IN ACUTE MYELOID LEUKEMIA PATIENTS WITH NORMAL KARYOTYPE

Ibanez, M.; (...); Cervera, J.

Meeting Abstract. 2016

Definition and Clinical Significance of the MGUS-like Phenotype: A Study in 5,114 Patients (Pts) with Monoclonal Gammopathies

Burgos, Leire; (...); Paiva, Bruno

Meeting Abstract. 10.1182/blood-2021-150092. 2021

Definition and Clinical Significance of the Monoclonal Gammopathy of Undetermined Significance-Like Phenotype in Patients With Monoclonal Gammopathies.

Burgos, Leire; (...); Paiva, Bruno

Article. 10.1200/JCO.22.01916. 2023

Depth of Response in Multiple Myeloma: A Pooled Analysis of Three PETHEMA/GEM Clinical Trials

Lahuerta, JJ; (...); GEM (Grupo Español de Mieloma)

Article. 10.1200/JCO.2016.69.2517. 2017

Depth of Response of Isatuximab (Isa) plus Carfilzomib (K) and Dexamethasone (d) in Relapsed Multiple Myeloma: IKEMA Updated Analysis

Joseph, Mikhael; (...); Meletios, A. Dimopoulos

Article. 2022

Depth of response of isatuximab plus carfilzomib and dexamethasone in relapsed multiple myeloma: IKEMA updated analysis

Hajek, Roman; (...); Dimopoulos, Meletios A.

Meeting Abstract. 2022

DESCRIPTIVE STUDY OF THE RECORD OF THROMBOTIC MICROANGIOPATHY IN A SINGLE CENTRE

Romero Dominguez, S.; (...); Sanz Alonso, M. A.

Meeting Abstract. 2015

Design and Validation of a Custom Next-Generation Sequencing Panel in Pediatric Acute Lymphoblastic Leukemia.

Gil, Jose Vicente; (...); Barragan, Eva

Article. 10.3390/ijms24054440. 2023

DESIGN AND VALIDATION OF AN ACUTE LYMPHOBLASTIC LEUKEMIA-TARGETED NEXT-GENERATION SEQUENCING PANEL

Gil, JV.; (...); Llop, M.

Meeting Abstract. 2023

Design of the randomized, Phase III, QUAZAR AML Maintenance trial of CC-486 (oral azacitidine) maintenance therapy in acute myeloid leukemia

Roboz GJ; (...); Kantarjian H

Article. 10.2217/fon.15.326. 2016

Detection of kinase domain mutations in BCR::ABL1 leukemia by ultra-deep sequencing of genomic DNA.

Sanchez, Ricardo; (...); Martinez-Lopez, Joaquin

Article. 10.1038/s41598-022-17271-3. 2022

Detection of methylation status changes in refractory anemia with ringed sideroblasts (RARS) by MS-MLPA

Valencia, A.; (...); Sanz, G. F.

Article. 10.1016/S0145-2126(07)70133-9. 2007

DETECTION OF MINIMAL RESIDUAL DISEASE (EMR) IN ACUTE MYELOID LEUKEMIA THROUGH HIGH DEPTH SEQUENCE

De La Fuente, EO; (...); Ayala, R.

Meeting Abstract. 2017

DETECTION OF MUTATIONS IN BCR-ABL1 WITH A SENSITIVITY OF 1% IN PATIENTS WITH PH plus LEUKEMIAS

Perez, RS; (...); Lopez, JM

Meeting Abstract. 2018

Detection of plasmid-mediated colistin resistance, mcr-1 gene, in Escherichia coli isolated from high-risk patients with acute leukemia in Spain

Lalaoui, R; (...); Rolain, JM

Article. 10.1016/j.jiac.2019.03.007. 2019

Determinants of low health-related quality of life in patients with myelodysplastic syndromes: EUMDS Registry study.

Stojkov I; (...); Siebert U

Article. 10.1182/bloodadvances.2022008360. 2023

DETERMINATION OF THE CHALLENGES AND OPPORTUNITIES ASSOCIATED WITH PLATELET TRANSFUSION IN THE MANAGEMENT OF PATIENTS WITH SEVERE THROMBOCYTOPENIA ASSOCIATED WITH CHRONIC LIVER DISEASE

Jarque, Ramos, I; (...); Shepherd, Moreno J.

Meeting Abstract. 2020

DETERMINING THE EPIDEMIOLOGY, PATIENT FLOW, TREATMENT AND UNMET NEEDS OF PATIENTS WITH CHRONIC LIVER DISEASE-ASSOCIATED SEVERE THROMBOCYTOPENIA UNDERGOING INVASIVE PROCEDURES IN SPAIN

Andrade, R.; (...); Shepherd, J.

Meeting Abstract. 2019

Development and psychometric validation of a brief comprehensive health status assessment scale in older patients with hematological malignancies: The GAH Scale

Bonanad S; (...); GAH Group

Article. 10.1016/j.jgo.2015.03.003. 2015

DEVELOPMENT AND VALIDATION OF A MCDA FRAMEWORK FOR EVALUATION AND DECISION-MAKING OF ORPHAN DRUGS IN SPAIN

Poveda, J. L.; (...); Vitoria, I

Meeting Abstract. 2019

Development and validation of a prognostic scoring system for patients with chronic myelomonocytic leukemia.

Such E; (...); Sanz G

Article. 10.1182/blood-2012-08-452938. 2013

Development and validation of an MCDA framework for evaluation and decision-making of orphan drugs in Spain

Badia, X; (...); Poved, JL

Article. 10.1080/21678707.2019.1652163. 2019

DEVELOPMENT OF A CELLULAR MODEL OF ACUTE MYELOID LEUKEMIA THROUGH CRISPR/CAS 9 TECHNOLOGY

Romero, EG; (...); Zamora, JVC

Meeting Abstract. 2017

Development of a core outcome set for myelodysplastic syndromes - a Delphi study from the EUMDS Registry Group.

Rochau U; (...); Stauder R

Article. 10.1111/bjh.16654. 2020

DEVELOPMENT OF A MASSIVE SEQUENCING TEST FOR THE SIMULTANEOUS DETECTION OF POTENTIAL MUTATIONS AND CHROMOSOMAL ALTERATIONS IN PATIENTS WITH MYELODISPLASIC SYNDROMES

Liquori, A.; (...); Zamora, JVC

Meeting Abstract. 2017

Development, Implementation and Assessment of Molecular Diagnostics by Next Generation Sequencing in Personalized Treatment of Cancer: Experience of a Public Reference Healthcare Hospital.

Simarro J; (...); Palanca S

Article. 10.3390/cancers11081196. 2019

Dexamethasone does not prevent malignant cell reintroduction in leukemia patients undergoing ovarian transplant: risk assessment of leukemic cell transmission by a xenograft model

Diaz-Garcia, C; (...); Pellicer, A

Article. 10.1093/humrep/dez115. 2019

Diagnosis and classification of myelodysplastic syndrome: International Working Group on Morphology of myelodysplastic syndrome (IWGM-MDS) consensus proposals for the definition and enumeration of myeloblasts and ring sideroblasts

Mufti, Ghulam J.; (...); Yoshimi, Ayami

Article. 10.3324/haematol.13405. 2008

Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel

Döhner H; (...); Bloomfield, CD

Review. 10.1182/blood-2016-08-733196. 2017

Diagnosis and Treatment of Chronic Myelomonocytic Leukemias in Adults Recommendations From the European Hematology Association and the European LeukemiaNet

Itzykson, R; (...); European LeukemiaNet

Article. 10.1097/HS9.0000000000000150. 2018

Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet.

Malcovati L; (...); European Leukemia Net

Article. 10.1182/blood-2013-03-492884. 2013

DIAGNOSIS OF NOONAN SYNDROME AFTER STUDY OF NGS BY ESSENTIAL THROMBOCITEMIA

Marco Ayala, J.; (...); Sanz, M. A.

Meeting Abstract. 2018

Diagnostic screening of paroxysmal nocturnal hemoglobinuria: Prospective multicentric evaluation of the current medical indications

Morado, M; (...); PNH working group of the Iberian Society of Cytometry (SIC)

Article. 10.1002/cyto.b.21480. 2017

Differences in ex-vivo Chemosensitivity to Anthracyclines in First Line Acute Myeloid Leukemia

Megias-Vericat, JE; (...); Spanish PETHEMA Grp

Article. 10.4084/MJHID.2019.016. 2019

Different Clinical Implications of Kinase Domain BCR-ABL1 Variants Detected in Chronic Myeloid Leukemia and Acute Lymphoblastic Leukemia Patients

Sanchez, Ricardo; (...); Martinez-Lopez, Joaquin

Meeting Abstract. 10.1182/blood-2019-127069. 2019

Differential diagnosis of myelodysplastic syndrome: anemia associated with copper deficiency

Villalba, A, Senent, L

Editorial Material. 10.1182/blood-2017-11-818013. 2018

Differentiation stage of myeloma plasma cells: biological and clinical significance

Paiva B; (...); San-Miguel JF

Article. 10.1038/leu.2016.211. 2017

Differentiation syndrome associated with treatment with IDH2 inhibitor enasidenib - pooled analysis from clinical trials.

Montesinos P; (...); DiNardo CD

Article. 10.1182/bloodadvances.2023011914. 2024

Differentiation syndrome in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline chemotherapy: characteristics, outcome, and prognostic factors

Article. 10.1182/blood-2008-07-168617. 2009

Differentiation Syndrome with Lower-intensity Treatments for Acute Myeloid Leukemia.

Fathi, Amir T; (...); de Botton, Stephane

Review. 10.1002/ajh.26142. 2021

Differing clinical features between Japanese and Caucasian patients with myelodysplastic syndromes: Analysis from the International Working Group for Prognosis of MDS

Miyazaki, Y; (...); Greenberg, PL

Article. 10.1016/j.leukres.2018.08.022. 2018

Disease Characteristics and International Prognostic Scoring Systems (IPSS, IPSS-R, IPSS-M) in Adult Patients with Higher-Risk Myelodysplastic Syndromes (MDS) Participating in Two Randomized, Double-Blind, Placebo-Controlled Studies with Intravenous Sabatolimab Added to Hypomethylating Agents (HMA) (STIMULUS-MDS1 and MDS2)

Santini, Valeria; (...); Zeidan, Amer M.

Meeting Abstract. 10.1182/blood-2022-160282. 2022

Disseminated toxoplasma infection after hematopoietic stem cell transplantation with myositis and encephalitis.

Asensi Cantó P; (...); Guerreiro M

Article. 10.1111/tid.14067. 2023

Distinct mutational pattern of myelodysplastic syndromes with and without 5q-treated with lenalidomide

Adema, V; (...); Sole, F

Letter. 10.1111/bjh.16558. 2020

Do Guidelines Influence Diagnostic and Therapeutic Practice in Immune Thrombocytopenia? Results of a Multicenter Retrospective Study

Luisa Lozano, Maria; (...); Vicente Garcia, Vicente

Meeting Abstract. 10.1182/blood-2019-125557. 2019

Do next-generation sequencing results drive diagnostic and therapeutic decisions in MDS?

Sanz GF, Ibañez M, Such E

Article. 10.1182/bloodadvances.2019000680. 2019

Do NPM1 and FLT3-ITD mutations modify prognosis in patients treated with non-intensive regimens?

Suárez EU; (...); Montesinos P

Article. 10.1007/s00277-024-05840-7. 2024

Does microgranular variant morphology of acute promyelocytic leukemia independently predict a less favorable outcome compared with classical M3 APL? A joint study of the North American Intergroup and the PETHEMA Group

Tallman, Martin S.; (...); Sanz, Miguel A.

Article. 10.1182/blood-2010-06-288613. 2010

Does RAD21 Co-Mutation Have a Role in DNMT3A Mutated AML? Results of Harmony Alliance AML Database

Azibeiro Melchor, Raul; (...); Ossenkoppele, Gert J.

Meeting Abstract. 10.1182/blood-2021-150766. 2021

Donor age and degree of HLA matching have a major impact on the outcome of unrelated donor haematopoietic cell transplantation for chronic myeloid leukaemia

Carreras, E; (...); Torres, A

Article. 10.1038/sj.bmt.1705195. 2006

Donor CTLA-4 genotype influences clinical outcome after T cell-depleted allogeneic hematopoietic stem cell transplantation from HLA-identical sibling donors.

Bosch-Vizcaya A; (...); Gallardo D

Article. 10.1016/j.bbmt.2011.05.021. 2012

Dose Escalation of HLA-A2-WT1 CD3 T-Cell Bispecific Antibody in a Phase I Study in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)

Hutchings, Martin; (...); Subklewe, Marion

Meeting Abstract. 10.1182/blood-2023-173302. 2023

Dose-intensive chemotherapy including rituximab in Burkitt's leukemia or lymphoma regardless of human immunodeficiency virus infection status: final results of a phase 2 study (Burkimab).

Ribera JM; (...); Bernal T

Article. 10.1002/cncr.27918. 2013

Drug-drug interactions associated with FLT3 inhibitors for acute myeloblastic leukemia: current landscape.

Solana-Altabella, Antonio; (...); Montesinos, Pau

Article. 10.1080/17512433.2023.2174523. 2023

Drug-drug interactions of newly approved small molecule inhibitors for acute myeloid leukemia

Jarque, Isidro, Sanz, Miguel A.

Review. 10.1007/s00277-020-04186-0. 2020

Dynamics of Mortality and Transformation Risk within Different Risk Groups of Patients with Myelodysplastic Syndromes Stratified According to the IPSS-R - Comparison of Treated and Untreated Patients and Consequences for the Description of Risk Categories

Pfeilstocker, Michael; (...); Greenberg, Peter L.

Meeting Abstract. 10.1182/blood-2022-158671. 2022

Early platelet count kinetics has prognostic value in lower-risk myelodysplastic syndromes

Itzykson, R; (...); European MDS Registry Members

Article. 10.1182/bloodadvances.2018020495. 2018

Early-Onset Myelodysplastic Syndromes (MDS) with Ring Sideroblasts (RS) without SF3B1 Mutations in Adults: Enrichment with Germline Variants in Genes Responsible for Congenital Sideroblastic Anemias

Jauregui, Sandra Novoa; (...); Jerez, Andres

Meeting Abstract. 10.1182/blood-2023-185836. 2023

EBV-associated post-transplant lymphoproliferative disorder after umbilical cord blood transplantation in adults with hematological diseases

Sanz J; (...); Sanz GF

Article. 10.1038/bmt.2013.190. 2014

Economic evaluation of azoles as primary prophylaxis for the prevention of invasive fungal infections in Spanish patients undergoing allogeneic haematopoietic stem cell transplant

Solano C; (...); Bow EJ

Article. 10.1111/myc.12552. 2017

Eculizumab for the treatment of pregnancy-related atypical hemolytic uremic syndrome

Cañigral C; (...); Sanz MA

Letter. 10.1007/s00277-013-1970-3. 2014

Editorial introductions

Curigliano, Giuseppe; (...); Mateos, Maria-Victoria

Editorial Material. 10.1097/CCO.0000000000001001. 2023

Editorial: Infectious diseases and hematology: diagnosis and management

Gonzalez-Lopez, Tomas Jose; (...); Di Micco, Pierpaolo

Editorial Material. 10.3389/fmed.2024.1385874. 2024

Editorial: Pediatric acute lymphoblastic leukemia: what's next?

Gil, J. V., Ribera, J., LLop, M.

Editorial Material. 10.3389/fped.2023.1358139. 2024

Effect of autologous umbilical cord blood transfusion in the development of retinopathy of prematurity: randomized clinical trial - study protocol.

Torrejon-Rodriguez L; (...); Aguar Carrascosa M

Article. 10.3389/fped.2023.1269797. 2023

Effect of Caplacizumab in the Recovery of ADAMTS13 Level in Patients with Autoimmune Thrombotic Thrombocytopenic Purpura. Analysis from the Spanish Registry (REPTT)

Eva Mingot, Maria; (...); Del Rio Garma, Julio

Meeting Abstract. 10.1182/blood-2023-182876. 2023

Effect of CD8(+) Cell Content on Umbilical Cord Blood Transplantation in Adults with Hematological Malignancies

Moscardó F; (...); Sanz GF

Article. 10.1016/j.bbmt.2014.06.038. 2014

Effect of donor-recipient HLA matching at HLA A, B, C, and DRB1 on outcomes after umbilical-cord blood transplantation for leukaemia and myelodysplastic syndrome: a retrospective analysis

Eapen, Mary; (...); Rocha, Vanderson

Article. 10.1016/S1470-2045(11)70260-1. 2011

Effect of enasidenib (ENA) plus azacitidine (AZA) on complete remission and overall response versus AZA monotherapy in mutant-IDH2 (mIDH2) newly diagnosed acute myeloid leukemia (ND-AML).

Dinardo, CD; (...); Dohner, H

Meeting Abstract. 2020

Effect of gilteritinib on survival in patients with FLT3-mutated (FLT3(mut+)) relapsed/refractory (RR) AML who have common AML co-mutations or a high FLT3-ITD allelic ratio.

Levis, MJ; (...); Bahceci, E

Meeting Abstract. 2019

Effect of graft source on unrelated donor haemopoietic stem-cell transplantation in adults with acute leukaemia: a retrospective analysis

Eapen, Mary; (...); Wagner, John E.

Article. 10.1016/S1470-2045(10)70127-3. 2010

EFFECT OF MISSENSE MUTATIONS IN THE SPLICING OF PATIENTS WITH ACUTE MYELOID LEUKAEMIA

Morote-Faubel, M.; (...); Cervera, J.

Meeting Abstract. 2019

Effect of olutasidenib (FT-2102) on complete remissions in patients with relapsed/refractory (R/R) mIDH1 acute myeloid leukemia (AML): Results from a planned interim analysis of a phase 2 clinical trial.

De Botton, Stephane; (...); Fenaux, Pierre

Meeting Abstract. 10.1200/JCO.2021.39.15_suppl.7006. 2021

EFFECT OF PREGNANCY IN THE CLINICAL COURSE OF PREGNANT WOMEN WITH PTI AND THEIR OFFSPRING. RESULTS OF A SERIES OF SPANISH CASES WITH 263 PREGNANCIES IN PRIMARY PTI

Lopez, TJG; (...); Hermida, G.

Meeting Abstract. 2017

Effect of Recombinant Zoster Vaccine on Incidence of Herpes Zoster After Autologous Stem Cell Transplantation A Randomized Clinical Trial

Bastidas, A; (...); ZOE-HSCT Study Grp Collaborators

Article. 10.1001/jama.2019.9053. 2019

Effectiveness and safety of different azacitidine dosage regimens in patients with myelodysplastic syndromes or acute myeloid leukemia

García-Delgado R; (...); Sanz G

Article. 10.1016/j.leukres.2014.03.004. 2014

EFFECTIVENESS AND SAFETY OF THE INFUSION OF DONOR LYMPHOCYTES AFTER HAPLOIDENTICAL TRANSPLANTATION OF HEMATOPOYETIC PROGENITOR CELLS WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE: MULTICENTRIC RETROSPECTIVE STUDY OF THE HEMATOPETIC SPANISH TRIPASHOLE GROUP

Martin-Sanchez, Guillermo; (...); Bermudez, Aranzazu

Meeting Abstract. 2020

EFFECTIVENESS AND TOXICITY OF THE USE OF INOTUZUMAB (INO) IN PATIENTS WITH RESISTANT OR RECALLING (R/R) ACUTE LYMPHOBLASTIC LEUKEMIA (LAL). STUDY OF PATIENTS INCLUDED IN INO'S EXPANDED USE PROGRAM

Ribera Santasusana, J. M.; (...); Valero, M.

Meeting Abstract. 2021

Effectiveness of azacitidine for the treatment of higher-risk myelodysplastic syndromes in daily practice: the authors' reply

Bernal, T; (...); Sanz, G

Letter. 10.1038/leu.2015.339. 2016

Effectiveness of azacitidine in unselected high-risk myelodysplastic syndromes: results from the Spanish registry

Bernal T; (...); Spanish Society of Hematology

Article. 10.1038/leu.2015.115. 2015

Effectiveness of Caplacizumab Nanobody in Acquired Thrombotic Thrombocytopenic Purpura Refractory to Conventional Treatment

Palanques-Pastor T; (...); Poveda Andrés JL

Article. 10.1159/000517813. 2021

EFFECTS OF B-MYB ABERRANT EXPRESSION ON HEMATOPOIETIC PROGENITOR CELL GROWTH AND DETECTION OF GENETIC VARIATIONS THAT MAY MODIFY ITS PROTEIN FUNCTION

Dolz, S.; (...); Sanz, M.

Article. 2013

Effects of telemonitoring on safety and health care costs with a web platform (TECCU) in complex IBD patients: A randomised controlled trial

Aguas, M.; (...); Nos, P.

Meeting Abstract. 2018

Effects of the Therapeutic Armamentarium on Survival and Time to Next Treatment in CMML Subtypes: An International Analysis of 950 Cases Coordinated By the AGMT Study Group

Pleyer, Lisa; (...); Greil, Richard

Meeting Abstract. 10.1182/blood-2019-123941. 2019

Efficacy and safety of native versus pegylated Escherichia coli asparaginase for treatment of adults with high-risk, Philadelphia chromosome-negative acute lymphoblastic leukemia

Ribera, JM; (...); PETHEMA Group, Spanish Society of Hematology

Article. 10.1080/10428194.2017.1397661. 2018

Efficacy and safety of rituximab in adult patients with idiopathic relapsing or refractory thrombotic thrombocytopenic purpura: Results of a Spanish multicenter study

de la Rubia, Javier; (...); Sanz, Miguel A.

Article. 10.1016/j.transci.2010.09.018. 2010

Efficacy and Safety of Single-Agent Quizartinib (Q), a Potent and Selective FLT3 Inhibitor (FLT3i), in Patients (pts) with FLT3-Internal Tandem Duplication (FLT3-ITD)-Mutated Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) Enrolled in the Global, Phase 3, Randomized Controlled Quantum-R Trial

Cortes, JE; (...); Levis, MJ

Meeting Abstract. 10.1182/blood-2018-99-110439. 2018

Efficacy and Safety of Single-Agent Quizartinib (Q), Potent and SeleEfficacy and Safety of Single-Agent Quizartinib (Q), a Potent and Selective FLT3 Inhibitor (FLT3i), in Patients (pts) with FLT3-Internal Tandem Duplication (FLT3-ITD)-Mutated Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) Enrolled in the Global, Phase 3, Randomized Controlled QuANTUM-R Trial

Cortes, JE; (...); Levis, MJ

Meeting Abstract. 2019

Efficacy and Safety of Single-Agent Quizartinib, a Potent and Selective FLT3 Inhibitor (FLT3i), in Patients (pts) With FLT3-Internal Tandem Duplication (FLT3-ITD) - Mutated Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) Enrolled in the Global, Phase 3, Randomized Controlled QuANTUM-R Trial

Jonas, BA; (...); Levis, MJ

Meeting Abstract. 10.1016/j.clml.2019.07.097. 2019

Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study

Fenaux, Pierre; (...); Silverman, Lewis R.

Article. 10.1016/S1470-2045(09)70003-8. 2009

El nuevo reto en oncologia: la secuenciacion NGS y su aplicacion a la medicina de precision.

Calabria I; (...); Castel V

Article. 10.1016/j.anpedi.2016.05.006. 2016

Elotuzumab plus bortezomib and dexamethasone (EBd) versus bortezomib and dexamethasone (Bd) in patients (Pts) with relapsed/refractory multiple myeloma (RRMM)-2-year follow-up

Palumbo, A; (...); Jakubowiak, A

Article. 2016

Eltrombopag Added to Immunosuppression in Severe Aplastic Anemia.

Peffault de Latour R; (...); Risitano AM

Article. 10.1056/NEJMoa2109965. 2022

ELTROMBOPAG ADDED TO STANDARD IMMUNOSUPPRESSION IMPROVES RESPONSE RATE IN SEVERE APLASTIC ANEMIA: RESULTS OF THE MULTICENTER PHASE III PROSPECTIVE RANDOMIZED RACE TRIAL

Risitano, A. M.; (...); de latour, R. Peffault

Meeting Abstract. 2021

ELTROMBOPAG ADDED TO STANDARD IST IS SUPERIOR TO IST ALONE AS FRONT-LINE TREATMENT FOR SEVERE APLASTIC ANEMIA: FINAL 2-YEAR ANALYSIS OF EBMT-SAAWP RACE STUDY

Risitano, Antonio Maria; (...); de Latour, Regis Peffault

Meeting Abstract. 2024

Eltrombopag safety and efficacy for primary chronic immune thrombocytopenia in clinical practice

González-López TJ; (...); González-Porras JR

Article. 10.1111/ejh.12725. 2016

Emerging FLT3 inhibitors for the treatment of acute myeloid leukemia.

Solana-Altabella, Antonio; (...); Montesinos, Pau

Article. 10.1080/14728214.2021.2009800. 2022

Emerging Mutations at Relapse in Patients with FLT3-Mutated Relapsed/Refractory Acute Myeloid Leukemia Who Received Gilteritinib Therapy in the Phase 3 Admiral Trial.

Smith CC; (...); Bahceci E

Article. 10.1182/blood-2019-122620. 2019

Emerging strategies for the treatment of older patients with acute myeloid leukemia

Sanz MA; (...); Venditti A

Review. 10.1007/s00277-016-2666-2. 2016

Enasidenib plus azacitidine versus azacitidine alone in patients with newly diagnosed, mutant-IDH2 acute myeloid leukaemia (AG221-AML-005): a single-arm, phase 1b and randomised, phase 2 trial.

DiNardo CD; (...); Döhner H

Article. 10.1016/S1470-2045(21)00494-0. 2021

Enasidenib vs conventional care in mutant-IDH2 relapsed/refractory acute myeloidleukemia: a randomized, phase 3 trial.

de Botton, Stephane; (...); DiNardo, Courtney D.

Article. 10.1182/blood.2021014901. 2022

Engaging Innate Immunity By AFM28, an Innate Cell Engager (ICE®) Targeting CD123-Positive Leukemic Cells in Patients with Relapsed/Refractory Acute Myeloid Leukemia: Safety and Efficacy Results of a First-in-Human Phase 1 Study

Montesinos, Pau; (...); Recher, Christian

Meeting Abstract. 10.1182/blood-2024-194356. 2024

Engraftment kinetics and graft failure after single umbilical cord blood transplantation using a myeloablative conditioning regimen

Ruggeri A; (...); Netcord

Article. 10.3324/haematol.2014.109280. 2014

Enhancing Cytogenetic Diagnostics: Incorporating Optical Genome Mapping in the Laboratory Routine

Diaz-Gonzalez, Alvaro; (...); Such, Esperanza

Meeting Abstract. 10.1182/blood-2023-180691. 2023

Enhancing roasted pepper quality sustainably: Impact of biodegradable mulches

Guerra, Marcos; (...); Casquero, Pedro Antonio

Article. 10.1016/j.jafr.2024.101393. 2024

Enumerating bone marrow blasts from nonerythroid cellularity improves outcome prediction in myelodysplastic syndromes and permits a better definition of the intermediate risk category of the Revised International Prognostic Scoring System (IPSS-R)

Calvo, X; (...); Florensa, L

Article. 10.1002/ajh.24732. 2017

Epidemiology of Hereditary Thrombotic Thrombocytopenic Purpura (TTP) in Spain: Preliminary Results of a Study of the Spanish TTP Registry (REPTT)

Segui, Ines Gomez; (...); Garma, Julio Del Rio

Meeting Abstract. 2024

Epidemiology of invasive fungal infections due to Aspergillus spp. and Zygomycetes

Sanz-Alonso MA; (...); Pemán J

Article. 10.1111/j.1469-0691.2006.01602.x. 2006

Epigenome profiling reveals aberrant DNA methylation signature in GATA2 deficiency.

Marin-Bejar, Oskar; (...); Giorgetti, Alessandra

Article. 10.3324/haematol.2022.282305. 2023

ERCC6L2 in Early-Onset Adult Myelodysplastic Syndrome without Pre-Existing Disorder

Carrillo-Tornel, Salvador; (...); Jerez, Andres

Meeting Abstract. 10.1182/blood-2022-168759. 2022

Erythrocyte deformability and aggregation in homozygous sickle cell disease

Vayá A; (...); Barragán E

Article. 10.3233/CH-131717. 2014

Erythrocyte deformability and hereditary elliptocytosis

Vayá A; (...); Fuster O

Article. 10.3233/CH-141889. 2014

Erythroleukemia shares biological features and outcome with myelodysplastic syndromes with excess blasts: a rationale for its inclusion into future classifications of myelodysplastic syndromes

Calvo X; (...); Florensa L

Article. 10.1038/modpathol.2016.146. 2016

Erythropoiesis-stimulating agents significantly delay the onset of a regular transfusion need in nontransfused patients with lower-risk myelodysplastic syndrome

Garelius, HKG; (...); Hellström-Lindberg E

Article. 10.1111/joim.12579. 2017

Escalated dosing schedules of CC-486 for patients experiencing first acute myeloid leukemia (AML) relapse: Results from the phase III QUAZAR AML-001 maintenance trial.

Dohner, H; (...); Roboz, GJ

Meeting Abstract. 2020

Estudio coste-efectividad de la estrategia empírica antifúngica en pacientes oncohematológicos.

Romá-Sánchez E; (...); Jarque-Ramos I

Abstract of Published Item. 2008

European Perspective on Multiple Myeloma Treatment Strategies in 2014

Ludwig H; (...); Palumbo A

Article. 10.1634/theoncologist.2014-0042. 2014

European perspective on multiple myeloma treatment strategies: update following recent congresses.

Ludwig H; (...); Palumbo A

Article. 10.1634/theoncologist.2011-0391. 2012

Evaluation of a disease risk index for adult patients undergoing umbilical cord blood transplantation for haematological malignancies

Paviglianiti, A; (...); Rocha, V

Article. 10.1111/bjh.14962. 2017

Evaluation of chimerism by quantitative PCR analysis of DNA polymorphism after allogeneic hematopoietic stem cell transplantation in a pediatric population with malignancies

Bautista, F.; (...); Verdeguer, A.

Article. 10.1111/j.1399-3046.2010.01416.x. 2011

Evaluation of Lenalidomide (LEN) Vs Placebo in Non-Transfusion Dependent Low Risk Del(5q) MDS Patients. Final Results of Sintra-REV Phase III International Multicenter Clinical Trial

Lopez Cadenas, Felix; (...); Diez-Campelo, Maria

Meeting Abstract. 10.1182/blood-2022-168718. 2022

Evaluation of minimal residual disease in relapsed/refractory multiple myeloma patients treated with venetoclax or placebo in combination with bortezomib and dexamethasone: BELLINI study analyses.

Moreau, P; (...); Kumar, S

Meeting Abstract. 2020

EVALUATION OF THE EFFECT OF DIFFERENT LIGANDS OF TLRS IN THE PROLIFERATION AND DIFFERENTIATION OF ACUTE MYELOID LEUKEMIA CELLS

Fernandez, JG; (...); Ribate, EV

Meeting Abstract. 2017

EVALUATION OF THE MUTATION OF FLT3 IN ACUTE MYELOID LEUKAEMIA: RESULTS OF THE DELPHI QUESTIONNAIRE OF THE SPANISH GROUP

Gomez-Casares, M. T.; (...); Sierra, J.

Meeting Abstract. 2019

Evaluation of the potential therapeutic effects of a double-stranded RNA mimic complexed with polycations in an experimental mouse model of endometriosis

García-Pascual CM; (...); Gómez R

Article. 10.1016/j.fertnstert.2015.07.1147. 2015

EVALUATION OF THE RETRO-TRANSCRIPTION Q-LAMP TEST: A NEW METHOD FOR ULTRA-FAST IDENTIFICATION OF BCR-ABL FUSION TRANSCRITES

Sargas, C.; (...); Barragan, E.

Meeting Abstract. 2019

Evaluation of the Stellae-123 prognostic gene expression signature in acute myeloid leukemia

Mosquera Orgueira, Adrian; (...); Perez Encinas, Manuel Mateo

Article. 10.3389/fonc.2022.968340. 2022

Evolution of iron overload in patients with low-risk myelodysplastic syndrome: iron chelation therapy and organ complications

Remacha ÁF; (...); Sanz G

Article. 10.1007/s00277-014-2274-y. 2015

Evolution of the Genetic and Biological Studies Performed at Diagnosis in Patients with Acute Myeloid Leukemia Included in the Pethema Epidemiological Registry (REALMOL Study)

Labrador, Jorge; (...); Manuel Alonso-Dominguez, Juan

Meeting Abstract. 10.1182/blood-2022-163016. 2022

Evolving patterns and clinical outcome of genetic studies performed at diagnosis in acute myeloid leukemia patients: Real life data from the PETHEMA Registry.

Labrador, Jorge; (...); Montesinos, Pau

Article. 10.1002/cncr.35431. 2024

Evolving patterns of care and outcomes in relapsed/refractory FLT3 mutated acute myeloid leukemia adult patients.

Boluda B; (...); Montesinos P

Article. 10.1080/10428194.2021.1938031. 2021

Evolving treatment patterns and outcomes in older patients (=60 years) with AML: changing everything to change nothing?

Martínez-Cuadrón D; (...); Montesinos P

Article. 10.1038/s41375-020-01058-4. 2020

Ex vivo T-cell depletion vs post-transplant cyclophosphamide, sirolimus, and mycophenolate mofetil as graft-vs-host disease prophylaxis for allogeneic hematopoietic stem cell transplantation.

Montoro, Juan; (...); Sanz, Jaime

Article. 10.1111/ejh.13529. 2021

Excess Mortality in Low-Risk MDS Can be Explained By MDS and AML Related Causes of Death

Madry, K; (...); Smith, A

Meeting Abstract. 10.1182/blood-2018-99-115928. 2018

Excess mortality in the myelodysplastic syndromes

Nomdedeu, M; (...); Spanish MDS Group

Article. 10.1002/ajh.24606. 2017

Executive summary of the consensus document of the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC), the Spanish Network for Research in Infectious Diseases (REIPI) and the Spanish Society of Haematology and Haemotherapy (SEHH) on the management of febrile neutropenia in patients with hematological malignancies.

Gudiol C; (...); de la Cámara R

Article. 10.1016/j.eimc.2019.01.013. 2020

Exome sequencing reveals novel and recurrent mutations with clinical impact in blastic plasmacytoid dendritic cell neoplasm

Menezes J; (...); Cigudosa JC

Article. 10.1038/leu.2013.283. 2014

EXPERIENCE IN THE DONATION OF HEMATOPOYETIC PROGENITORS (PH) OF PERIPHERAL BLOOD OF MINOR DONORS

Dominguez Hernandez, L.; (...); Gomez Segui, I

Meeting Abstract. 2019

Experience with IMGN632, a Novel CD123-Targeting Antibody-Drug Conjugate (ADC), in Frontline Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Pemmaraju, Naveen; (...); Daver, Naval

Meeting Abstract. 10.1182/blood-2021-146666. 2021

EXPLOITING CUTTING-EDGE TECHNOLOGIES TO ANALYZE LOSS OF HLA IN A GLOBAL MULTICENTRIC COHORT OF POST-TRANSPLANTATION RELAPSES: PRELIMINARY RESULTS FROM THE HLALOSS COLLABORATIVE STUDY

Vago, Luca; (...); Fleischhauer, Katharina

Meeting Abstract. 2018

Exploiting Cutting-Edge Technologies to Analyze Loss of HLA in a Global Multicentric Cohort of Post-Transplantation Relapses: Preliminary Results from the HLALOSS Collaborative Study

Vago, Luca; (...); Fleischhauer, Katharina

Meeting Abstract. 2018

EXPLOITING CUTTING-EDGE TECHNOLOGIES TO ANALYZE LOSS OF HLA IN A MULTICENTRIC COHORT OF POST-TRANSPLANTATION RELAPSES: RESULTS FROM THE HLALOSS GLOBAL COLLABORATIVE STUDY

Vago, L.; (...); Fleischhauer, K.

Meeting Abstract. 2018

Exploring Potential Molecular Mechanisms of Drug Response in FLT3-ITD Negative AML Patients Treated with Quizartinib Vs Placebo Plus Standard Chemotherapy in the Quiwi Trial

Mosquera Orgueira, Adrian; (...); Montesinos, Pau

Meeting Abstract. 10.1182/blood-2023-180710. 2023

Extracorporeal photopheresis vs standard therapies for steroid-refractory chronic graft-vs-host disease: Pharmacoeconomic assessment of hospital resource use in Spain.

Boluda, Blanca; (...); Montesinos, Pau

Article. 10.1002/jca.21901. 2021

Ex-vivo T-cell depleted peripheral blood stem cell transplantation from HLA-matched sibling donors for the treatment of severe aplastic anemia

Cano-Ferri, I.; (...); Sanz, G.

Meeting Abstract. 2015

Factor XIII deficiency in two Spanish families with a novel variant in gene F13A1 detected by next-generation sequencing; symptoms and clinical management.

Moret A; (...); Bonanad S

Article. 10.1007/s11239-020-02065-z. 2020

Factors Associated With Survival in Secondary Acute Myeloid Leukemia in Colombia

Sossa, Claudia; (...); Marcela Cuervo, Diana

Meeting Abstract. 2023

Factors influencing platelet transfusion refractoriness in patients undergoing allogeneic hematopoietic stem cell transplantation

Solves P; (...); Carpio N

Article. 10.1007/s00277-017-3168-6. 2018

Fatal hemolytic disease of the fetus and newborn possibly due to anti-Jra

Arriaga, Francisco; (...); Perales, Alfredo

Article. 10.1111/j.1537-2995.2009.02118.x. 2009

Feasibility and outcomes after dose reduction of immunochemotherapy in young adults with Burkitt lymphoma and leukemia: results of the BURKIMAB14 trial.

Ribera JM; (...); Sancho JM

Article. 10.3324/haematol.2023.283342. 2024

Feasibility and results of subtype-oriented protocols in older adults and fit elderly patients with acute lymphoblastic leukemia: Results of three prospective parallel trials from the PETHEMA group

Ribera, JM; (...); Spanish Soc Hematology

Article. 10.1016/j.leukres.2015.11.012. 2016

Feasibility of treatment discontinuation in chronic myeloid leukemia in clinical practice: results from a nationwide series of 236 patients

Hernandez-Boluda, JC; (...); GELMC

Article. 10.1038/s41408-018-0125-0. 2018

Fertility rescue and ovarian follicle growth promotion by bone marrow stem cell infusion

Herraiz, S; (...); Pellicer, A

Article. 10.1016/j.fertnstert.2018.01.004. 2018

FINAL ANALYSIS OF GLOBAL SURVIVAL OF THE FIRST TEST IN PATIENTS WITH MULTIPLE NEW DIAGNOSTIC MYELOMA

Oriol, A.; (...); Benboubker, L.

Meeting Abstract. 2017

Final Analysis of the Phase 2 ELM-2 Study: Odronextamab in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

Ayyappan, Sabarish; (...); Prince, H. Miles

Meeting Abstract. 10.1182/blood-2023-179818. 2023

FINAL RESULTS OF THE LAL-RI 08 PROTOCOL FOR ADOLESCENTS AND YOUNG ADULTS (AAJ) WITH LYMPHOBLASTIC ACUTE LEUKEMIA (LAL) OF STANDARD RISK (RE)

Santasusana, JMR; (...); Vale, AODCE

Meeting Abstract. 2018

Finding consistency in classifications of myeloid neoplasms: a perspective on behalf of the International Workshop for Myelodysplastic Syndromes.

Zeidan, Amer M.; (...); Santini, Valeria

Article. 10.1038/s41375-022-01724-9. 2022

First report of PhALLCON: A phase 3 study comparing ponatinib (pon) vs imatinib (im) in newly diagnosed patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph plus ALL).

Jabbour, Elias; (...); Ribera, Josep-Maria

Meeting Abstract. 2023

First Report of PhALLCON: A Phase 3 Study Comparing Ponatinib Versus Imatinib in Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphocytic Leukemia

Jabbour, Elias; (...); Ribera, Jose-Maria

Meeting Abstract. 2023

First-in-Human Phase I Study of Iadademstat (ORY-1001): A First-in-Class Lysine-Specific Histone Demethylase 1A Inhibitor, in Relapsed or Refractory Acute Myeloid Leukemia.

Salamero, Olga; (...); Somervaille TCP

Article. 10.1200/JCO.19.03250. 2020

FITNESS ASSESSMENT IN ACUTE MYELOID LEUKEMIA: RECOMMENDATIONS FROM AN EXPERT PANEL ON BEHALF OF EUROPEAN LEUKEMIA NET.

Venditti, Adriano; (...); Ossenkoppele, Gert J

Article. 10.1182/bloodadvances.2024013744. 2025

FLORENCE: a randomized, double-blind, phase III pivotal study of febuxostat versus allopurinol for the prevention of tumor lysis syndrome (TLS) in patients with hematologic malignancies at intermediate to high TLS risk

Spina M; (...); FLORENCE Study Group

Article. 10.1093/annonc/mdv317. 2015

FLT3 inhibition as a targeted therapy for acute myeloid leukemia

Sanz, Miguel; (...); Lowenberg, Bob

Article. 10.1097/CCO.0b013e32833118fd. 2009

FLT3 mutation Assay Laboratory Cross Validation: Results from the CALGB 10603/Ratify Trial in Patients with Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia (AML)

Thiede, C; (...); Dohner, K

Meeting Abstract. 10.1182/blood-2018-99-112127. 2018

Fluorescence in situ hybridization improves the detection of 5q31 deletion in myelodysplastic syndromes without cytogenetic evidence of 5q-

Mallo, Mar; (...); Sole, Francesc

Article. 10.3324/haematol.13012. 2008

Fluorescence in situ hybridization of TP53 for the detection of chromosome 17 abnormalities in myelodysplastic syndromes

Sánchez-Castro J; (...); Solé F

Article. 10.3109/10428194.2015.1028053. 2015

Focal Adhesion Genes Refine the Intermediate-Risk Cytogenetic Classification of Acute Myeloid Leukemia

Pallarès V; (...); Casanova, I

Article. 10.3390/cancers10110436. 2018

Follow-up of healthy donors receiving granulocyte colony-stimulating factor for peripheral blood progenitor cell mobilization and collection. Results of the Spanish Donor Registry

de la Rubia, Javier; (...); Sanz, Miguel A.

Article. 10.3324/haematol.12285. 2008

Follow-up of patients with FLT3-mutated R/R AML in the phase 3 ADMIRAL trial.

Perl, Alexander E.; (...); Levis, Mark J.

Meeting Abstract. 10.1200/JCO.2021.39.15_suppl.7013. 2021

Follow-up of Patients With FLT3-Mutated Relapsed or Refractory Acute Myeloid Leukaemia in the Phase 3 ADMIRAL Trial

Perl, Alexander E.; (...); Levis, Mark J.

Meeting Abstract. 2022

Follow-up of patients with R/R FLT3-mutation-positive AML treated with gilteritinib in the phase 3 ADMIRAL trial.

Perl AE; (...); Levis MJ

Article. 10.1182/blood.2021011583. 2022

Fostamatinib effectiveness and safety for immune thrombocytopenia in clinical practice.

Gonzalez-Lopez, Tomas Jose; (...); Garcia-Donas Gabaldon, Gloria

Article. 10.1182/blood.2024024250. 2024

Four new cases of therapy-related acute promyelocytic leukemia after mitoxantrone

Bosca, I.; (...); Sanz, M. A.

Article. 10.1212/01.wnl.0000324422.69067.e7. 2008

FRAGMENT LENGTH ANALYSIS SCREENING FOR CEBPA MUTATIONS DETECTION IN ACUTE MYELOID LEUKEMIA

Fuster, O.; (...); Sanz, M. A.

Article. 2009

Fragment length analysis screening for detection of CEBPA mutations in intermediate-risk karyotype acute myeloid leukemia.

Fuster O; (...); Sanz MÁ

Article. 10.1007/s00277-011-1234-z. 2012

Frequency and clinical impact of CDKN2A/ARF/CDKN2B gene deletions as assessed by in-depth genetic analyses in adult T cell acute lymphoblastic leukemia

Genesca, E; (...); Ribera, JM

Article. 10.1186/s13045-018-0639-8. 2018

FREQUENCY AND CLINICAL IMPACT OF CDKN2A/B GENE LOCUS IN AN ADULT T-ALL COHORT OF PATIENTS ENROLLED IN THE SPANISH PETHEMA GROUP PROTOCOLS

Genesca, E; (...); Ribera, JM

Meeting Abstract. 2017

Frequency and prognostic significance of additional cytogenetic abnormalities to the Philadelphia chromosome in young and older adults with acute lymphoblastic leukemia

Motllo C; (...); PETHEMA Group, Spanish Society of Hematology

Article. 10.1080/10428194.2017.1326596. 2018

Frequency and prognostic significance of t(v;11q23)/KMT2A rearrangements in adult patients with acute lymphoblastic leukemia treated with risk-adapted protocols

Motlló C; (...); PETHEMA Group, Spanish Society of Hematology

Article. 10.1080/10428194.2016.1177182. 2017

Frequency of dicentrics and contamination levels in Ukrainian children and adolescents from areas near Chernobyl 20 years after the nuclear plant accident.

Montoro A; (...); Villaescusa JI

Article. 10.3109/09553002.2013.809172. 2013

Frequency, Clinical Characteristics and Outcome of Adults With Acute Lymphoblastic Leukemia and COVID 19 Infection in the First vs. Second Pandemic Wave in Spain.

Ribera, Josep-Maria; (...); Pinana, Jose-Luis

Article. 10.1016/j.clml.2021.06.024. 2021

Frequency, characteristics and outcomes of Lymphoproliferative Disorders After Allogeneic Stem Cell Transplant: results of a multicenter study from the Grupo Espanol de Trasplante Hematopoyetico (GETH)

Garcia Cadenas, Irene; (...); Solano, Carlos

Meeting Abstract. 2018

Frequency, characteristics, and outcome of PTLD after allo-SCT: A multicenter study from the Spanish group of blood and marrow transplantation (GETH)

Garcia-Cadenas, I; (...); Spanish Grp Blood & Marrow Tran

Article. 10.1111/ejh.13226. 2019

FT-2102, an IDH1m Inhibitor, in Combination with Azacitidine in Patients with Acute Myeloid Leukemia (AML) or Myelodysplastic Ayndrome (MDS): Results from a Phase 1 Study

Cortes, JE; (...); Baer, MR

Meeting Abstract. 10.1182/blood-2018-99-114126. 2018

FUNCTIONAL CLASSIFICATION OF DEEP INTRONIC VARIANTS IN PATIENTS WITH ACUTE MYELOBLASTIC LEUKEMIA

Liquori, A.; (...); Cervera Zamora, J.

Meeting Abstract. 2019

Functional polymorphisms in SOCS1 and PTPN22 genes correlate with the response to imatinib treatment in newly diagnosed chronic-phase chronic myeloid leukemia.

Guillem V; (...); Hernández-Boluda JC

Article. 10.1016/j.leukres.2011.06.011. 2012

FUNCTIONAL RECLASSIFICATION THROUGH MINIGENE TESTS OF MISSENSE VARIANTS WITH EFFECT ON SPLICING IN PATIENTS WITH ACUTE MYELOID LEUKEMIA

Morote-Faubel, Mireya; (...); Cervera, Jose

Meeting Abstract. 2020

FUNCTIONAL STUDY OF SILENCED HMGCR GENE IN CELL LINES OF ACUTE MYELOID LEUKEMIA PATIENTS

De Matteo, B; (...); Zamora, JVC

Meeting Abstract. 2017

Fungemia due to Candida guilliermondii in a pediatric and adult population during a 12-year period.

Pemán J; (...); Gobernado M.

Article. 2008

Further psychometric validation of the GAH scale: Responsiveness and effect size

Cruz-Jentoft, AJ; (...); GAH Group

Article. 10.1016/j.jgo.2016.12.008. 2017

GAH SCALE PREDICTS TREATMENT TOLERABILITY IN OLDER PATIENTS (> 65 YEARS) DIAGNOSED WITH HEMATOLOGICAL MALIGNANCIES

Bonanad, S; (...); de la Rubia, J

Meeting Abstract. 2017

GAM: General Auxetic Metamaterial with Tunable 3D Auxetic Behavior Using the Same Unit Cell Boundary Connectivity

Ben-Yelun, Ismael; (...); Saucedo-Mora, Luis

Article. 10.3390/ma16093473. 2023

Gastric Bleeding in Stem Cell Transplantation: A Focus on Gastric Vascular Ectasia Under Post-Transplant Cyclophosphamide, Sirolimus, and Mycophenolate Mofetil Prophylaxis.

Eirís J; (...); Sanz J

Article. 10.1016/j.jtct.2024.10.009. 2024

Gastrointestinal Events and Management Strategies for Patients with Acute Myeloid Leukemia (AML) in First Remission Receiving CC-486 Maintenance Therapy in the Randomized, Placebo-Controlled, Phase III QUAZAR AML-001 Trial

Ravandi, Farhad; (...); Dombret, Herve

Meeting Abstract. 2020

Gastrointestinal events and management strategies for patients with acute myeloid leukemia (AML) in first remission receiving oral azacitidine (Oral-AZA) in the randomized, placebo-controlled, phase 3 QUAZAR AML-001 maintenance trial

Pfeilstocker, M.; (...); Dombret, H.

Meeting Abstract. 2021

Gene expression profiling identifies FLT3 mutation-like cases in wild-type FLT3 acute myeloid leukemia.

Mosquera Orgueira A; (...); Bello López JL

Article. 10.1371/journal.pone.0247093. 2021

Generation of Multimodal Longitudinal Synthetic Data By Artificial Intelligence to Improve Personalized Medicine in Hematology

D'Amico, Saverio; (...); Della Porta, Matteo Giovanni

Meeting Abstract. 10.1182/blood-2024-209541. 2024

GENES BELONGING TO THE SWI/SNF CHROMATIN REMODELING COMPLEXES ARE MUTATED AT HIGH FREQUENCY IN RARE T(11;17)(Q23;Q21)/ZBTB16-RARA ACUTE MYELOID LEUKEMIA PATIENTS

Fabiani, E.; (...); Voso, M. T.

Meeting Abstract. 2020

GENOME-WIDE ANALYSIS OF SINGLE NUCLEOTIDE POLYMORPHISM (SNPS) IN PATIENTS WITH DE NOVO ACUTE MYELOID LEUKEMIA WITH NORMAL KARYOTYPE

Ibanez, M.; (...); Cervera, J.

Meeting Abstract. 2016

Genome-wide association study identifies susceptibility loci for acute myeloid leukemia (vol 13, 2, 2022)

Lin, Wei-Yu; (...); Allan, James M.

Article. 10.1038/s41467-021-27679-6. 2022

Genome-wide association study identifies susceptibility loci for acute myeloid leukemia.

Lin WY; (...); Allan JM

Article. 10.1038/s41467-021-26551-x. 2021

Genomic analysis of high-risk smoldering multiple myeloma.

López-Corral L; (...); Gutiérrez NC

Article. 10.3324/haematol.2011.060780. 2012

GENOMIC AND TRANSCRIPTOMIC CHARACTERIZATION OF MYELODYSPLASTIC SYNDROMES/MYELOPROLIFERATIVE NEOPLASMS

Acha, P.; (...); Sole, F.

Meeting Abstract. 10.1016/j.leukres.2023.107253. 2023

GENOMIC CLASSIFICATION OF MYELODYSPLASTIC SYNDROMES

Bernard, E.; (...); Papaemmanuil, E.

Meeting Abstract. 10.1016/j.leukres.2023.107146. 2023

Genomic characterization of Citrobacter freundii strains coproducing OXA-48 and VIM-1 carbapenemase enzymes isolated in leukemic patient in Spain

Lalaoui, R; (...); Rolain, JM

Article. 10.1186/s13756-019-0630-3. 2019

Genomic characterization of patients with polycythemia vera developing resistance to hydroxyurea.

Alvarez-Larrán A; (...); Hernández-Boluda JC

Letter. 10.1038/s41375-020-0849-2. 2020

Genomic profiling of high-risk smoldering myeloma patients treated with a curative strategy: a biological study of the phase II GEM CESAR clinical trial

Medina, Alejandro; (...); Garcia-Sanz, Ramon

Meeting Abstract. 2023

Genomics improves risk stratification of adults with T-cell acute lymphoblastic leukemia patients enrolled in measurable residual disease-oriented trials.

Gonzalez-Gil, Celia; (...); Genesca, Eulalia

Article. 10.3324/haematol.2022.281196. 2023

Genotype FBN1/Phenotype relationship in a cohort of patients with Marfan syndrome.

Hernándiz A; (...); Sepúlveda P

Article. 10.1111/cge.13879. 2020

Genotypic and Phenotypic Characteristics of Acute Promyelocytic Leukemia Translocation Variants.

Mannan A; (...); Aljurf M

Article. 10.1016/j.hemonc.2020.05.007. 2020

Geriatric assessment in hematology scale predicts treatment tolerability in older patients diagnosed with hematological malignancies: The RETROGAH study.

de la Rubia J; (...); Bonanad, Santiago

Article. 10.1016/j.jgo.2022.10.016. 2022

GERMINAL PREDISPOSITION IN PATIENTS WITH MYELOID NEOPLASMS: ASSOCIATION BETWEEN MOLECULAR DISORDERS AND CLINICAL HISTORY

Marta, Santiago; (...); Jose, Cervera

Meeting Abstract. 2021

Germline and Acquired Genetic Variants in Myelodysplastic Syndromes in Young Adults without a Preexisting Disorder or Organ Dysfunction

Chen-Liang, TH; (...); Jerez, A

Meeting Abstract. 10.1182/blood-2018-99-116045. 2018

Germline assessment for alloHSCT candidates over 50 years: A 'Fast-Track' screening in myeloid neoplasms.

Torres-Esquius S; (...); Jerez A

Article. 10.1111/bjh.19460. 2024

Germline Predisposition in Myeloid Neoplasms Aged =50: A Novel Approach for Allogeneic Stem Cell -Transplantation Decision-Making

Torres-Esquius, Sara; (...); Jerez, Andres

Meeting Abstract. 10.1182/blood-2023-179234. 2023

GERMLINE PREDISPOSITION TO MYELOID MALIGNANCIES IN A CONSECUTIVE COHORT OF 183 PATIENTS

Santiago, M.; (...); Cervera-Zamora, J.

Meeting Abstract. 10.1016/j.leukres.2023.107247. 2023

GETH-CLL4: Long-term follow-up of a pilot trial evaluating the addition of ofatumumab to the conditioning regimen of patients with chronic lymphocytic leukemia undergoing allogeneic HCT

Montesinos, Pau; (...); Delgado, Julio

Meeting Abstract. 2018

Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3 -Mutated AML.

Perl AE; (...); Levis MJ

Article. 10.1056/NEJMoa1902688. 2019

Gilteritinib prolongs survival in patients with FLT3-mutated relapsed/refractory acute myeloid leukaemia who have common AML comutations or a high FLT3-internal tandem duplication allelic ratio

Levis, MJ; (...); Bahceci, E

Meeting Abstract. 2020

Gilteritinib significantly prolongs overall survival in patients with FLT3-mutated (FLT3mut+) relapsed/refractory (R/R) acute myeloid leukemia (AML): Results from the Phase III ADMIRAL trial

Perl, AE; (...); Levis, MJ

Meeting Abstract. 10.1158/1538-7445.AM2019-CT184. 2019

GILTERITINIB SIGNIFICANTLY PROLONGS OVERALL SURVIVAL IN PATIENTS WITH FLT3-MUTATED RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA: RESULTS FROM THE PHASE 3 ADMIRAL TRIAL

Perl, A. E.; (...); Levis, M. J.

Meeting Abstract. 2019

Gilteritinib significantly prolongs overall survival in patients with FLT3-mutated relapsed/refractory acute myeloid leukemia: results from the phase 3 ADMIRAL trial

Perl, A. E.; (...); Levis, M. J.

Meeting Abstract. 2019

Gilteritinib use in the treatment of relapsed or refractory acute myeloid leukemia with a FLT3 mutation.

Ballesta-López O; (...); Montesinos P

Review. 10.2217/fon-2020-0700. 2020

Glasdegib (GLAS) plus low-dose cytarabine (LDAC) in AML or MDS: BRIGHT AML 1003 final report and four-year overall survival (OS) follow-up.

Heuser, M; (...); Cortes, JE

Meeting Abstract. 2020

Glasdegib plus intensive or non-intensive chemotherapy for untreated acute myeloid leukemia: results from the randomized, phase 3 BRIGHT AML 1019 trial.

Sekeres MA; (...); Cortes JE

Article. 10.1038/s41375-023-02001-z. 2023

Glasdegib plus low-dose cytarabine in acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS): BRIGHT AML 1003 final report and 4-year overall survival follow-up

Heuser, M; (...); Cortes, JE

Meeting Abstract. 2020

Glasdegib Plus Low-Dose Cytarabine in Acute Myeloid Leukemia or Myelodysplastic Syndrome: BRIGHT AML 1003 Final Report and 4-Year Overall Survival Follow-Up

Heuser, Michael; (...); Cortes, Jorge E.

Meeting Abstract. 2020

Glasdegib with LDAC in Newly Diagnosed Patients with Acute Myeloid Leukemia (AML) Unsuitable for Intensive Chemotherapy: Effects on Transfusions and Marrow Recovery vs LDAC Alone

Wang, ES; (...); Cortes, JE

Meeting Abstract. 10.1016/j.clml.2019.07.114. 2019

Glomerulonephritis Secondary to Acute Promyelocytic Leukemia that Resolved after Induction Therapy.

Andres Regino, Carlos; (...); Angel Sanz, Miguel

Article. 10.1159/000528088. 2023

Guadecitabine vs TC in relapsed/refractory AML after intensive chemotherapy: randomized phase 3 ASTRAL-2 trial.

Roboz GJ; (...); Döhner H

Article. 10.1182/bloodadvances.2023012062. 2024

Guidelines for the Treatment of Invasive Fungal Disease by Aspergillus spp. and Other Fungi Issued by the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC). 2011 Update

Fortun, Jesus; (...); Cuenca-Estrella, Manuel

Article. 10.1016/j.eimc.2011.01.010. 2011

GUIDELINES OF PRESCRIPTION IN FIRST LINE OF PATIENTS WITH MULTIPLE MYELOMA NOT CANDIDATES TO TRANSPLANTATION STRATIFIED BY AGE IN REAL LIFE IN SPAIN BETWEEN 2012 AND 2016

Cejalvo, M. J.; (...); Sarra, J.

Meeting Abstract. 2019

Guidelines of the Spanish ITP Group for the diagnosis, treatment and follow-up of patients with immune thrombopenia.

Lozano ML, Sanz MA, Vicente V

Article. 10.1016/j.medcli.2021.03.017. 2021

Hairy cell leukemia treated initially with purine analogs: a retrospective study of 107 patients from the Spanish Cooperative Group on Chronic Lymphocytic Leukemia (GELLC)

López Rubio M; (...); Garcia-Marco JA

Article. 10.3109/10428194.2013.827187. 2014

Haplo-Cord transplantation compared to haploidentical transplantation with post-transplant cyclophosphamide in patients with AML

Kwon M; (...); Diez-Martin JL

Article. 10.1038/bmt.2017.36. 2017

Haploidentical non-manipulated stem cell transplant in patients with non-hodgkin lymphoma: Spanish experience

Dorado, N; (...); Diez-Martin, JL

Meeting Abstract. 2019

Harmony Alliance Provides a Machine Learning Researching Tool to Predict the Risk of Relapse after First Remission in AML Patients Treated without Allogeneic Haematopoietic Stem Cell Transplantation

Sobas, Marta; (...); Maria Hernandez-Rivas, Jesus

Meeting Abstract. 10.1182/blood-2021-149521. 2021

Healthcare Resource Utilization among Patients between 60-75 Years with Secondary Acute Myeloid Leukemia Receiving Intensive Chemotherapy Induction: A Spanish Retrospective Observational Study

Solana-Altabella, Antonio; (...); Martinez-Cuadron, David

Article. 10.3390/cancers14081921. 2022

Healthcare resource utilization in adult patients with relapsed/refractory FLT3 mutated acute myeloid leukemia: A retrospective chart review from Spain.

Solana-Altabella A; (...); Montesinos P

Article. 10.1111/ejh.13604. 2021

Health-Related Quality of Life (HRQoL) during Treatment with Enasidenib (ENA) Plus Azacitidine (AZA) in Patients with Newly Diagnosed Mutant IDH2 (m IDH2) Acute Myeloid Leukemia (AML) Not Eligible for Intensive Chemotherapy (IC)

DiNardo, Courtney D.; (...); Montesinos, Pau

Meeting Abstract. 10.1182/blood-2021-147601. 2021

Health-related quality of life (HRQoL) with enasidenib versus conventional care regimens in older patients with late-stage mutant-IDH2 relapsed or refractory acute myeloid leukemia (R/R AML).

Dinardo, Courtney Denton; (...); De Botton, Stephane

Meeting Abstract. 2022

Health-Related Quality of Life and Symptoms in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma Treated with Odronextamab Monotherapy in the Phase 2 ELM-2 Study

Iskierka-Jazdzewska, Elzbieta; (...); Ivanescu, Cristina

Meeting Abstract. 10.1182/blood-2023-180743. 2023

Health-related quality of life in lower-risk MDS patients compared with age- and sex-matched reference populations: a European LeukemiaNet study

Stauder, R; (...); de Witte, T

Article. 10.1038/s41375-018-0089-x. 2018

HEALTH-RELATEDQUALITYOF LIFE IS SUBSTANTIALLY IMPAIRED IN LOWER-RISK MDS WHEN COMPARED WITH REFERENCE POPULATIONS AND SIGNIFICANTLY AFFECTS OVERALL SURVIVAL

Stauder, R; (...); De Witte, T

Meeting Abstract. 10.1016/S0145-2126(17)30135-2. 2017

Helicobacter pylori in the diagnosis, treatment and follow-up of primary immune thrombocytopenia in Spain Reply

Article. 10.1016/j.medcli.2012.11.002. 2013

Helpful Criteria When Implementing NGS Panels in Childhood Lymphoblastic Leukemia.

Vega-Garcia N; (...); Camós M

Article. 10.3390/jpm10040244. 2020

Hematologic improvements with ivosidenib plus azacitidine compared to placebo plus azacitidine in patients with newly diagnosed acute myeloid leukemia.

Dohner, Hartmut; (...); De Botton, Stephane

Meeting Abstract. 2022

Hematology oncology practice in the Asia-Pacific APHCON survey results from the 6th international hematologic malignancies conference: bridging the gap 2015, Beijing, China

Huang XJ; (...); Issaragrisil S

Article. 10.18632/oncotarget.15655. 2017

Hematopoietic stem cell transplantation for adults with acute promyelocytic leukemia in the ATRA era: a survey of the European Cooperative Group for Blood and Marrow Transplantation

Sanz, M. A.; (...); EBMT

Article. 10.1038/sj.bmt.1705620. 2007

Hematopoietic stem cell transplantation for adults with relapsed acute promyelocytic leukemia in second complete remission.

Sanz, Jaime; (...); Marrow Transplantation (EBMT)

Article. 10.1038/s41409-020-01162-0. 2020

Hematopoietic stem cell transplantation with unrelated cord blood or haploidentical donor grafts in adult patients with secondary acute myeloid leukemia, a comparative study from Eurocord and the ALWP EBMT.

Ruggeri A; (...); Nagler A

Article. 10.1038/s41409-019-0582-5. 2019

HIDDEN MDS: A PROSPECTIVE STUDY TO CONFIRM OR EXCLUDE MDS IN PATIENTS WITH ANEMIA OF UNCERTAIN ETIOLOGY

Bastida Bermejo, J. M.; (...); Diez-Campelo, M.

Meeting Abstract. 2016

Hidden myelodysplastic syndrome (MDS): A prospective study to confirm or exclude MDS in patients with anemia of uncertain etiology

Bastida, JM; (...); Diez-Campelo, M

Article. 10.1111/ijlh.12933. 2019

High Delta Np73/TAp73 ratio is associated with poor prognosis in acute promyelocytic leukemia

Lucena-Araujo AR; (...); Rego EM

Article. 10.1182/blood-2015-01-623330. 2015

High Heterogeneity of Multidrug-Resistant Enterobacteriaceae Fecal Levels in Hospitalized Patients Is Partially Driven by Intravenous $\beta$-Lactams.

Djukovic, Ana; (...); Ubeda, Carles

Article. 2020

High heterogeneity of multidrug-resistant Enterobacteriaceae fecal levels in hospitalized patients is partially driven by intravenous beta-lactams.

Djukovic A; (...); Ubeda C

Article. 10.1128/AAC.01415-19. 2020

High prognostic value of measurable residual disease detection by flow cytometry in chronic lymphocytic leukemia patients treated with front-line fludarabine, cyclophosphamide, and rituximab, followed by three years of rituximab maintenance

Garcia-Marco, JA; (...); GELLC Study Grp

Article. 10.3324/haematol.2018.204891. 2019

High-level amplification of the RUNX1 gene in two cases of childhood acute lymphoblastic leukemia

Garcia-Casado, Zaida; (...); Sanz, Miguel A.

Article. 10.1016/j.cancergencyto.2006.05.011. 2006

High-resolution melting analysis for rapid screening of BRCA1 and BRCA2 Spanish mutations

de Juan, Inmaculada; (...); Bolufer, Pascual

Article. 10.1007/s10549-008-0073-7. 2009

High-risk cytogenetic abnormalities in multiple myeloma: PETHEMA-GEM experience

Rodriguez-Otero, Paula; (...); Gutierrez, Norma

Meeting Abstract. 2023

High-risk cytogenetic abnormalities in multiple myeloma: PETHEMA-GEM experience

Gonzalez-Calle, Veronica; (...); Gutierrez, Norma C.

Article. 10.1002/hem3.70031. 2024

High-risk cytogenetics and persistent minimal residual disease by multiparameter flow cytometry predict unsustained complete response after autologous stem cell transplantation in multiple myeloma.

Paiva B; (...); PETHEMA

Article. 10.1182/blood-2011-07-370460. 2012

History of Acute Promyelocytic Leukemia.

Sanz MA, Barragán E

Article. 10.2991/chi.k.210703.001. 2021

HLA-B0777 allele differs from B0707 by a single residue in the antigen binding groove

Balas, A.; (...); Vicario, J. L.

Article. 10.1111/j.1399-0039.2009.01378.x. 2009

How to Manage Patients with Lenalidomide-Refractory Multiple Myeloma

de Arriba de la Fuente, Felipe, Montes Gaisan, Carmen, de la Rubia Comos, Javier

Review. 10.3390/cancers15010155. 2023

How we prevent and treat differentiation syndrome in patients with acute promyelocytic leukemia

Sanz MA, Montesinos P

Review. 10.1182/blood-2013-10-512640. 2014

Human dental pulp stem cells improve left ventricular function, induce angiogenesis, and reduce infarct size in rats with acute myocardial infarction.

Gandia C; (...); Ramírez P

Article. 10.1634/stemcells.2007-0484. 2008

Human Mesenchymal Stem Cells Growth and Osteogenic Differentiation on Piezoelectric Poly(vinylidene fluoride) Microsphere Substrates

Sobreiro-Almeida, R.; (...); Sempere, A.

Article. 10.3390/ijms18112391. 2017

Hypomethylating agents in relapsed and refractory AML: outcomes and their predictors in a large international patient cohort.

Stahl M; (...); Zeidan AM

Article. 10.1182/bloodadvances.2018016121. 2018

Iadademstat in Combination with Azacitidine Generates Robust and Long Lasting Responses in AML Patients (ALICE Trial)

Salamero, Olga; (...); Montesinos, Pau

Meeting Abstract. 10.1182/blood-2021-152183. 2021

Iadademstat in combination with azacitidine in patients with newly diagnosed acute myeloid leukaemia (ALICE): an open-label, phase 2a dose-finding study.

Salamero, Olga; (...); Montesinos, Pau

Article. 10.1016/S2352-3026(24)00132-7. 2024

Idasanutlin Plus Cytarabine in Relapsed or Refractory Acute Myeloid Leukemia: Results of the MIRROS Trial.

Konopleva, Marina Y.; (...); Wei, Andrew H.

Article. 10.1182/bloodadvances.2021006303. 2022

Identification of a novel BRCA1 large genomic rearrangement in a Spanish breast/ovarian cancer family.

Palanca Suela, S.; (...); Bolufer Gilabert, P.

Article. 2008

Identification of Leukemia-Associated Immunophenotypes by Databaseguided Flow Cytometry Provides a Highly Sensitive and Reproducible Strategy for the Study of Measurable Residual Disease in Acute Myeloblastic Leukemia

Pinero, Paula; (...); Tarin, Fabian

Article. 10.3390/cancers14164010. 2022

Identifying prognostic gene panels in acute myeloid leukemia.

Sanchez-Garcia, Joaquin; (...); Montesinos, Pau

Article. 10.1080/17474086.2023.2193322. 2023

IDH1-mutated relapsed or refractory AML: current challenges and future prospects

Review. 10.2147/BLCTT.S177913. 2019

IDIOPATHIC UPPER GASTROINTESTINAL BLEEDING AFTER ALLOGENEIC STEM CELL TRANSPLANTATION: AN UNPRECEDENTED COMPLICATION

Eiris, Juan; (...); Balaguer-Rosello, Aitana

Meeting Abstract. 2024

IFISTRATEGY: Spanish National Survey of Invasive Fungal Infection in Hemato-Oncologic Patients.

Vallejo, Carlos; (...); Peman, Javier

Article. 10.3390/jof9060628. 2023

IgG antibody response to pneumococcal-conjugated vaccine (Prevenar®13) in children with immunodeficiency disorders.

Garrido-Jareño M; (...); Pemán-García J

Article. 10.1007/s00430-022-00759-0. 2023

IgG subclasses quantitation: Analytical performance of The Binding Site SPA(PLUS)(R) human assay and comparison with Siemens BNII (R) assay

Sarnago, A; (...); Fuster, O

Article. 10.1016/j.clinbiochem.2017.09.004. 2018

Imipenem/Cilastatin with or without Glycopeptide as Initial Antibiotic Therapy for Recipients of Autologous Stem Cell Transplantation: Results of a Spanish Multicenter Study

de la Rubia, Javier; (...); Sanz, Miguel A.

Article. 10.1016/j.bbmt.2008.12.505. 2009

Imiquimod inhibits growth and induces differentiation of myeloid leukemia cell lines

Villamon, E; (...); Gil, ML

Article. 10.1186/s12935-018-0515-1. 2018

Immune biomarkers of survival and infection-related mortality in multiple myeloma (MM) patients treated with lenalidomide and dexamethasone (Rd)

Maia, Catarina; (...); Paiva, Bruno

Meeting Abstract. 2022

Immune Biomarkers of Survival and Severe Infection in Newly Diagnosed Multiple Myeloma (NDMM) Patients (pts) Treated with the Backbone Regimen Lenalidomide and Dexamethasone (Rd)

Maia, Catarina; (...); Paiva, Bruno

Meeting Abstract. 10.1182/blood-2022-163058. 2022

Immune reconstitution after single-unit umbilical cord blood transplantation using anti-thymoglobulin and myeloablative conditioning in adults with hematological malignancies.

Cordón L; (...); Sanz J

Article. 10.1007/s00277-024-05758-0. 2024

Immune Reconstitution Profiling Suggests Antiviral Protection After Transplantation with Omidubicel: a Phase 3 Substudy.

Szabolcs, Paul; (...); Horwitz, Mitchell E.

Article. 10.1016/j.jtct.2023.04.018. 2023

Immune status of high-risk smoldering multiple myeloma patients and its therapeutic modulation under LenDex: a longitudinal analysis

Paiva B; (...); Spanish Myeloma Group

Article. 10.1182/blood-2015-10-662320. 2016

IMMUNE THROMBOCYTOPENIA AND PREGNANCY: A SPANISH CASE SERIES OF 270 PREGNANCIES IN PRIMARY ITP.

Gonzalez-Lopez, TJ; (...); Porras, JRG

Meeting Abstract. 2017

Immune thrombotic thrombocytopenic purpura in older patients: Results from the Spanish TTP Registry (REPTT).

Gomez-Segui, I; (...); de la Rubia Comos, J

Article. 10.1111/bjh.19109. 2023

Immunogenomic identification and characterization of granulocytic myeloid-derived suppressor cells in multiple myeloma

Perez, C; (...); Programa Estudio Terapeutica Hemop

Article. 10.1182/blood.2019004537. 2020

Immunohaematological events related to changes in haematic and seric ABO group in patients undergoing haematopoietic stem cell transplantation with major ABO mismatch.

Santiago, M; (...); Solves, P

Letter. 10.1111/tme.12538. 2019

Immunohistochemical, genetic and epigenetic profiles of hereditary and triple negative breast cancers. Relevance in personalized medicine

Murria R; (...); Bolufer P

Article. 2015

Immunoparesis recovery in newly diagnosed transplant ineligible multiple myeloma patients, an independent prognostic factor that complements minimal residual disease.

Lakhwani S; (...); Hernández MT

Article. 10.1007/s00277-024-06031-0. 2024

Immunoparesis Recovery in Transplant-Ineligible Newly Diagnosis Multiple Myeloma Patients: An Independent Prognosis Factor That Could Complement Prognostic Value of Minimal Residual Disease

Lakhwani, Sunil; (...); Hernandez, Miguel-Teodoro

Meeting Abstract. 10.1182/blood-2022-166826. 2022

Immunosuppressive profiles in liquid biopsy at diagnosis predict response to neoadjuvant chemotherapy in triple-negative breast cancer

Salvador-Coloma, C; (...); de Mora, JF

Article. 10.1016/j.ejca.2020.08.020. 2020

Immunosuppressive profiles in liquid biopsy predict response to neoadjuvant chemotherapy in triple negative breast cancer

Salvador-Coloma, C; (...); Santaballa, A

Meeting Abstract. 10.1158/1538-7445.SABCS18-P3-11-16. 2019

Immunotherapy in multiple myeloma.

Asensi Cantó P, Arnao Herraiz M, de la Rubia Comos J

Article. 10.1016/j.medcli.2023.11.019. 2024

Impact of ABC single nucleotide polymorphisms upon the efficacy and toxicity of induction chemotherapy in acute myeloid leukemia

Megias-Vericat, JE; (...); Aliño SF

Article. 10.1080/10428194.2016.1231405. 2017

Impact of adjunct cytogenetic abnormalities for prognostic stratification in patients with myelodysplastic syndrome and deletion 5q

Mallo, M.; (...); Sole, F.

Article. 10.1038/leu.2010.231. 2011

Impact of allele-level HLA matching on outcomes after myeloablative single unit umbilical cord blood transplantation for hematologic malignancy

Eapen M; (...); Rocha V

Article. 10.1182/blood-2013-05-506253. 2014

IMPACT OF ALLELIC STATUS OF TP53 MUTATIONS IN ACUTE MYELOID LEUKEMIA (AML)

Ibanez, Mariam; (...); Sanz, Guillermo

Meeting Abstract. 2020

Impact of Allogeneic Hematopoietic Cell Transplantation (allo-HCT) in First Complete Remission (CR1) in Addition to FLT3 Inhibition With Quizartinib in Acute Myeloid Leukemia (AML) With FLT3-Internal Tandem Duplication (FLT3-ITD): Results from the QuANTUM-First Trial

Schlenk, Richard F.; (...); Erba, Harry P.

Meeting Abstract. 2023

Impact of Allogeneic Hematopoietic Cell Transplantation in First Complete Remission in Addition to FLT3 Inhibition with Quizartinib in Acute Myeloid Leukemia with FLT3-Internal Tandem Duplication: Results from the Quantum-First Trial

Schlenk, Richard F.; (...); Erba, Harry P.

Meeting Abstract. 10.1182/blood-2022-169011. 2022

IMPACT OF ALLO-HCT IN FIRST COMPLETE REMISSION (CR1) IN ADDITION TO FLT3 INHIBITION WITH QUIZARTINIB IN AML WITH FLT3-ITD: RESULTS FROM THE QUANTUM-FIRST TRIAL

Schlenk, Richard F.; (...); Erba, Harry P.

Meeting Abstract. 2023

Impact of Center-related Characteristics and Macroeconomic Factors on the Outcome of Adult Patients With Acute Lymphoblastic Leukemia Treated With Pediatric-inspired Protocols.

Barba P; (...); Ribera JM

Article. 10.1097/HS9.0000000000000810. 2023

Impact of combinations of single-nucleotide polymorphisms of anthracycline transporter genes upon the efficacy and toxicity of induction chemotherapy in acute myeloid leukemia.

Article. 10.1080/10428194.2020.1839650. 2020

Impact of CTLA4 genotype and other immune response gene polymorphisms on outcomes after single umbilical cord blood transplantation

Cunha R; (...); Eurocord, Cord Blood Committee Cellular Therapy–Immunobiology Working Party of t

Article. 10.1182/blood-2016-06-722249. 2017

IMPACT OF CYTOGENETIC ABNORMALITIES DEFINING AML MYELODYSPLASIA-RELATED (WHO AND ICC 2022) IN FIRST LINE DECITABINE IN UNFIT AML PATIENTS

de la Fuente, Adolfo; (...); Tormo, Mar

Meeting Abstract. 2023

IMPACT OF CYTOGENETICS ON THE OUTCOME OF ADULT ACUTE LYMPHOBLASTIC LEUKEMIA: RESULTS FROM A SINGLE INSTITUTION

Gomez, I.; (...); Sanz, M.

Article. 2009

Impact of FLT3-ITD Mutation Status and Its Ratio in a Cohort of 2901 Patients Undergoing Upfront Intensive Chemotherapy: A PETHEMA Registry Study.

Ayala, Rosa; (...); Montesinos, Pau

Article. 10.3390/cancers14235799. 2022

Impact of Gender on Molecular AML Subclasses - a Harmony Alliance Study

Matteuzzi, Tommaso; (...); Bullinger, Lars

Meeting Abstract. 10.1182/blood-2021-152215. 2021

Impact of graft-versus-host disease prophylaxis on outcomes after myeloablative single-unit umbilical cord blood transplantation.

Sanz J; (...); GETH and GITMO

Article. 10.1016/j.bbmt.2013.07.004. 2013

Impact of HLA mismatch direction on outcomes after umbilical cord blood transplantation for hematological malignant disorders: a retrospective Eurocord-EBMT analysis

Cunha R; (...); Rocha V

Article. 10.1038/bmt.2013.120. 2014

Impact of in vivo T cell depletion in HLA-identical allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission conditioned with a fludarabine iv-busulfan myeloablative regimen: a report from the EBMT Acute Leukemia Working Party

Rubio, MT; (...); Nagler, A

Article. 10.1186/s13045-016-0389-4. 2017

Impact of Leukapheresis and Time to Chemotherapy on Outcomes of Newly Diagnosed Patients (pts) with Acute Myeloid Leukemia (AML) Presenting with Hyperleukocytosis: An Analysis from a Large International Patient Cohort

Stahl, M; (...); Zeidan, AM

Meeting Abstract. 10.1182/blood-2018-99-112495. 2018

Impact of measurable residual disease by decentralized flow cytometry: a PETHEMA real-world study in 1076 patients with acute myeloid leukemia.

Paiva B; (...); PETHEMA (Programa para el Estudio de la Terapéutica en Hemopatías Malignas) coop

Article. 10.1038/s41375-021-01126-3. 2021

Impact of minimal residual disease on outcomes after umbilical cord blood transplantation for adults with Philadelphia-positive acute lymphoblastic leukaemia: an analysis on behalf of Eurocord, Cord Blood Committee and the Acute Leukaemia working party of the European group for Blood and Marrow Transplantation

Tucunduva L; (...); Rocha V

Article. 10.1111/bjh.12970. 2014

Impact of NADPH oxidase functional polymorphisms in acute myeloid leukemia induction chemotherapy

Megias-Vericat, JE; (...); Aliño SF

Article. 10.1038/tpj.2017.19. 2018

Impact of natural-killer immune reconstitution on the development of cytomegalovirus infection, non-relapse mortality, and graft versus host disease after allogeneic stem cell transplantation

Rodriguez-Veiga, R.; (...); Sanz, M. A.

Meeting Abstract. 2015

Impact of novel polymorphisms related to cytotoxicity of cytarabine in the induction treatment of acute myeloid leukemia

Megias-Vericat, JE; (...); Aliño SF

Article. 10.1097/FPC.0000000000000286. 2017

Impact of NPM1/FLT3-ITD genotypes defined by the2017 European LeukemiaNet in patients with acute myeloid leukemia.

Döhner K; (...); Bloomfield CD

Article. 10.1182/blood.2019002697. 2020

IMPACT OF POSTTRANSPLANT CYCLOPHOSPHAMIDE ON TRANSFUSION REQUIREMENTS IN HLA MATCHED SIBLING PERIPHERAL BLOOD STEM CELL TRANSPLANTATION.

Marco-Ayala, Javier; (...); Solves, Pilar

Article. 10.1016/j.jtct.2023.01.009. 2023

Impact of prior rituximab on outcomes of autologous stem-cell transplantation in patients with relapsed or refractory aggressive B-cell lymphoma: a multicentre retrospective Spanish group of lymphoma/autologous bone marrow transplant study

Redondo AM; (...); Martín A

Article. 10.1111/bjh.12676. 2014

Impact of red blood cell transfusion dose density on progression-free survival in lower-risk myelodysplastic syndromes patients.

de Swart L; (...); EUMDS Registry Participants

Article. 10.3324/haematol.2018.212217. 2020

IMPACT OF RED BLOOD CELL TRANSFUSIONS ON SURVIVAL IN LOWER-RISK MDS PATIENTS INCLUDED IN THE EUROPEAN LEUKEMIANET MDS (EUMDS) REGISTRY

de Swart, L; (...); de Witte, T

Meeting Abstract. 10.1016/S0145-2126(17)30393-4. 2017

Impact of SNP array karyotyping on the diagnosis and the outcome of chronic myelomonocytic leukemia with low risk cytogenetic features or no metaphases

Palomo L; (...); Zamora L

Article. 10.1002/ajh.24227. 2016

Impact of somatic mutations in myelodysplastic patients with isolated partial or total loss of chromosome 7.

Crisà E; (...); Mufti GJ

Article. 10.1038/s41375-020-0728-x. 2020

Impact of t(11;14) according to induction regimen in newly diagnosed transplant-eligible multiple myeloma patients: long term follow-up of GEM05MENOS65 and GEM2012 PETHEMA/GEM studies

Moreno, David; (...); Rosinol, Laura

Meeting Abstract. 2021

Impact of the Conditioning Regimen in Patients With Multiple Myeloma Who Undergo Autologous Transplantation

de la Rubia, Javier, Lahuerta, Juan J.

Article. 10.1200/JCO.2010.33.7832. 2011

IMPACT OF THE TREATMENT OF THE PURE APLASIA OF THE RED SERIES; EXPERIENCE IN A CENTER

Marco, Ayala Javier; (...); Solves, Alcaina Pilar

Meeting Abstract. 2020

Impact of transplant eligibility and availability of a human leukocyte antigen-identical matched related donor on outcome of older patients with acute lymphoblastic leukemia

Barba P; (...); Ribera JM

Article. 10.3109/10428194.2015.1014365. 2015

Impact of Transporter Genes Polymorphisms in Standard Induction of Acute Myeloid Leukemia

Meeting Abstract. 2015

Impact of treatment with iron chelation therapy in patients with lower-risk myelodysplastic syndromes participating in the European MDS registry.

Hoeks M; (...); EUMDS Registry Participants

Article. 10.3324/haematol.2018.212332. 2020

Impact of trisomy 19 on outcome according to genetic makeup in patients with acute myeloid leukemia.

Kayser, Sabine; (...); Schlenk, Richard F.

Article. 10.3324/haematol.2022.282127. 2023

Impact on Outcomes of Human Leukocyte Antigen Matching by Allele-Level Typing in Adults with Acute Myeloid Leukemia Undergoing Umbilical Cord Blood Transplantation

Sanz J; (...); Sanz GF

Article. 10.1016/j.bbmt.2013.10.016. 2014

Impact-AML: A European Master Framework for Cohort Studies and Pragmatic Clinical Trials in Relapse or Refractory Acute Myeloid Leukemia

Marconi, Giovanni; (...); Martinelli, Giovanni

Meeting Abstract. 10.1182/blood-2023-184745. 2023

IMPLEMENTATION OF DIAGNOSIS AND CENTRALIZED FOLLOW-UP BY FLOW CYTOMETRY IN ACUTE MYELOID LEUKAEMIA (AML) IN CHILDREN IN THE NOPHO-DBH-AML-2012 CLINICAL TRIAL: PRELIMINARY RESULTS

Torrebadell, M.; (...); Fernandez, J. M.

Meeting Abstract. 2019

IMPLEMENTATION OF MASSIVE SEQUENCING TECHNOLOGIES TO THE DETECTION OF MUTATIONS IN THE ABL KINASE DOMAIN OF BCR-ABL REORDERING

Simarro, CS; (...); Gonzalez, EB

Meeting Abstract. 2017

Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes (vol 26, pg 1549, 2020)

Bernard, Elsa; (...); Elias, Harold K

Article. 10.1038/s41591-021-01367-w. 2021

Implications ofTP53allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes

Bernard, E; (...); Papaemmanuil, E

Article. 10.1038/s41591-020-1008-z. 2020

Improved outcomes in allo-HCT for multiple myeloma patients with thiotepa-busulfan-fludarabine conditioning regimen and post-transplant cyclophosphamide, sirolimus and mycophenolate mofetil

de la Rubia, Javier; (...); Sanz, Miguel

Meeting Abstract. 2023

Improving acute promyelocytic leukemia (APL) outcome in developing countries through networking, results of the International Consortium on APL.

Rego EM; (...); Sanz MA

Article. 10.1182/blood-2012-08-449918. 2013

Improving the prediction of acute myeloid leukaemia outcomes by complementing mutational profiling with ex vivo chemosensitivity.

Onecha E; (...); Ayala R

Article. 10.1111/bjh.16432. 2020

In MDS, is higher risk higher reward?

Sanz GF

Article. 10.1182/hematology.2019000042. 2019

In vitro all-trans retinoic acid sensitivity of acute myeloid leukemia blasts with NUP98/RARG fusion gene

Such E; (...); Sanz MA

Letter. 10.1007/s00277-014-2073-5. 2014

In vitro cytogenetic and genotoxic effects of curcumin on human peripheral blood lymphocytes.

Sebastià N; (...); Montoro A

Article. 10.1016/j.fct.2012.06.012. 2012

In vitro cytogenetic and genotoxic effects of curcumin on human peripheral blood lymphocytes.

Sebastià, N; (...); Montoro, A.

Article. 2012

IN VIVO MODELS FOR THE FUNCTIONAL STUDY OF CO-OCCURRING GENETIC AND EPIGENETIC MUTATIONS IN MYELODYSPLASTIC SYNDROMES

Martinez-Valiente, C.; (...); Sanjuan-Pla, A.

Meeting Abstract. 2018

IN VIVO MODELS TO STUDY THE COOPERATION BETWEEN SPLICING AND DNA METHYLATION IN MYELODYSPLASTIC SYNDROMES

Martinez-Valiente, Cristina; (...); Sanjuan-Pla, Alejandra

Meeting Abstract. 2020

Incidence and characteristics of acute promyelocytic leukemia in adult patients. A single centre registry study

Montesinos, Pau; (...); Sanz, Miguel

Article. 10.1182/blood.V110.11.4301.4301. 2007

INCIDENCE AND CHARACTERISTICS OF BACTERIAL INFECTIONS DURING THE THERAPY OF INDUCTION IN PATIENTS WITH MULTIPLE MYELOMA TREATED WITH NEW DRUGS. STUDY OF 67 PATIENTS FROM A SINGLE CENTRE

Martinez Garcia, M. F.; (...); Sanz Alonso, M. A.

Meeting Abstract. 2015

INCIDENCE AND CHARACTERISTICS OF POST-TRANSPLANT ALLOGENIC LYMPHOPROLIFERATIVE SYNDROMES. EXPERIENCE OF SPANISH GROUP OF HEMATOPOIETIC TRANSPLANT (GETH)

San Segundo, LY; (...); Solano, C.

Meeting Abstract. 2017

Incidence and Management of Aplastic Anemia in Spain (IMAS). An Ambispective Study of Biodonostia / Pethema

Vallejo, C; (...); Jarque, I

Meeting Abstract. 2020

Incidence and outcome after first molecular versus overt recurrence in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia included in the ALL Ph08 trial from the Spanish PETHEMA Group

Ribera, Josep-Maria; (...); Feliu, Evarist

Article. 10.1002/cncr.32156. 2019

Incidence and outcome of invasive fungal disease after front-line intensive chemotherapy in patients with acute myeloid leukemia: impact of antifungal prophylaxis.

Rodríguez-Veiga R; (...); Sanz GF

Article. 10.1007/s00277-019-03744-5. 2019

Incidence and prognostic impact of U2AF1 mutations and other gene alterations in myelodysplastic neoplasms with isolated 20q deletion.

Castillo MI; (...); Díaz TM

Article. 10.1002/cam4.6300. 2023

Incidence and Risk Factors for Development of Cardiac Toxicity in Adult Patients with Newly Diagnosed Acute Myeloid Leukemia

Boluda, Blanca; (...); Montesinos, Pau

Article. 10.3390/cancers15082267. 2023

Incidence and risk factors of post-engraftment invasive fungal disease in adult allogeneic hematopoietic stem cell transplant recipients receiving oral azoles prophylaxis

Montesinos P; (...); Sanz MA

Article. 10.1038/bmt.2015.181. 2015

Incidence of HLA Loss in a Global Multicentric Cohort of Post-Transplantation Relapses: Results from the Hlaloss Collaborative Study

Vago, L; (...); Fleischhauer, K

Meeting Abstract. 10.1182/blood-2018-99-112142. 2018

Incidence, clinical and biological characteristics and outcome of secondary acute lymphoblastic leukemia after solid organ or hematologic malignancy

Kelleher, N; (...); Spanish Soc Hematology

Article. 10.3109/10428194.2015.1040013. 2016

Incidence, Clinical Associations, and Co-Mutation Patterns of UBA1 Mutations in MDS

Sirenko, Maria; (...); Papaemmanuil, Elli

Meeting Abstract. 10.1182/blood-2022-162397. 2022

Incidence, Diagnosis, and Outcome of Acquired Thrombotic Thrombocytopenic Purpura (aTTP): A Nationwide Survey By the Spanish Apheresis Group

Izquierdo, Maria Cristina Pascual; (...); Salinas, Ramon

Meeting Abstract. 10.1182/blood-2019-123258. 2019

Incidence, diagnosis, and outcome of immune-mediated thrombotic thrombocytopenic purpura: A nationwide survey by the Spanish registry of thrombotic thrombocytopenic purpura

Pascual-Izquierdo, C; (...); Salinas, R

Article. 10.1002/jca.21894. 2021

Incidence, risk factors and therapy response of acute graft-versus-host disease after myeloablative hematopoietic stem cell transplantation with posttransplant cyclophosphamide.

Asensi Cantó P; (...); Sanz J

Article. 10.1038/s41409-024-02391-3. 2024

Incidence, risk factors, and outcome of bacteremia following autologous hematopoietic stem cell transplantation in 720 adult patients

Pinana JL; (...); Sanz MA

Article. 10.1007/s00277-013-1872-4. 2014

Incidence, Risk Factors, and Outcome of Cytomegalovirus Infection and Disease in Patients Receiving Prophylaxis with Oral Valganciclovir or Intravenous Ganciclovir after Umbilical Cord Blood Transplantation

Montesinos, Pau; (...); Sanz, Guillermo F.

Article. 10.1016/j.bbmt.2009.03.002. 2009

Incidence, risk factors, and outcome of pulmonary invasive fungal disease after respiratory virus infection in allogeneic hematopoietic stem cell transplantation recipients

Pinana, JL; (...); Navarro, D

Article. 10.1111/tid.13158. 2019

Incidence, risk factors, and outcomes of BK hemorrhagic cystitis in hematopoietic stem cell transplantation from HLA-matched and haploidentical donors with post-transplant cyclophosphamide.

Chorao, Pedro; (...); Sanz, Jaime

Article. 10.1016/j.jtct.2024.12.006. 2024

Incidence, risk factors, and outcomes of second neoplasms in patients with acute promyelocytic leukemia: the PETHEMA-PALG experience.

Sobas, Marta; (...); Montesinos, Pau

Article. 10.1007/s00277-023-05582-y. 2023

INCORPORATION OF DARATUMUMAB IN COMBINATION TO THE THERAPEUTIC PANORAMA OF PATIENTS WITH MULTIPLE MYELOMA IN RECAIDA: RESULTS OF HABITUAL CLINICAL PRACTICE IN SPAIN. GEMINI STUDY

Rios-Tamayo, R.; (...); Mateos Manteca, M., V

Meeting Abstract. 2019

Increased survival due to lower toxicity for high-risk T-cell acute lymphoblastic leukemia patients in two consecutive pediatric-inspired PETHEMA trials

Barba, P; (...); Ribera, JM

Article. 10.1111/ejh.13178. 2019

Independent Impact of Iron Overload and Transfusion Dependency on Survival and Leukemic Evolution in Patients with Myelodysplastic Syndrome

Sanz, Guillermo; (...); Cervera, Jose

Article. 2008

In-depth analysis of responders in the phase 3 PhALLCON trial of ponatinib vs imatinib in newly diagnosed Ph plus ALL.

Jabbour, Elias; (...); Ribera-Santasusana, Jose-Maria

Meeting Abstract. https://doi.org/10.1200/JCO.2024.42.16_suppl.6533. 2024

In-depth Responder Analysis of PhALLCON, a Phase 3 Trial of Ponatinib Versus Imatinib in Newly Diagnosed Ph plus ALL

Jabbour, Elias; (...); Ribera-Santasusana, Jose-Maria

Meeting Abstract. 10.1016/S2152-2650(24)00426-9. 2024

Individualized Prophylactic Treatment with Recombinant Factor VIII in Severe or Moderate Haemophilia a Patients. Association Between Pharmacokinetic Parameters and Clinical Variables

Megias-Vericat, Juan Eduardo; (...); Bonanad, Santiago

Meeting Abstract. 10.1182/blood.V128.22.3802.3802. 2016

Indolent Acute Myeloid Leukemia with Long Survival in Patients Treated with Best Supportive Care Only: A Pethema Registry Study

Labrador, Jorge; (...); Montesinos, Pau

Meeting Abstract. 10.1182/blood-2022-162591. 2022

Infections of the Central Nervous System after Untelated Donor Umbilical Cord Blood Transplantation or Human teukocyte Antigen-Matched Sibling Transplantation

Balaguer Rosello A; (...); Sanz, J

Article. 10.1016/j.bbmt.2016.10.005. 2017

INFECTIONS OF THE CENTRAL NERVOUS SYSTEM IN THE ALOGENIC TRANSPLANTATION OF HEMATOPOYETIC PROGENITORS

Balaguer Rosello, A.; (...); Sanz Caballer, J.

Meeting Abstract. 2018

Infectious Complications after Umbilical Cord-Blood Transplantation from Unrelated Donors.

Montoro, J; (...); Sanz, J

Review. 10.4084/MJHID.2016.051. 2016

Influence of ABCB1 polymorphisms upon the effectiveness of standard treatment for acute myeloid leukemia: A systematic review and meta-analysis of observational studies

Megías-Vericat JE; (...); Aliño SF

Review. 10.1038/tpj.2014.80. 2015

Influence of age and gender on red blood cell distribution width

Alis R; (...); Vaya A

Letter. 10.1515/cclm-2014-0756. 2015

Influence of Age on Treatment with Thrombopoietin Receptor Agonists in Patients with Immune Thrombocytopenia; A Retrospective Multicenter Study

Luisa Lozano, Maria; (...); Vicente Garcia, Vicente

Meeting Abstract. 10.1182/blood-2019-122237. 2019

Influence of cytarabine metabolic pathway polymorphisms in acute myeloid leukemia induction treatment

Megias-Vericat, JE; (...); Aliño SF

Article. 10.1080/10428194.2017.1323267. 2017

Influence of genetic polymorphisms on the risk of developing leukemia and on disease progression

Bolufer, Pascual; (...); Sanz, Miguel A.

Review. 10.1016/j.leukres.2006.01.016. 2006

Influence of inflammatory and lipidic parameters on red blood cell distribution width in a healthy population

Vayá A; (...); Romagnoli M

Article. 10.3233/CH-141862. 2015

Influence of lipids on blood and plasma viscosity

Vayá A; (...); Fuster Ó

Letter. 10.3233/CH-141890. 2014

Influence of Nucleated Cell Dose on Overall Survival of Unrelated Cord Blood Transplantation for Patients with Severe Acquired Aplastic Anemia: A Study by Eurocord and the Aplastic Anemia Working Party of the European Group for Blood and Marrow Transplantation

de Latour, Regis Peffault; (...); Rocha, Vanderson

Article. 10.1016/j.bbmt.2010.06.011. 2011

Influence of polymorphisms in anthracyclines metabolism genes in the standard induction chemotherapy of acute myeloid leukemia.

Article. 10.1097/FPC.0000000000000431. 2021

Influence of Single Nucleotide Polymorphisms in Anthracycline Metabolism Pathway in Standard Induction of Acute Myeloid Leukemia

Jarque, Isidro, Angel Sanz, Miguel

Meeting Abstract. 2015

Influence on Busilvex (R) Pharmacokinetics of Clonazepam Compared to Previous Phenytoin Historical Data

Carreras, E.; (...); Vernant, J. P.

Article. 2010

Infusion of Haploidentical Stem Cell after Consolidation in Younger Patients with Acute Myeloid Leukemia: Preliminary Results of a Phase I-II Study

Boluda, Blanca; (...); Sanz, Miguel A.

Meeting Abstract. 10.1182/blood.V128.22.1614.1614. 2016

INHIBITORS OF THE MUTATED DEHYDROGENASE (MIDH), IVOSIDENIB OR ENASIDENIB, IN COMBINATION WITH AZACITINE (AZA) IN PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML)

Montesinos, P; (...); Vyas, P

Meeting Abstract. 2018

IN-SILICO AND IN VITRO STUDY OF MUTATIONS THAT ALTER THE SPLICING PROCESS IN PATIENTS WITH MYELODISPLASIC SYNDROMES

Boluda-Navarro, M.; (...); Cervera, J.

Meeting Abstract. 2019

Integrated flow cytometry and sequencing to reconstruct evolutionary patterns from dysplasia to acute myeloid leukemia.

Simoes C; (...); Paiva B

Article. 10.1182/bloodadvances.2022008141. 2023

INTENSIVE CHEMOTHERAPY VERSUS DECITABINE FIRST LINE LAM OVER 60 YEARS OLD

De la Fuente, A.; (...); Montesinos, P.

Meeting Abstract. 2019

INTERLABORATORY STUDY OF MUTATIONS DETECTION IN MYELOID NEOPLASMS THROUGH NEW GENERATION SEQUENCING

Rodriguez, CF; (...); Bellosillo, B

Meeting Abstract. 2017

Internal tandem duplication of the FLT3 gene confers poor overall survival in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline-based chemotherapy: an International Consortium on Acute Promyelocytic Leukemia study

Lucena-Araujo AR; (...); Rego EM

Article. 10.1007/s00277-014-2142-9. 2014

International Randomized Phase III Study of Elacytarabine Versus Investigator Choice in Patients With Relapsed/Refractory Acute Myeloid Leukemia

Roboz GJ; (...); Giles FJ

Article. 10.1200/JCO.2013.52.8562. 2014

Intravenous Acetaminophen for Analgesia: Back to Square One

Fuster-Lluch, O, Zapater-Hernandez, P, Geronimo-Pardo, M

Letter. 10.1002/jcph.982. 2017

Intravenous busulfan and melphalan as a conditioning regimen for autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: a matched comparison to a melphalan-only approach.

Blanes M; (...); de la Rubia J

Article. 10.1016/j.bbmt.2012.08.009. 2013

Intravenous busulfan for autologous stem cell transplantation in adult patients with acute myeloid leukemia: a survey of 952 patients on behalf of the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation

Nagler A; (...); Mohty M

Article. 10.3324/haematol.2014.105197. 2014

Intravenous busulfan plus melphalan versus melphalan alone as conditioning regimen for patients with multiple myeloma

Blanes, M; (...); de la Rubia, J

Letter. 10.1007/s00277-019-03663-5. 2019

Intravenous Busulfan-Melphalan vs Melphalan as Preparative Regimen for Newly Diagnosed Multiple Myeloma: Long-Term Follow-Up of a Case-Control Study

Blanes, M; (...); de la Rubia, J

Meeting Abstract. 10.1016/j.clml.2019.09.473. 2019

Intravenous busulphan plus melphalan versus melphalan alone as conditioning regimen for newly diagnosed patients with multiple myeloma: Long-term follow-up of a matched case-controlled study

Blanes, M; (...); de la Rubia, J

Meeting Abstract. 2019

Invasive fungal disease in patients undergoing umbilical cord blood transplantation after myeloablative conditioning regimen

Montoro, J; (...); Pinana, JL

Article. 10.1111/ejh.13202. 2019

INVASIVE FUNGAL INFECTION IN ADULT PATIENTS SUBMITTED TO UMBILICAL CORD BLOOD TRANSPLANTATION

Montoro, J.; (...); Pinana, J. L.

Meeting Abstract. 2018

Invasive mould disease in haematological patients

Ruiz-Camps, I, Jarque, I

Review. 10.1016/j.riam.2014.06.002. 2014

Invasive yeast infections in neutropenic patients

Camps, IR, Jarque, I

Review. 10.1016/j.riam.2015.11.001. 2016

Investigation of HLA loss relapse after allogeneic stem cell transplantation in a global multicentric cohort (HLALOSS Consortium)

Fleischhauer, K; (...); Vago, L

Meeting Abstract. 2018

Iron overload and chelation therapy in patients with low-risk myelodysplastic syndromes with transfusion requirements

Remacha, Angel F.; (...); Villegas, Ana

Article. 10.1007/s00277-009-0794-7. 2010

Is erythrocyte sedimentation rate a useful inflammatory marker independently of the hematocrit? Comparison results with plasma viscosity

Fuster O; (...); Laiz B

Letter. 10.3233/CH-141864. 2014

Isatuximab plus carfilzomib and dexamethasone in patients with relapsed multiple myeloma according to prior lines of treatment and refractory status: IKEMA subgroup analysis.

Hajek, Roman; (...); Dimopoulos, Meletios A.

Meeting Abstract. 10.1200/JCO.2021.39.15_suppl.8034. 2021

Isatuximab plus carfilzomib and dexamethasone in patients with relapsed multiple myeloma based on prior lines of treatment and refractory status: IKEMA subgroup analysis.

Dimopoulos, Meletios A.; (...); Hajek, Roman

Article. 10.1002/ajh.26602. 2022

Isohaemagglutinin production after minor ABO incompatible umbilical cord blood transplantation

Solves, P; (...); Sanz, MA

Letter. 10.1111/tme.12386. 2017

Isolated and Dynamic Peripheral Blood Residual Disease Status Characterized By Mass Spectrometry Predicts Outcome in Patients with High Risk Smoldering Multiple Myeloma Treated in the GEM-CESAR Trial

Puig, Noemi; (...); Victoria Mateos, Maria

Meeting Abstract. 10.1182/blood-2023-182964. 2023

ITHACA, a randomized multicenter phase 3 study of Isatuximab in combination with Lenalidomide and Dexamethasone in high-risk smoldering Multiple Myeloma: safety run-in preliminary results

Ghobrial, Irene; (...); Mateos, Maria-Victoria

Meeting Abstract. 2021

Ivosidenib and Azacitidine in IDH1-Mutated Acute Myeloid Leukemia.

Montesinos, Pau; (...); Dohner, Hartmut

Article. 10.1056/NEJMoa2117344. 2022

Ivosidenib and Azacitidine in IDH1-Mutated AML. Reply.

Montesinos, Pau, de Botton, Stephane, Dohner, Hartmut

Letter. 10.1056/NEJMc2206489. 2022

Ivosidenib plus Azacitidine vs Placebo plus Azacitidine in Patients With Newly-Diagnosed Acute Myeloid Leukemia: Updated Long-term Efficacy and Safety Results From the AGILE Study

de Botton, Stephane; (...); Doehner, Hartmut

Meeting Abstract. 2023

Ixazomib Plus Lenalidomide/Dexamethasone (IRd) Versus Lenalidomide /Dexamethasone (Rd) Maintenance after Autologous Stem Cell Transplant in Patients with Newly Diagnosed Multiple Myeloma: Results of the Spanish GEM2014MAIN Trial

Rosinol, Laura; (...); Blade Creixenti, Joan

Meeting Abstract. 10.1182/blood-2021-146798. 2021

JUVENILE MYELOMONOCITIC LEUKEMIA IN PATIENTS WITH NOONAN SYNDROME AND NOONAN-LIKE SYNDROMES: EXPERIENCE OF THE SPANISH YOUTH MYELOMONOCITIC LEUKEMIA REGISTRATION

Arques Martinez, L.; (...); Catala Temprano, A.

Meeting Abstract. 2019

Karyotypic complexity rather than chromosome 8 abnormalities aggravates the outcome of chronic lymphocytic leukemia patients with TP53 aberrations

Blanco, G; (...); Espinet, B

Article. 10.18632/oncotarget.13106. 2016

Killer Cell Immunoglobulin-Like Receptor Ligand Matching and Outcomes after Unrelated Cord Blood Transplantation in Acute Myeloid Leukemia

Rocha, V; (...); Ctr Int Blood Marrow Transplant Re

Article. 10.1016/j.bbmt.2016.04.007. 2016

Kinetics of Complete Remission (CR) and CR Duration and Its Impact on Overall Survival (OS) and Event-Free Survival (EFS) in Quantum-First

Montesinos, Pau; (...); Dombret, Herve

Meeting Abstract. 10.1182/blood-2023-187286. 2023

KIR-ligand incompatibility in the graft-versus-host direction improves outcomes after umbilical cord blood transplantation for acute leukemia

Willemze, R.; (...); Rocha, V.

Article. 10.1038/leu.2008.365. 2009

KIR-ligand incompatibility in the graft-versus-host direction improves outcomes after umbilical cord blood transplantation for acute leukemia (vol 23, pg 492, 2009)

Willemze, R.; (...); Rocha, V.

Correction. 10.1038/leu.2009.11. 2009

K-Means Clustering Identifies Diverse Clinical Phenotypes in COVID-19 Patients: Implications for Mortality Risks and Remdesivir Impact.

Garcia-Vidal C; (...); Soriano A

Article. 10.1007/s40121-024-00938-x. 2024

Lack of negative impact of Philadelphia chromosome in older patients with acute lymphoblastic leukaemia in the thyrosine kinase inhibitor era: comparison of two prospective parallel protocols.

Ribera JM; (...); PETHEMA Group

Letter. 10.1111/bjh.12043. 2012

Lack of RPS14 promoter aberrant methylation supports the haploinsufficiency model for the 5q-syndrome

Valencia, Ana; (...); Sanz, Guillermo F.

Letter. 10.1182/blood-2008-05-159707. 2008

ladademstat Combination with Azacitidine Is a Safe and Effective Treatment in First Line Acute Myeloid Leukemia. Final Results of the Alice Trial

Salamero, Olga; (...); Montesinos, Pau

Meeting Abstract. 10.1182/blood-2022-168945. 2022

LAG3 genotype of the donor and clinical outcome after allogeneic transplantation from HLA-identical sibling donors.

Cruz, David; (...); Gallardo, David

Article. 10.3389/fimmu.2023.1066393. 2023

Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Myeloma

Benboubker L; (...); FIRST Trial Team

Article. 10.1056/NEJMoa1402551. 2014

Lenalidomide and dexamethasone maintenance with or without ixazomib, tailored by residual disease status in myeloma.

Rosinol, Laura; (...); Blade, Joan

Article. 10.1182/blood.2022019531. 2023

LENALIDOMIDE IN COMBINATION WITH R-ESHAP IN PATIENTS WITH DIFFUSE LARGE B CELL LYMPHOMAS (DLBCL) REFRACTORY OR IN RELAPSE: STUDY PHASE 2 OF THE GELTAMO SPANISH GROUP

Baile, M.; (...); Martin, A. A.

Meeting Abstract. 2017

Lenalidomide in combination with R-ESHAP in patients with relapsed or refractory diffuse large B-cell lymphoma: A phase 2 study from GELTAMO.

Martin Garcia-Sancho, A.; (...); Caballero, D.

Article. 10.1111/bjh.18989. 2023

Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma.

Mateos MV; (...); San Miguel JF

Article. 10.1056/NEJMoa1300439. 2013

Lenalidomide plus dexamethasone versus observation in patients with high-risk smouldering multiple myeloma (QuiRedex): long-term follow-up of a randomised, controlled, phase 3 trial

Mateos, MV; (...); Miguel, JFS

Article. 10.1016/S1470-2045(16)30124-3. 2016

Lineage switch from B lymphoblastic leukemia with KMT2A-rearranged to mixed-phenotype acute leukemia under daratumumab

Marco-Ayala, J; (...); Peris, MLS

Editorial Material. 10.5045/br.2020.2020059. 2020

Live donor kidney transplantation. Situation analysis and roadmap.

de la Oliva Valentín M; (...); Domínguez-Gil B

Article. 10.1016/j.nefroe.2022.02.002. 2022

Long Term Discontinuation of Eltrombopag after Remission in Primary Immune Thrombocytopenia: 8-Year Follow-up Data from 15 Spanish Centers

Jose Gonzalez-Lopez, Tomas; (...); Sanz, Miguel A.

Meeting Abstract. 10.1182/blood-2019-129274. 2019

Long Term Survival Analysis of Multiple Myeloma Patients Receiving Induction Therapy plus Autologous STEM CELL Trasplantation, Comparing Velcade-Dexametasone to Alkylating Polichemotherapy As Induction Therapy

Caceres, S; (...); Burgues, JMMB

Meeting Abstract. 10.1182/blood-2018-99-116924. 2018

Longitudinal outcome over four decades of allogeneic stem cell transplantation: a single center experience.

Sanz, Miguel Angel; (...); Sanz, Jaime

Article. 10.1038/s41409-024-02319-x. 2024

Longitudinal outcomes of obeticholic acid therapy in ursodiol-nonresponsive primary biliary cholangitis: Stratifying the impact of add-on fibrates in real-world practice.

Gomez, E; (...); Fernandez-Rodriguez, C M

Article. 10.1111/apt.18004. 2024

Long-term management of chronic immune thrombocytopenic purpura in adults.

Palau, Javier, Jarque, Isidro, Sanz, Miguel A

Article. 10.2147/IJGM.S4722. 2010

Long-term outcome of older patients with newly diagnosed de novo acute promyelocytic leukemia treated with ATRA plus anthracycline-based therapy

Martínez-Cuadrón D; (...); Sanz MA

Article. 10.1038/leu.2017.178. 2018

Long-Term Outcomes After Autologous Versus Allogeneic Stem Cell Transplantation in Molecularly-Stratified Patients With Intermediate Cytogenetic Risk Acute Myeloid Leukemia: A PETHEMA Study

Rodriguez-Arboli, E; (...); GETH Grp Espanol Trasplante Hemato

Article. 10.1016/j.jtct.2020.12.029. 2021

Long-term prognostic significance of response in multiple myeloma after stem cell transplantation

Martinez-Lopez, Joaquin; (...); Jose Lahuerta, Juan

Article. 10.1182/blood-2011-01-332320. 2011

Long-term survival after intensive chemotherapy or hypomethylating agents in AML patients aged 70 years and older: a large patient data set study from European registries.

Recher, Christian; (...); Montesinos, Pau

Article. 10.1038/s41375-021-01425-9. 2022

Long-term survival with oral azacitidine for patients with acute myeloid leukemia in first remission after chemotherapy: updated results from the randomized, placebo-controlled, phase 3 QUAZAR AML-001 trial.

Wei, Andrew H.; (...); Roboz, Gail J.

Letter. 10.1002/ajh.26847. 2023

Los aspectos epidemiológicos cambiantes de la candidemia y sus implicaciones clinicoterapéuticas

Salavert M, Jarque I, Pemán J

Article. 2006

Los elementos decorativos ambientales en el Area de Imagen Medica mejoran la percepcion de agradabilidad del paciente.

Garcia Marcos R; (...); Diaz Dho R

Abstract of Published Item. 10.1016/j.rx.2012.07.006. 2014

Low penetrance alleles as risk modifiers in familial and sporadic breast cancer

Esteban Cardenosa, Eva; (...); Bolufer Gilabert, Pascual

Article. 10.1007/s10689-012-9563-1. 2012

Low-Dose Cytarabine With or Without Glasdegib in Newly Diagnosed Patients with Acute Myeloid Leukemia: Long-Term Analysis of a Phase 2 Randomized Trial

Papayannidis, C; (...); Cortes, JE

Meeting Abstract. 10.1016/j.clml.2019.07.111. 2019

Low-dose cytarabine with or without glasdegib in newly diagnosed patients with acute myeloid leukemia: Long-term analysis of a phase 2 randomized trial.

Smith, BD; (...); Cortes, JE

Meeting Abstract. 2019

Lymphocyte Subpopulations in Community-Acquired Pneumonia: Role of Cell-Mediated Immunity

Mendez, R; (...); Menendez, R

Meeting Abstract. 2018

Lymphoid and myeloid immune cell reconstitution after nicotinamide-expanded cord blood transplantation

de Koning, Coco; (...); Nierkens, Stefan

Article. 10.1038/s41409-021-01417-4. 2021

LYMPHOPENIA IS HIGHLY PREVALENT IN MDS AND PROVIDES ADDITIONAL PROGNOSTIC INFORMATION FOR IPSS-R VERY-LOW AND LOW-RISK PATIENTS. AN ANALYSIS FROM THE EU-MDS REGISTRY

Silzle, T.; (...); Smith, A.

Meeting Abstract. 2021

Lymphopenia is highly prevalent in MDS and provides prognostic information for IPSS-R (very)-low-risk patients. An analysis from the EU-MDS registry

Silzle, T.; (...); Smith, A.

Meeting Abstract. 2021

Lymphopenic community-acquired pneumonia is associated with a dysregulated immune response and increased severity and mortality

Mendez, R; (...); Torres, A

Article. 10.1016/j.jinf.2019.04.006. 2019

Machine Learning Allows the Identification of New Co-Mutational Patterns with Prognostic Implications in NPM1 Mutated AML - Results of the European Harmony Alliance

Hernandez Sanchez, Alberto; (...); Bullinger, Lars

Meeting Abstract. 10.1182/blood-2022-167138. 2022

Machine Learning Provides Individualized Prediction of Outcomes after First Complete Remission in Adult AML Patients - Results from the Harmony Platform

Hernandez Sanchez, Alberto; (...); Bullinger, Lars

Meeting Abstract. 10.1182/blood-2023-183029. 2023

Magrolimab plus azacitidine vs physician's choice for untreated TP53-mutated acute myeloid leukemia: the ENHANCE-2 study.

Zeidner, Joshua F; (...); Vyas, Paresh

Article. 10.1182/blood.2024027408. 2025

Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet

Sanz, Miguel A.; (...); Lo-Coco, Francesco

Review. 10.1182/blood-2008-04-150250. 2009

Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet

Sanz, MA; (...); Lo-Coco, F

Article. 10.1182/blood-2019-01-894980. 2019

Management of adult patients with CMML undergoing allo-HCT: recommendations from the EBMT PH&G Committee.

Onida F; (...); Pleyer L

Article. 10.1182/blood.2023023476. 2024

Management of Adult Patients with Primary Immune Thrombocytopenia (ITP) in Clinical Practice: A Consensus Approach of the Spanish ITP Expert Group.

Mingot-Castellano ME; (...); González Porras JR

Article. 10.1155/2019/4621416. 2019

Management of adverse events in patients with acute myeloid leukemia in remission receiving oral azacitidine: experience from the phase 3 randomized QUAZAR AML-001 trial

Ravandi, F; (...); Dombret, H

Article. 10.1186/s13045-021-01142-x. 2021

Management of chronic liver disease-associated severe thrombocytopenia in Spain: a view from the experts

Calleja-Panero, JL; (...); Gil, A

Article. 10.17235/reed.2020.6895/2020. 2020

Management of hyperleukocytosis and impact of leukapheresis among patients with acute myeloid leukemia (AML) on short- and long-term clinical outcomes: a large, retrospective, multicenter, international study.

Stahl M; (...); Zeidan AM

Article. 10.1038/s41375-020-0783-3. 2020

Management of MDS with Isolated Del(5q) Patients in the European MDS (EUMDS) Registry, a Unique Prospective Real-World Dataset

Bowen, David; (...); de Witte, Theo M.

Meeting Abstract. 10.1182/blood-2021-150322. 2021

Management of MDS with Isolated Del(5q) Patients in the European MDS (EUMDS) Registry: A Report on 197 Cases

Smoljanovic, Inga Mandac; (...); Bowen, David

Meeting Abstract. 10.1182/blood-2022-167716. 2022

Managing hematological cancer patients during the COVID-19 pandemic: an ESMO-EHA Interdisciplinary Expert Consensus.

Buske C; (...); Passamonti F

Article. 10.1016/j.esmoop.2022.100403. 2022

MASS SEQUENCING DIRECTED TO THE STUDY OF REARRANGEMENTS AND CHANGES IN GENIC EXPRESSION IN ACUTE MYELOID LEUKEMIA

Sargas Simarro, C.; (...); Barragan Gonzalez, E.

Meeting Abstract. 2019

Mass spectrometry vs immunofixation for treatment monitoring in multiple myeloma.

Puig, Noemi; (...); Mateos, Maria-Victoria

Article. 10.1182/bloodadvances.2021006762. 2022

Maternal and fetal outcomes in pregnant women with acute promyelocytic leukemia

Sanz MA; (...); Perales A

Article. 10.1007/s00277-015-2372-5. 2015

MDS Diagnosis: Many Patients May Not Require Bone Marrow Examination

Oster, HS; (...); Mittelman, M

Meeting Abstract. 10.1182/blood-2018-99-111838. 2018

Measurable Residual Disease Assessed by Flow-Cytometry Is a Stable Prognostic Factor for Pediatric T-Cell Acute Lymphoblastic Leukemia in Consecutive SEHOP Protocols Whereas the Impact of Oncogenetics Depends on Treatment.

Vega-García N; (...); Camós M

Article. 10.3389/fped.2020.614521. 2021

Measurable Residual Disease by Next-Generation Flow Cytometry in Multiple Myeloma.

Paiva B; (...); GEM (Grupo Español de Mieloma)

Article. 10.1200/JCO.19.01231. 2020

Measurable residual disease in elderly acute myeloid leukemia: results from the PETHEMA-FLUGAZA phase 3 clinical trial.

Simoes C; (...); Montesinos P

Article. 10.1182/bloodadvances.2020003195. 2021

Methylation of tumor suppressor genes is related with copy number aberrations in breast cancer

Murria R; (...); Bolufer P

Article. 2015

Micafungin in invasive candidiasis among oncohematological patients

Article. 10.1016/S1130-1406(09)70013-0. 2009

MicroRNA signatures in hereditary breast cancer

Murria Estal, Rosa; (...); Bolufer Gilabert, Pascual

Article. 10.1007/s10549-013-2723-7. 2013

Midostaurin in patients with acute myeloid leukemia and FLT3-TKD mutations: a subanalysis from the RATIFY trial.

Voso MT; (...); Lo-Coco F

Article. 10.1182/bloodadvances.2020002904. 2020

Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation

Stone, RM; (...); Döhner H

Article. 10.1056/NEJMoa1614359. 2017

Midostaurin plus daunorubicin or idarubicin for young and older adults with FLT3-mutated AML: a phase 3b trial

Sierra, Jorge; (...); Venditti, Adriano

Article. 10.1182/bloodadvances.2023009847. 2023

Midostaurin reduces relapse in FLT3-mutant acute myeloid leukemia: the Alliance CALGB 10603/RATIFY trial.

Larson RA; (...); Stone RM

Article. 10.1038/s41375-021-01179-4. 2021

Minimal Residual Disease Detection By Single Cell DNA Sequencing Technology: A Feasible Approach for Clinical Application and Identification of the Landscape of MRD Clones

Alfonso Pierola, Ana; (...); Prosper, Felipe

Meeting Abstract. 10.1182/blood-2023-188865. 2023

Minimal residual disease detection in acute myeloid leukemia by mutant nucleophosmin (NPM1): Comparison with WT1 gene expression

Barragan, Eva; (...); Bolufer, Pascual

Article. 10.1016/j.cca.2008.05.021. 2008

Minimal residual disease evaluation by flow cytometry is a complementary tool to cytogenetics for treatment decisions in acute myeloid leukaemia

Vidriales, MB; (...); PETHEMA Programa Estudio Terapeuti

Article. 10.1016/j.leukres.2015.10.002. 2016

Minimal residual disease monitoring and immune profiling in multiple myeloma in elderly patients

Paiva B; (...); Grupo Español de Mieloma

Article. 10.1182/blood-2016-03-705319. 2016

MIRROS: a randomized, placebo-controlled, Phase III trial of cytarabine +/- idasanutlin in relapsed or refractory acute myeloid leukemia

Montesinos, P; (...); Fenaux, P

Article. 10.2217/fon-2020-0044. 2020

MIRROS: An ongoing randomized phase 3 trial of idasanutlin plus ARA-C in patients with relapsed or refractory acute myeloid leukemia.

Montesinos, P; (...); Fenaux, P

Meeting Abstract. 2019

MLL amplification in acute myeloid leukemia

Pajuelo-Gamez, Juan C.; (...); Sanz, Miguel A.

Article. 10.1016/j.cancergencyto.2006.11.019. 2007

MODELING OF IDH2 GENE MUTATIONS IN THE CAENORHABDITIS ELEGANS ORGANISM. DEVELOPMENT OF A NEW STUDY MODEL

Gonzalez-Romero, E.; (...); Cervera-Zamora, J.

Meeting Abstract. 2021

Modern Approaches to Treating Acute Promyelocytic Leukemia

Sanz, Miguel A., Lo-Coco, Francesco

Review. 10.1200/JCO.2010.32.1067. 2011

Molecular and clinical presentation of UBA1-mutated myelodysplastic syndromes.

Sirenko, Maria; (...); Papaemmanuil, Elli

Article. 10.1182/blood.2023023723. 2024

MOLECULAR APPROACH TO CHRONIC LYMPHOPROLIFERATIVE SYNDROMES IN THE DAILY CLINICAL PRACTICE OF A SINGLE CENTER

Mariam, Ibanez; (...); Irene, Luna

Meeting Abstract. 2021

Molecular Characteristics of Response to Olutasidenib (FT-2102) in Patients with Relapsed/Refractory mIDH(1) Acute Myeloid Leukemia

De Botton, Stephane; (...); Fenaux, Pierre

Meeting Abstract. 10.1182/blood-2021-144912. 2021

MOLECULAR CHARACTERIZATION OF ACUTE LEUKAEMIA OF CHILD, ADOLESCENT AND YOUNG ADULT THROUGH MASSIVE GUIDED SEQUENCING

Llop Garcia, M.; (...); Barragan Gonzalez, E.

Meeting Abstract. 2019

MOLECULAR CHARACTERIZATION OF CELLULAR MODELS OF ACUTE MYELOBLASTIC LEUKEMIA (AML) BY MASS SEQUENCING

Navarro, MB; (...); Cervera, J

Meeting Abstract. 2017

Molecular Characterization of Clinical Response and Relapse in Patients with IDH1m ND-AML Treated with Ivo plus AZA in the AGILE Study

Doehner, Hartmut; (...); De Botton, Stephane

Meeting Abstract. 10.1182/blood-2022-159473. 2022

Molecular characterization of clinical response in patients with newly diagnosed acute myeloid leukemia treated with ivosidenib plus azacitidine compared to placebo plus azacitidine.

De Botton, Stephane; (...); Dohner, Hartmut

Meeting Abstract. 2022

MOLECULAR CHARACTERIZATION OF MULTIPLE MYELOMA PATIENTS BY USING A SINGLE ENRICHMENT PANEL IDENTIFYING SNVS, INDELS, CNVS AND TRANSLOCATIONS

Juan Manuel, Rosa-Rosa; (...); Joaquin, Martinez-Lopez

Meeting Abstract. 2021

MOLECULAR CHARACTERIZATION OF PATIENTS WITH HEREDITARY MYELOID NEOPLASIAS THROUGH MASS SEQUENCING

Pardo-Lorente, N.; (...); Cervera, J.

Meeting Abstract. 2018

MOLECULAR CHARACTERIZATION OF VARIANTS THAT ALTER SPLICING (VAS) IN PATIENTS WITH MYELODYSPLASIC SYNDROMES

Boluda-Navarro, M.; (...); Cervera, J.

Meeting Abstract. 2020

Molecular detection of Spanish delta beta-thalassemia associated with beta-thalassemia identified during prenatal diagnosis

Barragan, E; (...); Sanz, MA

Article. 10.1016/j.cca.2005.12.041. 2006

Molecular landscape and prognostic impact of FLT3-ITD insertion site in acute myeloid leukemia: RATIFY study results

Rücker FG; (...); Doehner, Konstanze

Article. 10.1038/s41375-021-01323-0. 2021

Molecular Landscape and Validation of New Genomic Classification in 2668 Adult AML Patients: Real Life Data from the PETHEMA Registry.

Sargas, Claudia; (...); On Behalf Of Pethema Group

Article. 10.3390/cancers15020438. 2023

Molecular profiling refines minimal residual disease-based prognostic assessment in adults with Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia.

Ribera J; (...); Ribera JM

Article. 10.1002/gcc.22788. 2019

Molecular remission as a therapeutic objective in acute promyelocytic leukemia

Cicconi, L; (...); Lo-Coco, F

Review. 10.1038/s41375-018-0219-5. 2018

Molecular Taxonomy of Myelodysplastic Syndromes and Its Clinical Implications

Bernard, Elsa; (...); Papaemmanuil, Elli

Meeting Abstract. 10.1182/blood-2023-186863. 2023

Molecular Taxonomy of Myelodysplastic Syndromes and its Clinical Implications.

Bernard, Elsa; (...); Papaemmanuil, Elli

Article. 10.1182/blood.2023023727. 2024

MONITORING MINIMUM RESIDUAL DISEASE (EMR) THROUGH NGS CONFIRMS PROGNOSTIC VALUE

De La Fuente, EO; (...); Diaz, RA

Meeting Abstract. 2018

Monosomal karyotype in MDS: explaining the poor prognosis?

Schanz J; (...); Haase D

Article. 10.1038/leu.2013.187. 2013

Morbidity and transplant-related mortality of CBV and BEAM preparative regimens for patients with lymphoid malignancies undergoing autologous stem-cell transplantation

Puig, Noemi; (...); Sanz, Miguel A.

Article. 10.1080/10428190500527769. 2006

MRD ANALYSIS BY NEXT-GENERATION SEQUENCING APPROACH FOR ACUTE MYELOID LEUKEMIA FOLLOW-UP

De la Fuente, EO; (...); Ayala, R

Meeting Abstract. 2017

MRS as endogenous molecular imaging for brain and prostate tumors: FP6 project "eTUMOR".

Celda B; (...); Cervera J

Article. 2006

MTHFR and VDR Polymorphisms Improve the Prognostic Value of MYCN Status on Overall Survival in Neuroblastoma Patients

Olivera, GG; (...); Herrero, MJ

Article. 10.3390/ijms21082714. 2020

Multicenter Long-Term Follow-Up of Allogeneic Hematopoietic Cell Transplantation with Omidubicel: A Pooled Analysis of Five Prospective Clinical Trials.

Lin, Chenyu; (...); Horwitz, Mitchell E.

Article. 10.1016/j.jtct.2023.01.031. 2023

Multicenter, Open-Label, 3-Arm Study of Gilteritinib, Gilteritinib Plus Azacitidine, or Azacitidine Alone in Newly Diagnosed FLT3 Mutated (FLT3(mut+)) Acute Myeloid Leukemia (AML) Patients Ineligible for Intensive Induction Chemotherapy: Findings from the Safety Cohort

Esteve, J; (...); Bahceci, E

Meeting Abstract. 10.1182/blood-2018-99-110976. 2018

Multicentre Implementation of Next Generation Sequencing to Acute Myeloid Leukemia Patients in PETHEMA Spanish Collaborative Group

Sargas, C; (...); Barragan, E

Meeting Abstract. 2019

Multidimensional assessment of patient condition and mutational analysis in peripheral blood, as tools to improve outcome prediction in myelodysplastic syndromes: A prospective study of the Spanish MDS group

Ramos, F; (...); Spanish Group for Myelodysplastic Syndromes (GESMD)

Article. 10.1002/ajh.24813. 2017

Multidisciplinary approach to the treatment of invasive fungal infections in adult patients. Prophylaxis; empirical; preemptive or targeted therapy; which is the best in the different hosts?

Zaragoza R; (...); Cantón E.

Article. 2008

Multiomics Characterization of Normal CD34+Hematopoietic Progenitor Cells (HPC) and Blasts in the Bone Marrow (BM) and Peripheral Blood (PB) of Patients with Acute Myeloid Leukemia (AML)

Simoes, Catia; (...); Paiva, Bruno

Meeting Abstract. 10.1182/blood-2023-185760. 2023

Multiparameter flow cytometry evaluation of plasma cell DNA content and proliferation in 595 transplant-eligible patients with myeloma included in the Spanish GEM2000 and GEM2005<65y trials.

Paiva B; (...); San Miguel JF

Article. 10.1016/j.ajpath.2012.07.020. 2012

Multiple Congenital Anomalies-Hypotonia-Seizures Syndrome 2 Caused by a Novel PIGA Variant Not Associated with a Skewed X-Inactivation Pattern

Gabaldon-Albero, Alba; (...); Martinez, Francisco

Article. 10.3390/genes15060802. 2024

Multiple phenotypes and epigenetic profiles in a three-generation family history with GATA2 deficiency.

Romero-Moya, Damia; (...); Giorgetti, Alessandra

Article. 10.1038/s41375-025-02519-4. 2025

Multivariable Time-Dependent Analysis Of The Impact Of 5 Azacitidine In Patients With Lower-Risk Myelodysplastic Syndrome and Unfavorable Specific Lower-Risk Score

Falantes, Jose F.; (...); Sanz, Guillermo

Article. 10.1182/blood.V122.21.2754.2754. 2013

Multivariable time-dependent analysis of the impact of azacitidine in patients with lower-risk myelodysplastic syndrome and unfavorable specific lower-risk score

Falantes J; (...); Sanz G

Article. 10.1016/j.leukres.2014.10.004. 2015

Multivariate time-dependent comparison of the impact of lenalidomide in lower-risk myelodysplastic syndromes with chromosome 5q deletion

Sánchez-García J; (...); Sanz GF

Article. 10.1111/bjh.12876. 2014

Mutant IDH (mIDH) inhibitors, ivosidenib or enasidenib, with azacitidine (AZA) in patients with acute myeloid leukemia (AML).

Dinardo, CD; (...); Vyas, P

Meeting Abstract. 10.1200/JCO.2018.36.15_suppl.7042. 2018

MUTATIONAL PROFILE IN PATIENTS DIAGNOSED WITH LOW-RISK SMD WITHOUT THE RINGED SIDEROBLASTS

Abaigar, M; (...); Campelo, MD

Meeting Abstract. 2018

Mutational profile of ZBTB16-RARA-positive acute myeloid leukemia

Fabiani E; (...); Voso MT

Article. 10.1002/cam4.3904. 2021

MUTATIONS IN BCR-ABL1 IN PATIENTS WITH PH LEUKAEMIAS. CORRELATION WITH CLINICAL DATA

Sanchez Perez, R.; (...); Martinez-Lopez, J.

Meeting Abstract. 2019

Mutations in the DNA methylation pathway and number of driver mutations predict response to azacitidine in myelodysplastic syndromes

Cedena, MT; (...); Martinez-Lopez, J

Article. 10.18632/oncotarget.22157. 2017

Mutations in TP53 and JAK2 are independent prognostic biomarkers in B-cell precursor acute lymphoblastic leukaemia

Forero-Castro, M; (...); Hernandez-Rivas, JM

Article. 10.1038/bjc.2017.152. 2017

Myeloablative cord blood transplantation in adults with acute leukemia: comparison of two different transplant platforms.

Sanz J; (...); Brunstein C

Article. 10.1016/j.bbmt.2013.09.015. 2013

Myelodysplastic syndromes with 20q deletion: incidence, prognostic value and impact on response to azacitidine of ASXL1 chromosomal deletion and genetic mutations

Martin, I; (...); Tormo, M

Article. 10.1111/bjh.17675. 2021

Myelodysplastic syndromes: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Fenaux P; (...); ESMO Guidelines Working Group

Article. 10.1093/annonc/mdu180. 2014

Myelodysplastic syndromes: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Fenaux, P; (...); ESMO Guidelines Comm

Article. 10.1016/j.annonc.2020.11.002. 2021

NATIONAL EXPERIENCE WITH THE USE OF VENETOCLAX IN PATIENTS WITH RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA

Labrador, J.; (...); Montesinos, P.

Meeting Abstract. 2020

National Survey on the Use of Mobile Applications in Patients with Hemophilia and Other Coagulopathies

Eduardo Megias, Juan; (...); Poveda Andres, Jose Luis

Meeting Abstract. 10.1182/blood-2022-169938. 2022

NEDD9, an independent good prognostic factor in intermediate-risk acute myeloid leukemia patients

Pallares, V; (...); Mangues, R

Article. 10.18632/oncotarget.18537. 2017

Negative impact on clinical outcome of the mutational co-occurrence of SF3B1 and DNMT3A in refractory anemia with ring sideroblasts (RARS)

Martin, I; (...); Sanz, G

Article. 10.1080/10428194.2016.1246725. 2017

Networking for advanced molecular diagnosis in acute myeloid leukemia patients is possible: the PETHEMA NGS-AML project.

Sargas C; (...); Montesinos P

Article. 10.3324/haematol.2020.263806. 2021

NEUROLOGIC COMPLICATIONS AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION WITH CALCINEURIN-FREE GRAFT-VERSUS-HOST DISEASE PROPHYLAXIS

Balaguer Rosello, Aitana; (...); Sanz, Jaime

Meeting Abstract. 2023

NEUTROPHILIA AND ONCOGENE CSF3R MUTATION

Segarra, MG; (...); Alonso, MAS

Meeting Abstract. 2017

New Cases and Mutations in SEC23B Gene Causing Congenital Dyserythropoietic Anemia Type II.

Musri, Melina Mara; (...); Sanchez, Mayka

Article. 10.3390/ijms24129935. 2023

New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge.

Schanz J; (...); Haase D

Article. 10.1200/JCO.2011.35.6394. 2012

New challenges of advanced therapies.

Megías-Vericat JE; (...); Poveda Andrés JL

Article. 10.1016/j.farma.2023.11.008. 2024

NEW MODEL TO QUANTIFY THE IN VITRO PHARMACOLOGICAL ACTIVITY OF BI-SPECIFIC ANTIBODIES IN HAEMATOLOGIC MALIGNANCIES

Primo, D.; (...); Ballesteros, J.

Meeting Abstract. 2017

New mutations found by Next-Generation Sequencing screening of Spanish patients with Nemaline Myopathy

Moreau-Le Lan, S; (...); Pedrola, L

Article. 10.1371/journal.pone.0207296. 2018

Next generation sequencing in bleeding disorders: two novel variants in the F5 gene (Valencia-1 and Valencia-2) associated with mild factor V deficiency.

Moret, A; (...); Bonanad, S

Article. 10.1007/s11239-019-01911-z. 2019

NGS ANALYSIS AND IMPACT OF VARIANT ALLELIC FREQUENCY AT RELAPSE AND REFRACTORINESS STATUS IN AML PATIENTS

De la Fuente, EO; (...); Ayala, R

Meeting Abstract. 2017

NGS ANALYSIS IN ADULTS GREATER THAN 65 YEARS DIAGNOSED OF ACUTE MYELOID LEUKEMIA IN LOW INTENSITY TREATMENTS

Garcia, AB; (...); Lopez, JM

Meeting Abstract. 2017

NGS-Based Molecular Karyotyping of Multiple Myeloma: Results from the GEM12 Clinical Trial.

Rosa-Rosa, Juan Manuel; (...); Martinez-Lopez, Joaquin

Article. 10.3390/cancers14205169. 2022

Nicord Single Unit Expanded Umbilical Cord Blood Transplantation (UCBT): Final Results of a Multicenter Phase I/II Trial

Horwitz, ME; (...); Sanz, G

Meeting Abstract. 10.1016/j.bbmt.2017.12.628. 2018

No Evidence that CD33 rs12459419 Polymorphism Predicts Gemtuzumab Ozogamicin Response in Consolidation Treatment of Acute Myeloid Leukemia Patients: Experience of the PETHEMA Group.

Castano-Bonilla, Tamara; (...); Montesinos, Pau

Article. 10.1155/2022/3132941. 2022

Noninfectious Neurologic Complications after Allogeneic Hematopoietic Stem Cell Transplantation

Balaguer-Rosello, A; (...); Sanz, Jaime

Article. 10.1016/j.bbmt.2019.05.024. 2019

Non-infectious neurologic complications after allogeneic hematopoietic stem cell transplantation (ALLO-HSCT)

Balaguer Rosello, Aitana; (...); Sanz, Jaime

Meeting Abstract. 2019

Nonmyeloablative stem cell transplantation is an effective therapy for refractory or relapsed Hodgkin lymphoma: Results of a Spanish prospective cooperative protocol

Alvarez, I; (...); Sierra, J

Article. 10.1016/j.bbmt.2005.09.009. 2006

Novel dynamic outcome indicators and clinical endpoints in myelodysplastic syndrome; the European LeukemiaNet MDS Registry and MDS-RIGHT project perspective.

De Witte T; (...); Smith A

Article. 10.3324/haematol.2020.266817. 2020

Novel microgel culture system as semi-solid three-dimensional in vitro model for the study of multiple myeloma proliferation and drug resistance

Clara-Trujillo S; (...); Gómez Ribelles JL

Article. 10.1016/j.bioadv.2022.212749. 2022

Novel real-time polymerase chain reaction assay for simultaneous detection of recurrent fusion genes in acute myeloid leukemia.

Dolz S; (...); Sanz MA

Article. 10.1016/j.jmoldx.2013.04.003. 2013

Obesity is a risk factor for acute promyelocytic leukemia: evidence from population and cross-sectional studies studies and correlation with flt3 mutations and polyunsaturated fatty acid metabolism.

Mazzarella L; (...); Pelicci PG

Article. 10.3324/haematol.2019.223925. 2020

OBSERVATIONAL CLINICAL TRIAL FOR THE VALIDATION OF A TEST OF PRECISION MEDICINE IN ACUTE MYELOID LEUKEMIA

Montesinos, P.; (...); Sanz, M.

Meeting Abstract. 2017

Observational study to describe the impact of treatment combinations with Daratumumab versus other alternative regimens in patients with relapsed / refractory multiple myeloma. Spain real world evidence (RWE) data. GeminiS study

Tamayo, RR; (...); Mateos, MV

Meeting Abstract. 10.1016/j.clml.2019.09.245. 2019

Odronextamab in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): Results from a Prespecified Analysis of the Pivotal Phase II Study ELM-2

Kim, Won-Seog; (...); Walewski, Jan

Meeting Abstract. 10.1182/blood-2022-158406. 2022

Ofatumumab as part of reduced intensity conditioning in high risk B-cell lymphoma patients: final long-term analysis from a prospective multicenter Phase-II Trial

Cabrero M; (...); Caballero D

Article. 10.1038/s41409-023-02171-5. 2024

Ofatumumab as Part of Reduced Intensity Conditioning in High Risk b-cell Lymphoma Patients: Results from a Prospective Multicenter Phase-II Trial

Cabrero, M; (...); Caballero, D

Meeting Abstract. 2020

Olutasidenib (FT-2102) in Combination with Azacitidine Induces Durable Complete Remissions in Patients with mIDH1 Acute Myeloid Leukemia

Cortes, Jorge E.; (...); Wei, Andrew H.

Meeting Abstract. 10.1182/blood-2021-144905. 2021

Olutasidenib (FT-2102) induces durable complete remissions in patients with relapsed or refractory IDH1-mutated AML.

de Botton, Stephane; (...); Cortes, Jorge

Article. 10.1182/bloodadvances.2022009411. 2023

Olutasidenib (FT-2102) Induces Durable Complete Remissions in Patients with Relapsed/Refractory mIDH1 Acute Myeloid Leukemia. Results from a Planned Interim Analysis of a Phase 2 Pivotal Clinical Trial

Cortes, Jorge E.; (...); De Botton, Stephane

Meeting Abstract. 10.1182/blood-2022-167330. 2022

Olutasidenib (FT-2102), an IDH1m Inhibitor As a Single Agent or in Combination with Azacitidine, Induces Deep Clinical Responses with Mutation Clearance in Patients with Acute Myeloid Leukemia Treated in a Phase 1 Dose Escalation and Expansion Study

Watts, Justin M.; (...); Cortes, Jorge E.

Meeting Abstract. 10.1182/blood-2019-123920. 2019

Olutasidenib alone or with azacitidine in IDH1-mutated acute myeloid leukaemia and myelodysplastic syndrome: phase 1 results of a phase 1/2 trial.

Watts, Justin M.; (...); Cortes, Jorge E.

Article. 10.1016/S2352-3026(22)00292-7. 2022

Olutasidenib in combination with azacitidine induces durable complete remissions in patients with relapsed or refractory mIDH1 acute myeloid leukemia: a multicohort open-label phase 1/2 trial

Cortes, Jorge E.; (...); Olutasidenib Combination Therapy Study Grp

Article. 10.1186/s13045-024-01657-z. 2025

Olutasidenib in post-venetoclax patients with mutant isocitrate dehydrogenase 1 (mIDH1) acute myeloid leukemia (AML).

Cortes J; (...); Watts JM

Article. 10.1080/10428194.2024.2333451. 2024

Omidubicel vs standard myeloablative umbilical cord blood transplantation: results of a phase 3 randomized study.

Horwitz, ME; (...); Sanz, G

Article. 10.1182/blood.2021011719. 2021

One-Unit versus Two-Unit Cord-Blood Transplantation

Sanz, J, Sanz, GF, Sanz, MA

Letter. 2015

One-unit versus two-unit cord-blood transplantation.

Sanz J, Sanz GF, Sanz MA

Letter. 2015

Open issues on bleeding and thrombosis in acute promyelocytic leukemia

Sanz, Miguel A., Montesinos, Pau

Article. 10.1016/S0049-3848(10)70013-X. 2010

Optimised molecular genetic diagnostics of Fanconi anaemia by whole exome sequencing and functional studies.

Bogliolo M; (...); Surralles J

Article. 10.1136/jmedgenet-2019-106249. 2020

OPTIMIZATION OF THE EFFICIENCY OF GENETIC EDITING OF HEMAPOYETIC PROGENITOR CELLS USING CRISPR/CAS9 RIBONUCLEOPROTEINS

Martinez-Valiente, C.; (...); Sanjuan-Pla, A.

Meeting Abstract. 2019

Oral Azacitidine (Oral-AZA) improves Overall Survival (OS) and Relapse-free Survival (RFS) for patients with Acute Myeloid Leukemia (AML) in first remission after Intensive Chemotherapy (IC), regardless of amount of consolidation received: Results of the QUAZAR AML-001 maintenance trial

Dohner, H.; (...); Ravandi, F.

Meeting Abstract. 2021

Oral Azacitidine (Oral-AZA) in Patients with Acute Myeloid Leukaemia (AML) in First Remission after Intensive Chemotherapy (IC): Long-Term Overall Survival (OS) Results from the Phase 3 QUAZAR AML-001 Trial

Wei, Andrew; (...); Roboz, Gail

Meeting Abstract. 2022

Oral Azacitidine Maintenance Therapy for Acute Myeloid Leukemia in First Remission.

Wei AH; (...); Roboz GJ

Article. 10.1056/NEJMoa2004444. 2020

Osteogenic differentiation of human mesenchymal stem cells on electroactive substrates.

Tamaño-Machiavello MN; (...); Ribelles JLG

Article. 10.1016/j.heliyon.2024.e28880. 2024

Outcome of a Real-Life Population of Patients With Acute Promyelocytic Leukemia Treated According to the PETHEMA Guidelines: The Polish Adult Leukemia Group (PALG) Experience.

Sobas M; (...); Giebel S

Article. 10.1016/j.clml.2019.09.616. 2020

Outcome of Acute Myeloid Leukemia with Inv(3)(Q21q26.2)/ T(3;3)(Q21;Q26.2). Experience of the Spanish PETHEMA and CETLAM Groups

Sitges, M; (...); CETLAM Cooperative Grp

Meeting Abstract. 2019

Outcome of Antifungal Combination Therapy for Invasive Mold Infections in Hematological Patients is Independent of the Chosen Combination.

Rojas R; (...); Torres A

Article. 10.4084/MJHID.2012.011. 2012

Outcome of graft failure after allogeneic stem cell transplant: study of 89 patients

Ferrà C; (...); Ribera JM

Article. 10.3109/10428194.2014.930849. 2015

Outcome of Human Parainfluenza Virus infection in allogeneic stem cell transplantation recipients: possible impact of ribavirin therapy.

Perez, Ariadna; (...); Pinana, Jose Luis

Article. 10.1007/s15010-024-02213-0. 2024

Outcome of lower-risk myelodysplastic syndrome with ring sideroblasts (MDS-RS) after failure of erythropoiesis- stimulating agents

Park, Sophie; (...); Fenaux, Pierre

Letter. 10.1016/j.leukres.2020.106472. 2020

OUTCOME OF LOWER-RISK PATIENTS WITH MYELODYSPLASTIC SYNDROMES WITHOUT 5Q DELETION AFTER FAILURE OF ERYTHROPOIESIS STIMULATING AGENTS

Park, S; (...); Fenaux, P

Meeting Abstract. 10.1016/S0145-2126(17)30162-5. 2017

Outcome of Lower-Risk Patients With Myelodysplastic Syndromes Without 5q Deletion After Failure of Erythropoiesis-Stimulating Agents

Park S; (...); Fenaux P

Article. 10.1200/JCO.2016.71.3271. 2017

Outcome of older (=70 years) APL patients frontline treated with or without arsenic trioxide-an International Collaborative Study.

Kayser S; (...); Montesinos P

Article. 10.1038/s41375-020-0758-4. 2020

Outcome of older (>= 70 years) APL patients frontline treated with or without arsenic trioxide-an International Collaborative Study (vol 34, pg 2333, 2020)

Kayser, Sabine; (...); Montesinos, Pau

Correction. 10.1038/s41375-021-01358-3. 2021

Outcome of patients with chronic myeloid leukemia and a low-risk score: allogeneic hematopoietic stem cell transplantation in the era of targeted therapy. A report from the EBMT Chronic Malignancies Working Party

Koenecke, C; (...); Finke, J

Letter. 10.1038/bmt.2016.97. 2016

Outcomes after intensive chemotherapy for secondary and myeloid-related changes acute myeloid leukemia patients aged 60 to 75 years old: a retrospective analysis from the PETHEMA registry

Martinez-Cuadron, David; (...); Montesinos, Pau

Article. 10.3324/haematol.2022.282506. 2024

Outcomes and effect of somatic mutations after erythropoiesis stimulating agents in patients with lower-risk myelodysplastic syndromes.

Caballero, Juan Carlos; (...); Diez Campelo, Maria

Article. 10.1177/20406207231218157. 2024

Outcomes and prognostic factors of adults with acute lymphoblastic leukemia who relapse after allogeneic hematopoietic cell transplantation. An analysis on behalf of the Acute Leukemia Working Party of EBMT.

Spyridonidis A; (...); Immunotherapy Subcommittee of Acute Leukemia Working Party

Article. 10.1038/leu.2011.351. 2012

Outcomes and prognostic factors of adults with refractory or relapsed T-cell acute lymphoblastic leukemia included in measurable residual disease-oriented trials

Ribera, JM; (...); PETHEMA Grp

Article. 10.1002/hon.2910. 2021

Outcomes for Patients with Late-Stage Mutant-IDH2 (m IDH2) Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) Treated with Enasidenib Vs Other Lower-Intensity Therapies in the Randomized, Phase 3 IDHentify Trial

DiNardo, Courtney D.; (...); de Botton, Stephane

Meeting Abstract. 10.1182/blood-2021-147593. 2021

Outcomes in Chemotherapy-Ineligible Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia Treated with Venetoclax Plus Azacitidine: A Pooled Analysis

Venditti, Adriano; (...); Pullarkat, Vinod

Meeting Abstract. 10.1182/blood-2023-182045. 2023

Outcomes in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with isolated deletion 5q treated with lenalidomide: a subset analysis from the MDS-004 study

Giagounidis A; (...); Fenaux P

Article. 10.1111/ejh.12380. 2014

Outcomes of Patients with Newly-Diagnosed Acute Myeloid Leukemia and Hyperleukocytosis Who Did Not Undergo Intensive Chemotherapy: Results from a Large International Database

Shallis, RM; (...); Zeidan, AM

Meeting Abstract. 10.1182/blood-2018-99-119755. 2018

Outcomes of unrelated cord blood transplantation in patients with multiple myeloma: a survey on behalf of Eurocord, the Cord Blood Committee of Cellular Therapy and Immunobiology Working Party, and the Chronic Leukemia Working Party of the EBMT

Paviglianiti, A; (...); Mohty, M

Article. 10.3324/haematol.2015.138917. 2016

P-137: ITHACA, a randomized multicenter phase 3 study of Isatuximab in combination with Lenalidomide and Dexamethasone in high-risk smoldering Multiple Myeloma: safety run-in preliminary results (vol 21, pg S109, 2021)

Ghobrial, Irene M.; (...); Mateos, Maria-Victoria

Correction. 10.1016/j.clml.2022.03.011. 2022

p53 protein expression independently predicts outcome in patients with lower-risk myelodysplastic syndromes with del(5q)

Saft L; (...); Hellström-Lindberg E

Article. 10.3324/haematol.2013.098103. 2014

Panel Sequencing for Clinically Oriented Variant Screening and Copy Number Detection in Chronic Lymphocytic Leukemia Patients

Ibanez, Mariam; (...); Luna I

Article. 10.3390/diagnostics12040953. 2022

Panobinostat as part of induction and maintenance for elderly patients with newly diagnosed acute myeloid leukemia: phase Ib/II panobidara study

Ocio EM; (...); PETHEMA Group

Article. 10.3324/haematol.2015.129577. 2015

Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial

San-Miguel, JF; (...); Richardson, PG

Article. 10.1016/S1470-2045(14)70440-1. 2014

PAN-STAKEHOLDER CORE OUTCOME SET (COS) DEFINITION FOR HEMATOLOGICAL MALIGNANCIES IN THE FRAMEWORK OF THE EU PROJECT, HARMONY: THE HEALTHCARE ALLIANCE FOR RESOURCEFUL MEDICINE OFFENSIVE AGAINST NEOPLASMS IN HEMATOLOGY

Lang, K.; (...); Bullinger, L.

Meeting Abstract. 2023

Pan-Stakeholder Core Outcome Set (COS) Definition for Hematological Malignancies within the Framework of Harmony and Harmony PLUS Projects

Lang, Katharina M.; (...); Bullinger, Lars

Meeting Abstract. 10.1182/blood-2022-157549. 2022

Pan-Stakeholder Core Outcome Set (COS) Definition for Selected Hematological Malignancies - Results of the Harmony Alliance

Lang, Katharina M.; (...); Bullinger, Lars

Meeting Abstract. 10.1182/blood-2021-145002. 2021

Paradoxical Findings in Patients with Paroxysmal Nocturnal Hemoglobinuria Treated with C5 Inhibitors: Suboptimal Disease Control Perceived As Satisfactory

Gaya, Anna; (...); Vallejo, Carlos

Meeting Abstract. 10.1182/blood-2023-185939. 2023

Parasitic Infections in Hematopoietic Stem Cell Transplantation.

Jarque I, Salavert M, Pemán J

Article. 10.4084/MJHID.2016.035. 2016

Partial T Cell-Depleted Peripheral Blood Stem Cell Transplantation from HLA-Identical Sibling Donors for Patients with Severe Aplastic Anemia.

Sanz J; (...); Piñana JL

Article. 10.1016/j.bbmt.2019.08.020. 2020

Passenger lymphocyte syndrome in liver transplant recipients: a description of 12 cases

Romero S; (...); Sanz MÁ

Article. 10.2450/2015.0148-14. 2015

Patient Reported Outcomes in Patients with Newly Diagnosed FLT3(mut+) acute Myeloid Leukemia Ineligible for Intensive Induction Chemotherapy from Lacewing: A Randomized Phase 3 Trial of Gilteritinib and Azacitidine Versus Azacitidine Alone

Wang, Eunice S.; (...); Shah, Manasee V.

Meeting Abstract. 10.1182/blood-2021-144977. 2021

Patient-reported Outcomes in Adults With Newly Diagnosed Ph plus Acute Lymphoblastic Leukemia Treated With Ponatinib or Imatinib in Combination With Reduced-Intensity Chemotherapy: Results From the Phase III PhALLCON Study

Ashaye, Ajibade; (...); Guo, Shien

Meeting Abstract. 2024

PATTERNS OF RESCUE TREATMENT IN PATIENTS WITH ACUTE MYELOID LEUKEMIA TREATED IN THE FIRST LINE WITH AZACITIDINE AND DECITABIN: RESULTS OF THE PETHEMA AML REGISTRY

Jorge, Labrador; (...); Miguel-Angel, Sanz

Meeting Abstract. 2021

PCR-Based Strategy for Introducing CRISPR/Cas9 Machinery into Hematopoietic Cell Lines.

González-Romero E; (...); Vázquez-Manrique RP

Article. 10.3390/cancers15174263. 2023

Performance evaluation of low platelet count and platelet clumps detection on Mindray BC-6800 hematology analyzer

Fuster, O, Andino, B, Laiz, B

Letter. 10.1515/cclm-2015-0409. 2016

Performance of prognostic scoring systems in elderly patients with acute myeloid leukaemia on intensive chemotherapy: A PETHEMA registry study

Rodriguez-Medina, C; (...); Fernandez, PM

Article. 10.1016/j.leukres.2020.106352. 2020

Performance of the Medical Research Council (MRC) and the Leukemia Research Foundation (LRF) score in predicting survival benefit with hypomethylating agent use in patients with relapsed or refractory acute myeloid leukemia

Stahl, M; (...); Zeidan, AM

Letter. 10.1080/10428194.2018.1468893. 2019

Peripheral Blood CD34+Cell Count Before Apheresis in Healthy Volunteer Donors Significantly Influences the Efficacy of the Collection

Carpio, N.; (...); Sanz, M. A.

Article. 2009

Peripheral nerve hyperexcitability: a clinical and immunologic study of 38 patients.

Ramírez P; (...); Bataller L

Article. 10.1212/WNL.0b013e3182061b1e. 2011

Personalized Medicine: Learning to Walk

Gargallo, P.; (...); Canete, A.

Meeting Abstract. 2018

Personalized Survival Prediction of Patients With Acute Myeloblastic Leukemia Using Gene Expression Profiling

Orgueira, AM; (...); Lopez, JLB

Article. 10.3389/fonc.2021.657191. 2021

Pethema NGS-AML Project. Final Analysis and Clinical Validation of New Genomic Classifications

Sargas, Claudia; (...); Montesinos, Pau

Meeting Abstract. 10.1182/blood-2022-166639. 2022

PHARMACOECONOMIC ANALYSIS OF THE USE OF VORICONAZOLE, POSACONAZOLE AND MICAFUNGIN IN THE PRIMARY PROPHYLAXIS OF INVASIVE FUNGAL INFECTIONS IN RECIPIENTS OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTS IN SPAIN

Grau S; (...); Rubio-Terrés C

Meeting Abstract. 10.1016/j.jval.2015.09.1944. 2015

Pharmacogenetics of Metabolic Genes of Anthracyclines in Acute Myeloid Leukemia

Review. 10.2174/1389200218666171101124931. 2018

Pharmacogenomics and the treatment of acute myeloid leukemia

Megías-Vericat JE; (...); Aliño SF

Review. 10.2217/pgs-2016-0055. 2016

Pharmacokinetic Study of Intravenous Acetaminophen Administered to Critically Ill Multiple-Trauma Patients at the Usual Dosage and a New Proposal for Administration

Fuster-Lluch, O, Zapater-Hernandez, P, Geronimo-Pardo, M

Article. 10.1002/jcph.903. 2017

Pharmacologic evaluation of bispecific antibodies: A novel method to quantify their in vitro activity in hematologic samples.

Primo, D; (...); Ballesteros, J

Meeting Abstract. 2017

Pharmacological Profiles of Acute Myeloid Leukemia Treatments in Patient Samples by Automated Flow Cytometry: A Bridge to Individualized Medicine

Bennett TA; (...); Ballesteros J

Article. 10.1016/j.clml.2013.11.006. 2014

Phase 1 study of LP-108 as monotherapy and in combination with azacitidine in patients with relapsed or refractory myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML), or acute myeloid leukemia (AML).

Walker, Alison R.; (...); William Burke, Patrick

Meeting Abstract. 2022

Phase 1/2 study of SEL24/MEN1703, a first-in-class dual PIM/FLT3 kinase inhibitor, in patients with IDH1/2-mutated acute myeloid leukemia: The DIAMOND-01 trial.

Martinelli, Giovanni; (...); Montesinos, Pau

Meeting Abstract. 2022

Phase 2 multiple-dose study of an FcRn inhibitor, rozanolixizumab, in patients with primary immune thrombocytopenia

Robak, T; (...); Jolles, S

Article. 10.1182/bloodadvances.2020002003. 2020

Phase 3 Study of Lenalidomide (LEN) Vs Placebo in Non-Transfusion Dependent (TD) Low Risk Del(5q) - Preliminary Blinded Analysis of the European Sintra-REV Trial

Cadenas, FL; (...); Diez-Campelo, M

Meeting Abstract. 10.1182/blood-2018-99-119430. 2018

Phase 3 Trial of Gilteritinib Plus Azacitidine Vs Azacitidine for Newly Diagnosed FLT3mut+ AML Ineligible for Intensive Chemotherapy.

Wang, Eunice S.; (...); Tiu, V, Ramon

Article. 10.1182/blood.2021014586. 2022

Phase 3, Open-Label, Randomized Study of Gilteritinib and Azacitidine Vs Azacitidine for Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia in Patients Ineligible for Intensive Induction Chemotherapy

Wang, Eunice S.; (...); Tiu, Ramon V.

Meeting Abstract. 10.1182/blood-2021-145379. 2021

Phase I trials of the lysine-specific demethylase 1 inhibitor, GSK2879552, as mono- and combination-therapy in relapsed/refractory acute myeloid leukemia or high-risk myelodysplastic syndromes.

Roboz, Gail J.; (...); Wei, Andrew H.

Letter. 10.1080/10428194.2021.2012667. 2022

Phase I/II Study of Stem-Cell Transplantation Using a Single Cord Blood Unit Expanded Ex Vivo With Nicotinamide

Horwitz, ME; (...); Sanz, G

Article. 10.1200/JCO.18.00053. 2019

Phase II Study of Yttrium-90-Ibritumomab Tiuxetan as Part of Reduced-Intensity Conditioning (with Melphalan, Fludarabine Thiotepa) for Allogeneic Transplantation in Relapsed or Refractory Aggressive B Cell Lymphoma: A GELTAMO Trial

Cabrero, M; (...); Caballero, D

Article. 10.1016/j.bbmt.2016.10.003. 2017

Phase II trial to assess the safety and efficacy of clofarabine in combination with low-dose cytarabine in elderly patients with acute myeloid leukemia

Martínez-Cuadrón D; (...); Sanz MA

Article. 10.1007/s00277-013-1914-y. 2014

Phase IV open-label study of the efficacy and safety of deferasirox after allogeneic stem cell transplantation

Vallejo C; (...); Jarque I

Article. 10.3324/haematol.2014.105908. 2014

Pivekimab sunirine (IMGN632), a novel CD123-targeting antibody-drug conjugate, in relapsed or refractory acute myeloid leukaemia: a phase 1/2 study.

Daver NG; (...); Kantarjian HM

Article. 10.1016/S1470-2045(23)00674-5. 2024

Pivekimab Sunirine (PVEK, IMGN632), a CD123-Targeting Antibody-Drug Conjugate, in Combination with Azacitidine and Venetoclax in Patients with Newly Diagnosed Acute Myeloid Leukemia

Daver, Naval; (...); Sweet, Kendra

Meeting Abstract. 10.1182/blood-2023-173413. 2023

PLZF-RAR(alpha), NPM1-RAR(alpha), and Other Acute Promyelocytic Leukemia Variants: The PETHEMA Registry Experience and Systematic Literature Review

Sobas, M; (...); Montesinos, P

Review. 10.3390/cancers12051313. 2020

Ponalfil trial for adults with Philadelphia chromosome-positive acute lymphoblastic leukemia: Long-term results.

Ribera, Josep-Maria; (...); Garcia-Sanz, Ramon

Article. 10.1002/hem3.67. 2024

PONATINIB AND CHEMOTHERAPY IN YOUNG ADULTS WITH ACUTE LYMPHOBLASTIC LEUKAEMIA WITH PHILADELPHIA CHROMOSOME. RESULTS OF THE PONALFIL CLINICAL TRIAL WITH COMPLETE RECRUITMENT

Ribera, J. M.; (...); Garcia-Sanz, R.

Meeting Abstract. 2020

PONATINIB AND CHEMOTHERAPY IN YOUNG ADULTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA WITH PHILADELPHIA CHROMOSOME. PRELIMINARY RESULTS OF THE PONALFIL CLINICAL TRIAL

Ribera Santasusana, J. M.; (...); Garcia-Sanz, R.

Meeting Abstract. 2019

PONATINIB AND CHEMOTHERAPY IN YOUNG ADULTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA WITH PHILADELPHIC CHROMOSOME (LAL PH plus ). RESULTS OF THE PONALFIL CLINICAL TRIAL WITH MEDIUM 2-YEAR FOLLOW-UP

Ribera Santasusana, J. M.; (...); Garcia-Sanz, R.

Meeting Abstract. 2021

Ponatinib and Chemotherapy in Young Adults with De Novo Philadelphia Chromosome-Positive Acute Lymphoblstic Leukemia. Preliminary Results of Ponalfil Clinical Trial

Ribera, Josep-Maria; (...); Garcia-Sanz, Ramon

Meeting Abstract. 10.1182/blood-2019-125558. 2019

Ponatinib Versus Imatinib in Patients with Newly Diagnosed Ph plus ALL: Subgroup Analysis of the Phase 3 Phallcon Study

Aldoss, Ibrahim; (...); Jabbour, Elias

Meeting Abstract. 10.1182/blood-2023-179537. 2023

Ponatinib vs Imatinib in Frontline Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Randomized Clinical Trial.

Jabbour, Elias; (...); Ribera, Jose-Maria

Article. 10.1001/jama.2024.4783. 2024

Ponatinib, Chemotherapy, and Transplant in Adults with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia.

Ribera, Josep-Maria; (...); Garcia-Sanz, Ramon

Article. 10.1182/bloodadvances.2022007764. 2022

Positive impact of ABCB1 polymorphisms in overall survival and complete remission in acute myeloid leukemia: a systematic review and meta-analysis

Megías-Vericat JE; (...); Aliño SF

Letter. 10.1038/tpj.2015.79. 2016

Post-transplant cyclophosphamide and sirolimus based graft-versus-host disease prophylaxis after allogeneic stem cell transplantation for acute myeloid leukemia.

Lazzari, Lorenzo; (...); Sanz, Jaime

Article. 10.1038/s41409-022-01725-3. 2022

Post-transplant cyclophosphamide-based haplo-identical transplantation as alternative to matched sibling or unrelated donor transplantation for non-Hodgkin lymphoma: a registry study by the European society for blood and marrow transplantation

Dietrich, S; (...); EBMT Lymphoma Working Party

Letter. 10.1038/leu.2016.125. 2016

Post-transplant lymphoproliferative disorders after solid organ and hematopoietic stem cell transplantation.

Romero S; (...); Sanz J

Article. 10.1080/10428194.2018.1474462. 2019

Practical Considerations for Treatment of Relapsed/Refractory FLT3-ITD Acute Myeloid Leukaemia with Quizartinib: Illustrative Case Reports.

Martínez-Cuadrón D; (...); Montesinos P

Article. 10.1007/s40261-019-00881-7. 2020

Practical guide to emergency treatment of thrombotic microangiopathy

Romero S; (...); Grupo de Microangiopatía Trombótica del Hospital Universitario y Politécnico La

Editorial Material. 10.1016/j.medcli.2018.01.013. 2018

Practical recommendations on the use of lenalidomide in the management of myelodysplastic syndromes

Giagounidis, Aristoteles; (...); Wells, Richard A.

Review. 10.1007/s00277-008-0449-0. 2008

Practical use of azacitidine in higher-risk myelodysplastic syndromes: An expert panel opinion

Fenaux, Pierre; (...); Santini, Valeria

Review. 10.1016/j.leukres.2010.05.021. 2010

Precision medicine in acute myeloid leukemia: where are we now and what does the future hold?

Review. 10.1080/17474086.2020.1818559. 2020

Precision Medicine Test Is Similar but Faster Than Conventional Cytogenetics Predicting Response in AML Patients and Provides Alternative Treatments

Ballesteros, J; (...); Montesinos, P

Meeting Abstract. 10.1182/blood-2018-99-115849. 2018

Predictive Factors for Thrombopoietin Receptor Agonist Free Responses in Chronic ITP Patients: A Multicenter Retrospective Study with Long-Term Follow-up

Luisa Lozano, Maria; (...); Vicente Garcia, Vicente

Meeting Abstract. 10.1182/blood-2019-125580. 2019

Predictive value of 1q21 gain in multiple myeloma is strongly dependent on concurrent cytogenetic abnormalities and first-line treatment

Minguela, Alfredo; (...); Periago, Adela

Article. 2021

Predictive value of 1q21 gain in multiple myeloma is strongly dependent on concurrent cytogenetic abnormalities and first-line treatment.

Minguela, Alfredo; (...); Periago, Adela

Article. 2021

Predictors of thrombohemorrhagic early death in children and adolescents with t(15;17)-positive acute promyelocytic leukemia treated with ATRA and chemotherapy

Abla, O; (...); Sanz, MA

Article. 10.1007/s00277-017-3042-6. 2017

PREDICTORS OF TREATMENT FREE RESPONSES WITH THROMBOPOIETIN RECEPTOR AGONISTS IN PATIENTS WITH PTI

Lozano Almela, M. L.; (...); Vicente, V.

Meeting Abstract. 2019

PRELIMINARY ANALYSIS OF EFFICACY AND SAFETY OF SINTRA-REV CLINICAL TRIAL, LENALIDOMIDE VS PLACEBO PHASE 3 STUDY IN LOW/INT-1 MDS PATIENTS WITH DEL(5Q) AND TRANSFUSION INDEPENDENCY

Cadenas, FL; (...); Diez-Campelo, M

Meeting Abstract. 2017

Preliminary Safety and Efficacy of Bgb-11417, a Novel Bcl-2 Inhibitor, in Combination with Azacitidine in Patients with Acute Myeloid Leukemia (AML)

Shortt, Jake; (...); Wei, Andrew H.

Meeting Abstract. 10.1182/blood-2022-166937. 2022

Presence of acute and chronic renal failure in patients with paroxysmal nocturnal hemoglobinuria: results of a retrospective analysis from the Spanish PNH Registry

Villegas, A; (...); Urbano, A

Article. 10.1007/s00277-017-3059-x. 2017

Presenting features and treatment outcome of acute promyelocytic leukemia arising after multiple sclerosis

Ammatuna, Emanuele; (...); Lo-Coco, Francesco

Article. 10.3324/haematol.2010.036657. 2011

Prevalence, Vascular Distribution, and Multiterritorial Extent of Subclinical Atherosclerosis in a Middle-Aged Cohort The PESA (Progression of Early Subclinical Atherosclerosis) Study

Fernández-Friera L; (...); Fuster V

Article. 10.1161/CIRCULATIONAHA.114.014310. 2015

Prevention, recognition, and management of adverse events associated with gemtuzumab ozogamicin use in acute myeloid leukemia.

Cortes JE; (...); Wang ES

Review. 10.1186/s13045-020-00975-2. 2020

Primary and secondary immune thrombocytopenia (ITP): Time for a rethink.

Gonzalez-Lopez, Tomas Jose; (...); Fernandez-Fuertes, Fernando

Article. 10.1016/j.blre.2023.101112. 2023

Primary paraesophageal Ewing's sarcoma: an uncommon case report and literature review

Tarazona N; (...); Cervantes A

Article. 10.2147/OTT.S80879. 2015

Profile of polymorphisms of drug-metabolising enzymes and the risk of therapy-related leukaemia

Bolufer, Pascual; (...); Sanz, Miguel-Angel

Article. 10.1111/j.1365-2141.2006.06469.x. 2007

Prognosis and Survival of Acute Myeloid Leukemia: Experience of a Single Center in Colombia

Sossa, CL; (...); Jimenez, SI

Meeting Abstract. 10.1182/blood-2018-99-119927. 2018

Prognosis Value of Measurable Residual Disease By Multiparameter Flow Cytotometry in Patients with Acute Myeloblastic Leukemia Prior to Allogeneic Hematopoietic Cell Transplantation

Caballero, Teresa; (...); Perez-Simon, Jose A.

Meeting Abstract. 10.1182/blood-2021-151533. 2021

PROGNOSIS VALUE OF MINIMAL DETECTABLE DISEASE (MDD) BY 2(nd) GENERATION ALLOGENIC PRE-TRANSPLANTATION CYTOMETRY IN PATIENTS WITH ACUTE MYELOBLASTIC LEUKEMIA

Velazquez Teresa, Caballero; (...); Jose Antonio, Perez Simon

Meeting Abstract. 2021

Prognostic factors for adult single cord blood transplantation among European and Japanese populations: the Eurocord/ALWP-EBMT and JSHCT/JDCHCT collaborative study

Kanda, J; (...); Gluckman, E

Meeting Abstract. 2018

Prognostic factors for adult single cord blood transplantation among European and Japanese populations: the Eurocord/ALWP-EBMT and JSHCT/JDCHCT collaborative study.

Kanda J; (...); Gluckman E

Article. 10.1038/s41375-019-0534-5. 2020

Prognostic factors of overall (OS) and relapse-free survival (RFS) for patients with acute myeloid leukemia (AML) in remission after intensive chemotherapy (IC): Multivariate analyses from the QUAZAR AML-001 trial of oral azacitidine (Oral-AZA).

Roboz, Gail J.; (...); Dohner, Hartmut

Meeting Abstract. 10.1200/JCO.2021.39.15_suppl.7014. 2021

Prognostic impact of a suboptimal number of analyzed metaphases in normal karyotype lower-risk MDS

de Swart, L; (...); de Witte, T

Article. 10.1016/j.leukres.2018.01.022. 2018

PROGNOSTIC IMPACT OF ADDITIONAL CHROMOSOMAL ABERRATIONS TO 5Q-IN PATIENTS WITH PRIMARY MYELODYSPLASTIC SYNDROMES

Mallo, M.; (...); Florensa, L.

Article. 2008

Prognostic Impact of Anthracycline Metabolism Gene Polymorphisms in Newly Diagnosed Acute Myeloid Leukemia Adults

Article. 2014

Prognostic Impact of Cytarabine Pathway Gene Polymorphisms in Acute Myeloid Leukemia Adults Undergoing Induction Chemotherapy

Sanz, Miguel A., Montesinos, Pau

Article. 2014

Prognostic impact of chromosomal translocations in myelodysplastic syndromes and chronic myelomonocytic leukemia patients. A study by the spanish group of myelodysplastic syndromes

Nomdedeu, M; (...); Costa, D

Article. 10.1002/gcc.22333. 2016

Prognostic impact of gene mutations in myelodysplastic syndromes with ring sideroblasts

Martin, I; (...); Sanz, G

Article. 10.1038/s41408-017-0016-9. 2017

Prognostic Impact of Insertion Site in Acute Myeloid Leukemia (AML) with FLT3 Internal Tandem Duplication: Results from the Ratify Study (Alliance 10603)

Rucker, FG; (...); Dohner, K

Meeting Abstract. 10.1182/blood-2018-99-116149. 2018

Prognostic impact of KMT2E transcript levels on outcome of patients with acute promyelocytic leukaemia treated with all-trans retinoic acid and anthracycline-based chemotherapy: an International Consortium on Acute Promyelocytic Leukaemia study

Lucena-Araujo AR; (...); Rego EM

Article. 10.1111/bjh.12921. 2014

Prognostic Impact of NPM1 and FLT3 Mutations at Diagnosis and Presence of Measurable Residual Disease (MRD) after Intensive Chemotherapy (IC) for Patients with Acute Myeloid Leukemia (AML) in Remission: Outcomes from the QUAZAR AML-001 Trial of Oral Azacitidine (Oral-AZA) Maintenance

Dohner, Hartmut; (...); de Menezes, Daniel Lopes

Meeting Abstract. 10.1182/blood-2021-147465. 2021

Prognostic impact of NPM1 and FLT3 mutations in patients with AML in first remission treated with oral azacitidine.

Dohner, Hartmut; (...); Lopes de Menezes D

Article. 10.1182/blood.2022016293. 2022

Prognostic Impact of NPM1 and FLT3-ITD Mutations in Patients Treated with Non-Intensive Regimens: A Pethema Registry Study

Uriel Suarez, Edwin; (...); Montesinos, Pau

Meeting Abstract. 10.1182/blood-2022-167365. 2022

PROGNOSTIC IMPACT OF TRANSPORTER GENE POLYMORPHISMS IN NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA ADULTS

Megias Vericat, J. E.; (...); Sanz, M. A.

Article. 2015

Prognostic impact on survival of an unsuccessful conventional cytogenetic study in patients with myelodysplastic syndromes (MDS)

Cervera, J.; (...); Sanz, G. F.

Article. 10.1016/S0145-2126(09)70110-9. 2009

Prognostic Significance of Complex Karyotype and Monosomal Karyotype in Adult Patients With Acute Lymphoblastic Leukemia Treated With Risk-Adapted Protocols

Motlló C; (...); Feliu E

Article. 10.1002/cncr.28950. 2014

Prognostic significance of copy number alterations in adolescent and adult patients with precursor B acute lymphoblastic leukemia enrolled in PETHEMA protocols

Ribera J; (...); Ribera JM

Article. 10.1002/cncr.29579. 2015

Prognostic significance of FLT3-ITD length in AML patients treated with intensive regimens.

Castaño-Bonilla T; (...); Montesinos, P

Article. 10.1038/s41598-021-00050-x. 2021

Prognostic Value of Antigen Expression in Multiple Myeloma (MM): A Large GEM/Pethema Study Based in Four Consecutive Clinical Trials

Paiva, Bruno; (...); San Miguel, Jesus

Meeting Abstract. 2015

Prognostic value of antigen expression in multiple myeloma: a PETHEMA/GEM study on 1265 patients enrolled in four consecutive clinical trials

Arana P; (...); San Miguel JF

Article. 10.1038/leu.2017.320. 2018

PROGNOSTIC VALUE OF B-MYB AND ITS REGULATION BY MIRNAS IN ACUTE MYELOID LEUKEMIA

LLop, M.; (...); Angel Sanz, M.

Article. 2013

Prognostic value of cytogenetics in adult patients with Philadelphia-negative acute lymphoblastic leukemia.

Gómez-Seguí I; (...); Sanz MA

Article. 10.1007/s00277-011-1331-z. 2012

Prognostic Value of Chromosome 1 Abnormalities in Myelodysplastic Syndrome

Ibarrondo, Paloma; (...); Batlle-Lopez, Ana

Article. 2014

PROGNOSTIC VALUE OF EARLY DROP IN PLATELETS IN LOWER-RISK MDS. A SUB-STUDY FROM THE EUROPEAN LEUKEMIANET LOWER-RISK MDS (EUMDS) REGISTRY

Itzykson, R; (...); de Witte, T

Meeting Abstract. 10.1016/S0145-2126(17)30132-7. 2017

Prognostic value of FLT3 mutations in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline monochemotherapy

Barragan, Eva; (...); Sanz, Miguel A.

Article. 10.3324/haematol.2011.044933. 2011

Prognostic Value of Immune Profiling Multiple Myeloma Patients during Minimal Residual Disease Monitoring in the Pethema/GEM2010MAS65 Study

Arana, Paula; (...); San Miguel, Jesus

Meeting Abstract. 2015

Prognostic Value of Measurable Residual Disease in Patients with AML Undergoing HSCT: A Multicenter Study.

Caballero-Velazquez, Teresa; (...); Perez-Simon, Jose A.

Article. 10.3390/cancers15051609. 2023

Prognostic Value of Serum Paraprotein Response Kinetics in Patients With Newly Diagnosed Multiple Myeloma.

Tamariz-Amador, Luis-Esteban; (...); Troconiz, Inaki F.

Article. 10.1016/j.clml.2022.04.024. 2022

Prognostic value of trisomy 8 as a single anomaly and the influence of additional cytogenetic aberrations in primary myelodysplastic syndromes.

Saumell S; (...); Solé F

Article. 10.1111/bjh.12035. 2012

Progression-free survival at 2years post-autologous transplant: a surrogate end point for overall survival in follicular lymphoma

Jimenez-Ubieto, A; (...); GELTAMO (Grupo Español de Linfomas y Trasplantes de Médula Ósea) cooperative stu

Article. 10.1002/cam4.1217. 2017

Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System

Kantarjian, Hagop; (...); Garcia-Manero, Guillermo

Article. 10.1002/cncr.23697. 2008

Proposed global prognostic score for systemic mastocytosis: a retrospective prognostic modelling study.

Muñoz-González JI; (...); Orfao A

Article. 10.1016/S2352-3026(20)30400-2. 2021

PROPOSED MOLECULAR CLASSIFICATION OF ACUTE MYELOBLASTIC LEUKEMIA (AML) BASED ON SPLICING EVENTS

Liquori, A.; (...); Cervera Zamora, J.

Meeting Abstract. 2021

Prospective Randomized Study Comparing Myeloablative Unrelated Umbilical Cord Blood Transplantation versus HLA-Haploidentical Related Stem Cell Transplantation for Adults with Hematologic Malignancies.

Sanz J; (...); Piñana JL

Article. 10.1016/j.bbmt.2019.10.014. 2020

Prospective study of amphotericin B formulations in immunocompromised patients in 4 European countries

Ullmann, Andrew J.; (...); Gerth, William C.

Article. 10.1086/505969. 2006

Protein-Functionalized Microgel for Multiple Myeloma Cells' 3D Culture.

Marín-Payá JC; (...); Gomez Ribelles, Jose Luis

Article. 10.3390/biomedicines10112797. 2022

Pulmonary cytomegalovirus (CMV) DNA shedding in allogeneic hematopoietic stem cell transplant recipients: Implications for the diagnosis of CMV pneumonia

Pinana, JL; (...); Navarro, D

Article. 10.1016/j.jinf.2019.02.009. 2019

Pulmonary invasive fungal disease after community acquire respiratory virus infection in allogeneic hematopoietic stem cell transplantation recipients: Results from a prospective observational study

Pinana, Jose; (...); Navarro, David

Meeting Abstract. 2019

Pure red cell aplasia after major or bidirectional ABO incompatible hematopoietic stem cell transplantation: to treat or not to treat, that is the question.

Marco-Ayala J; (...); Solves P

Review. 10.1038/s41409-020-01124-6. 2021

Púrpura trombocitopénica trombótica inmune: sospecha y manejo básico en los servicios de urgencias. Revisión y consenso de un grupo de expertos de las sociedades científicas SEHH y SEMES.

Pascual-Izquierdo, Cristina; (...); de la Rubia Comos, Javier

Article. 10.55633/s3me/E099.2023. 2023

Purtscher-like retinopathy associated with dermatomyositis and hemophagocytic lymphohistiocytosis.

Barreiro-González A; (...); Azorín Villena I

Article. 10.1016/j.oftal.2017.03.009. 2018

qMetforminintreatment Overcomes AT-Resistance in Acute Promyelocytic Leukemia Foxo3A Expression

Pereira-Martins, DA; (...); Rego, EM

Meeting Abstract. 10.1182/blood-2018-99-115068. 2018

Quality of thawed plasma inactivated with methylene blue after 48-hour storage

Balaguer A; (...); Sanz MÁ

Letter. 10.1016/j.transci.2014.11.005. 2015

QUANTIFICATION OF CIRCULATING TUMOR CELLS IS THE MOST RELEVANT PROGNOSTIC FACTOR AT DIAGNOSIS IN PATIENTS WITH MULTIPLE MYELOMA, WHO ARE TRANSPLANT CANDIDATES, Abstracts

Juan-Jose, Garces; (...); Bruno, Paiva

Meeting Abstract. 2021

Quantitative Expression Analysis of WT1 Main Isoforms in AML

Luna, Irene; (...); Sanz, Miguel A.

Article. 2011

QuANTUM-First Trial: FLT3-Internal Tandem Duplication (FLT3-ITD)-Specific Measurable Residual Disease (MRD) Clearance Is Associated With Improved Overall Survival (OS)

Levis, Mark J.; (...); Perl, Alexander E.

Meeting Abstract. 2023

Quantum-First Trial: FLT3-ITD-Specific MRD Clearance Is Associated with Improved Overall Survival

Levis, Mark J.; (...); Perl, Alexander

Meeting Abstract. 10.1182/blood-2022-162739. 2022

Quantum-First Trial: FMS-like Tyrosine Kinase 3-Internal Tandem Duplication ( FLT3-ITD)-Specific Measurable Residual Disease (MRD) Clearance Assessed through Induction ( IND) and Consolidation CONS) Is Associated with Improved Overall Survival (OS) in Newly Diagnosed (nd) FLT3-ITD+ AML Patients (pts)

Perl, Alexander; (...); Levis, Mark J.

Meeting Abstract. 10.1182/blood-2023-186785. 2023

QuANTUM-First Trial: FMS-like Tyrosine Kinase 3-Internal Tandem Duplication (FLT3-ITD)-Specific Measurable Residual Disease (MRD) Clearance Assessed Through Induction and Consolidation Is Associated with Improved Overall Survival (OS) in Newly Diagnosed (ND) FLT3-ITD+ AML Patients

Perl, Alexander E.; (...); Levis, Mark J.

Meeting Abstract. 2024

QuANTUM-First: Efficacy by Age in Newly Diagnosed (nd) Patients With FMS-Like Tyrosine Kinase 3-Internal Tandem Duplication-Positive (FLT3-ITD+) Acute Myeloid Leukemia (AML)

Erba, Harry P.; (...); Montesinos, Pau

Meeting Abstract. 2024

QuANTUM-First: phase 3, double-blind, placebo-controlled study of quizartinib in combination with induction and consolidation chemotherapy, and as maintenance therapy in patients (pts) with newly diagnosed (NDx) FLT3-ITD acute myeloid leukemia (AML)

Schlenk, R; (...); Erba, H

Meeting Abstract. 2017

QuANTUM-R: phase 3, randomised trial of Quizartinib in patients with FLT3-Internal tandem duplication (FLT3-ITD)-positive relapsed/refractory (R/R) acute myeloid meukaemia (AML)

Radsak, M. P.; (...); Levis, M. J.

Meeting Abstract. 2019

Quizartinib in FLT3-ITD-Mutated Relapsed/Refractory Acute Myeloid Leukemia: QuANTUM-R Trial Results

Cortes, JE; (...); Levis, MJ

Meeting Abstract. 10.1093/annonc/mdz374.003. 2019

Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial.

Erba, Harry P.; (...); Schlenk, Richard F.

Article. 10.1016/S0140-6736(23)00464-6. 2023

Quizartinib prolongs Life compared to Placebo plus intensive Induction Therapy and Consolidation Therapy followed by Monotherapy Treatment in Patients aged 18-75 Years with newly diagnosed FLT3-ITD and AML

Schlenk, R.; (...); Erba, H.

Meeting Abstract. 2022

Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial

Cortes, JE; (...); Levis, MJ

Article. 10.1016/S1470-2045(19)30150-0. 2019

Rabbit antithymocyte globulin versus horse antithymocyte globulin for treatment of acquired aplastic anemia: a retrospective analysis

Vallejo C; (...); Rayón C

Article. 10.1007/s00277-015-2305-3. 2015

Radioprotective activity and cytogenetic effect of resveratrol in human lymphocytes: an in vitro evaluation.

Sebastià N; (...); Montoro A

Article. 10.1016/j.fct.2012.10.013. 2013

Radioprotective activity and cytogenetic effect of resveratrol in human lymphocytes: an in vitro evaluation.

Sebastià, N; (...); Montoro, A.

Article. 2013

Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome

Cortes, JE; (...); Heuser, M

Article. 10.1038/s41375-018-0312-9. 2019

Randomized Phase 1-2 Study to Assess Safety and Efficacy of Low-Dose (LD) Oral Decitabine/ Cedazuridine (ASTX727) in Lower-Risk Myelodysplastic Syndromes (LR-MDS) Patients: Interim Safety Analysis

Garcia-Manero, Guillermo; (...); Yacoub, Abdulraheem

Meeting Abstract. 2023

RANDOMIZED PHASE 2 STUDY TO ASSESS SAFETY AND EFFICACY OF LOW-DOSE (LD) ORAL DECITABINE/CEDAZURIDINE (ASTX727) IN LOWER-RISK MYELODYSPLASTIC SYNDROMES (LR-MDS) PATIENTS: INTERIM SAFETY ANALYSIS

Garcia-Manero, G.; (...); Yacoub, A.

Meeting Abstract. 10.1016/j.leukres.2023.107270. 2023

Rapid and Robust CD4+and CD8+T-, NK-, B- and Monocyte Cell Reconstitution after Nicotinamide-Expanded Cord Blood Transplantation

Boelens, JJ; (...); Nierkens, S

Meeting Abstract. 10.1182/blood-2018-99-116700. 2018

Rapid and Robust CD4+and CD8+T-, NK-, B-Cell, Dendritic Cell, and Monocyte Reconstitution after Nicotinamide-Expanded Cord Blood Transplantation

de Koning, Coco; (...); Boelens, Jaap-Jan

Meeting Abstract. 2019

Rapid Detection of KIT Mutations in Core-Binding Factor Acute Myeloid Leukemia Using High-Resolution Melting Analysis

Fuster, Oscar; (...); Angel Sanz, Miguel

Article. 10.2353/jmoldx.2009.090043. 2009

RAPID DETECTION OF THE TRANSCRIBED PML-RARA DIRECTLY IN RNA IN ONE STEP BY MEANS OF RETRO-TRANSCRIPTION LOOP MEDIATED AMPLIFICATION (RT-Q-LAMP)

Sargas, C.; (...); Barragan, E.

Meeting Abstract. 2019

Rapid screening of ASXL1, IDH1, IDH2, and c-CBL mutations in de novo acute myeloid leukemia by high-resolution melting.

Ibáñez M; (...); Sanz MA

Article. 10.1016/j.jmoldx.2012.06.006. 2012

Ratify (Alliance 10603): Prognostic Impact of FLT3 tyrosine Kinase Domain (TKD) and NPM1 Mutation Status in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) Treated with Midostaurin or Placebo Plus Standard Chemotherapy

Voso, MT; (...); Lo-Coco, F

Meeting Abstract. 10.1182/blood-2018-99-114318. 2018

Real life experience with frontline azacitidine in a large series of older adults with acute myeloid leukemia stratified by MRC/LRF score: results from the expanded international E-ALMA series (E-ALMA plus )

Falantes, J; (...); European ALMA?+?Investigators

Article. 10.1080/10428194.2017.1365854. 2018

Real life outcomes of patients aged =75 years old with acute promyelocytic leukemia: experience of the PETHEMA registry.

Salamero O; (...); PETHEMA and PALG Groups

Article. 10.1080/10428194.2019.1607327. 2019

Real world evaluation of teclistamab in patients with RRMM: results from the IMF immunotherapy database project

Costa, Luciano; (...); Wong, Sandy

Meeting Abstract. 2023

Real-life clinical practice in Spain in the setting of new drug availability for ITP treatment. A Delphi-based Spanish expert panel consensus.

Gonzalez-Lopez, Tomas Jose; (...); Jarque, Isidro

Article. 10.1080/09537104.2024.2336104. 2024

Real-Life Evidence of Treatment with Venetoclax in Patients with Relapsed or Refractory Acute Myeloid Leukemia

Saiz-Rodriguez, M; (...); Pethema Grp

Meeting Abstract. 2021

REAL-LIFE EVIDENCE OF VENETOCLAX TREATMENT IN PATIENTS WITH ACUTE REPLAPSE OR REFRACTORY LEUKEMIA MYELOID

Jorge, Labrador; (...); Pau, Montesinos

Meeting Abstract. 2021

Real-World Characteristics and Outcome of Patients Treated With Single-Agent Ibrutinib for Chronic Lymphocytic Leukemia in Spain (IBRORS-LLC Study).

Abrisqueta, Pau; (...); Villanueva, Miguel

Article. 10.1016/j.clml.2021.07.022. 2021

Real-world effectiveness of caplacizumab vs standard of care in immune thrombotic thrombocytopenic purpura.

Pascual Izquierdo, Maria Cristina; (...); Del Rio-Garma, Julio

Article. 10.1182/bloodadvances.2022008028. 2022

Real-World Experience in Extracorporeal photopheresisfor adults with graft-versus-host disease.

Asensi Cantó P; (...); Gómez-Seguí I

Article. 10.1016/j.jtct.2023.09.001. 2023

Real-world experience with CPX-351 in high-risk acute myeloid leukemia.

Lemoli, Roberto M., Montesinos, Pau, Jain, Akriti

Article. 10.1016/j.critrevonc.2023.103984. 2023

Real-World Outcomes Using Front-Line Midostaurine in Combination with Intensive Chemotherapy for Patients Aged = 60 Years Old with FLT3 Mutated Acute Myeloid Leukemia

Requena, Gaspar Aspas; (...); Matinez-Cuadron, David

Meeting Abstract. 10.1182/blood-2023-190128. 2023

Real-World Validation of Molecular International Prognostic Scoring System (IPSS-M) for Myelodysplastic Syndromes

Sauta, Elisabetta; (...); Della Porta, Matteo G.

Meeting Abstract. 10.1182/blood-2022-163634. 2022

Real-World Validation of Molecular International Prognostic Scoring System for Myelodysplastic Syndromes.

Sauta, Elisabetta; (...); Della Porta, Matteo Giovanni

Article. 10.1200/JCO.22.01784. 2023

Rearrangements involving 11q23.3/KMT2A in adult AML: mutational landscape and prognostic implications - a HARMONY study.

Hernandez-Sanchez, Alberto; (...); Bullinger, Lars

Article. 10.1038/s41375-024-02333-4. 2024

Rearrangements Involving 11q23/KMT2A: Mutational Landscape and Prognostic Implications - Results of the Harmony Alliance AML Database

Hernandez Sanchez, Alberto; (...); Bullinger, Lars

Meeting Abstract. 10.1182/blood-2022-167480. 2022

Reasons for noncompliance with the national guidelines for initial antiretroviral therapy of HIV-infected patients in Spain, 2010-2015

Gonzalez, J; (...); Cohort Spanish HIV Res Network Co

Article. 10.1016/j.eimc.2019.02.007. 2019

Recent advances in the treatment of APL.

Sanz, Miguel A

Article. 2006

Reciprocal translocations in myelodysplastic syndromes and chronic myelomonocytic leukemias: review of 5,654 patients with an evaluable karyotype.

Costa D; (...); Nomdedeu B

Article. 10.1002/gcc.22071. 2013

Recombinant X chromosome in a prenatal diagnosis.

Orellana C; (...); Prieto F

Article. 10.1159/000089890. 2006

Recommendations for management of Chagas disease in organ and hematopoietic tissue transplantation programs in nonendemic areas

Pinazo, Maria-Jesus; (...); Shikanai-Yasuda, Maria Aparecida

Article. 10.1016/j.trre.2010.12.002. 2011

Recommendations for the Clinical Approach to Immune Thrombocytopenia: Spanish ITP Working Group (GEPTI).

Mingot-Castellano, Maria Eva; (...); Pascual-Izquierdo, Cristina

Article. 10.3390/jcm12206422. 2023

Recommendations for the diagnosis and treatment of patients with thrombotic thrombocytopenic purpura.

Mingot Castellano, Maria Eva; (...); Grp Espanol Aferesis GEA

Practice Guideline. 10.1016/j.medcli.2021.03.040. 2022

Recommendations for the study of monoclonal gammopathies in the clinical laboratory. A consensus of the Spanish Society of Laboratory Medicine and the Spanish Society of Hematology and Hemotherapy. Part I: update on laboratory tests for the study of monoclonal gammopathies.

Cardenas, Maria C.; (...); Cruz-Iglesias, Elena

Article. 10.1515/cclm-2023-0326. 2023

Recommendations for the study of monoclonal gammopathies in the clinical laboratory. A consensus of the Spanish Society of Laboratory Medicine and the Spanish Society of Hematology and Hemotherapy. Part II: methodological and clinical recommendations for the diagnosis and follow-up of monoclonal gammopathies

Cardenas, Maria C.; (...); Cruz-Iglesias, Elena

Article. 10.1515/cclm-2023-0325. 2023

Recommendations for the treatment of invasive fungal infection caused by filamentous fungi in the hematological patient

Barberan, Jose; (...); de la Torre Cisneros, Julian

Article. 2011

Recovery of Uninvolved Heavy/Light Chain Pair Immunoparesis during Maintenance Is an Independent Prognostic Factor for Multiple Myeloma and Could Complement Prognosis Value of Minimal Residual Disease

Lakhwani, Sunil; (...); Hernandez, Miguel-Teodoro

Meeting Abstract. 10.1182/blood-2022-167247. 2022

Recovery of uninvolved heavy/light chain pair immunoparesis in newly diagnosed transplant-eligible myeloma patients complements the prognostic value of minimal residual disease detection.

Lakhwani S; (...); Hernández MT

Article. 10.3324/haematol.2023.284154. 2024

REDEFINING OUTCOMES IN IMMUNE TTP: AN INTERNATIONAL WORKING GROUP CONSENSUS REPORT.

Cuker A; (...); Scully M

Article. 10.1182/blood.2020009150. 2021

Reduced corticosteroid use in adult patients with primary immune thrombocytopenia receiving romiplostim

Michel, Marc; (...); Kreuzbauer, Georg

Article. 10.1179/102453311X13025568942005. 2011

Reduced incidence of neurologic complications after allogeneic hematopoietic stem cell transplantation with calcineurin-free graft-versus-host disease prophylaxis.

Balaguer-Rosello, Aitana; (...); Sanz, Jaime

Article. 10.1016/j.jtct.2023.07.008. 2023

Reduced SLIT2 is Associated with Increased Cell Proliferation and Arsenic Trioxide Resistance in Acute Promyelocytic Leukemia.

Weinhäuser I; (...); Rego EM

Article. 10.3390/cancers12113134. 2020

Reduced-intensity conditioning for allogeneic haematopoietic stem cell transplantation in relapsed and refractory Hodgkin lymphoma: impact of alemtuzumab and donor lymphocyte infusions on long-term outcomes

Peggs, Karl S.; (...); Mackinnon, Stephen

Article. 10.1111/j.1365-2141.2007.06759.x. 2007

Reduced-Intensity Conditioning With Fludarabine and Busulfan Versus Fludarabine and Melphalan for Patients With Acute Myeloid Leukemia: A Report From the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation

Baron F; (...); Mohty M

Article. 10.1002/cncr.29163. 2015

Reduced-Intensity Versus Myeloablative Conditioning for Unrelated Cord Blood Transplantation in Adults with Acute Leukemia: A Report from Eurocord, the Acute Leukemia Working Party and the Cord Blood Committee of the Cellular Therapy & Immunobiology Working Party of the European Group for Blood and Marrow Transplantation

Baron, Frederic; (...); Nagler, Arnon

Article. 2015

Reference Values to Assess Hemodilution and Warn of Potential False-Negative Minimal Residual Disease Results in Myeloma.

Puig, Noemi; (...); Paiva, Bruno

Article. 10.3390/cancers13194924. 2021

Regions of homozygosity confer a worse prognostic impact in myelodysplastic syndrome with normal karyotype.

Mallo, Mar; (...); Sole, Francesc

Article. 10.1002/jha2.651. 2023

Relapse Prevention in Acute Myeloid Leukemia: The Role of Immunotherapy with Histamine Dihydrochloride and Low-Dose Interleukin-2.

Montesinos, Pau; (...); Heuser, Michael

Article. 10.3390/cancers16101824. 2024

Relationship of immunohistochemistry, copy number aberrations and epigenetic disorders with BRCAness pattern in hereditary and sporadic breast cancer

Estal, RM; (...); Gilabert, PB

Article. 10.1007/s10689-015-9864-2. 2016

Relevancia de la anfotericina B liposomal en el tratamiento de las infecciones fúngicas invasoras en pacientes oncohematológicos.

García-Vidal C, Vázquez L, Jarque I

Article. 10.1016/j.riam.2021.03.001. 2021

REMOVAL OF GERMINAL LINE MUTATIONS IN PATIENTS WITH MDS AND AML: WHO SHOULD BE PERFORMED?

Santiago, Marta; (...); Cervera, Jose

Meeting Abstract. 2020

Renal response to rescue treatments in Relapsed Refractory Multiple Myeloma (RRMM) patients with renal impairment: final data of a large, observational, prospective study (MIR50)

Garcia-Guinon, Antonio; (...); de la Rubia, Javier

Meeting Abstract. 2021

Reply.

Lozano Almela, Maria Luisa, Sanz Alonso, Miguel Angel, Vicente Garcia, Vicente

Letter. 10.1016/j.medcli.2021.09.029. 2022

Reproducibility of the World Health Organization 2008 criteria for myelodysplastic syndromes.

Senent L; (...); Florensa L

Article. 10.3324/haematol.2012.071449. 2013

RESCUE TREATMENT WITH DECITABINE AFTER PROGRESSION TO AZACITIDINE IN AML

De la Fuente, A; (...); Montesinos, P

Meeting Abstract. 2018

RESPONSE TO AZACITIDINE IN A SERIES OF 94 PATIENTS WITH CHRONIC MYELOMONOCYTIC LEUKEMIA FROM THE SPANISH GROUP OF MYELODYSPLASTIC SYNDROMES

Triguero, A; (...); Sanz, G

Meeting Abstract. 10.1016/S0145-2126(17)30232-1. 2017

Response to azacitidine in patients with chronic myelomonocytic leukemia according to overlap myelodysplastic/myeloproliferative neoplasms criteria*

Triguero, A.; (...); Sanz, G.

Article. 10.1016/j.leukres.2022.106836. 2022

Response to erythropoietic-stimulating agents in patients with chronic myelomonocytic leukemia

Xicoy B; (...); Sanz G

Article. 10.1111/ejh.12679. 2016

Response to lenalidomide in myelodysplastic syndromes with del(5q): influence of cytogenetics and mutations.

Mallo M; (...); Solé F

Article. 10.1111/bjh.12354. 2013

Results from a Global Randomized Phase 3 Study of Guadecitabine (G) Vs Treatment Choice (TC) in 302 Patients with Relapsed or Refractory (r/r) Acute Myeloid Leukemia after Intensive Chemotherapy (ASTRAL-2 Study)

Roboz, Gail J.; (...); Dohner, Hartmut

Meeting Abstract. 10.1182/blood-2021-147769. 2021

Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse

Levis, Mark; (...); Smith, B. Douglas

Article. 10.1182/blood-2010-08-301796. 2011

Results of a preoperative autologous blood donation program for patients undergoing elective major spine surgery.

Solves P; (...); Sanz MA

Article. 10.1016/j.transci.2013.06.016. 2013

Results of a randomized phase 3 study of oral sapacitabine in elderly patients with newly diagnosed acute myeloid leukemia (SEAMLESS)

Kantarjian, Hagop M.; (...); Chiao, Judy H.

Article. 10.1002/cncr.33828. 2021

Results of allogeneic stem cell transplantation in the Spanish MDS registry: Prognostic factors for low risk patients

Díez Campelo M; (...); Spanish Registry of MDS

Article. 10.1016/j.leukres.2014.07.009. 2014

Results of the compassionate program of inotuzumab ozogamicin for adult patients with relapsed or refractory acute lymphoblastic leukemia in Spain.

Torrent, Anna; (...); Ribera, Josep-Maria

Article. 10.1111/ejh.14031. 2023

Results of the Ebmt Saawp Phase III Prospective Randomized Multicenter Race Study of Horse Atg and Ciclosporin with or Without Eltrombopag in Naive Saa Patients

de Latour, RP; (...); Risitano, A

Meeting Abstract. 2020

RESULTS OF THE PEGASUS PHASE III TRIAL FOR THE COMPARISON OF PEGCETACOPLAN WITH ECULIZUMAB IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA

Jarque, Isidro; (...); Peffault, de latour Regis

Meeting Abstract. 2020

RESULTS OF THE TREATMENT OF LYMPHOBLASTIC LYMPHOMA WITH PROTOCOLS OF LYMPHOBLASTIC ACUTE LEUKEMIA OF PETHEMA GROUP

Sagues, M.; (...); Ribera, J. M.

Meeting Abstract. 2019

Results of treatment with azacitidine in patients aged >= 75 years included in the Spanish Registry of Myelodysplastic Syndromes

Xicoy B; (...); Sanz G

Article. 10.3109/10428194.2013.834532. 2014

Results of two protocols for platelet transfusion in patients undergoing abo incompatible hematopoietic stem cell transplantation

Solves, P; (...); Sanz, G

Letter. 10.1016/j.transci.2019.02.002. 2019

RETROSPECTIVE CONTROL CASE STUDY ON THE EFFICACY OF AUTOLOGOUS TRANSPLANTATION OF HAEMATOPOIETIC PROGENITORS IN THE FIRST LINE TREATMENT OF PATIENTS WITH PERIPHERAL T CELL LYMPHOMA

Parra, ML; (...); Martin, A. A.

Meeting Abstract. 2017

RETROSPECTIVE STUDY OF AZACITIDINE IN PATIENTS OF ADVANCED AGE WITH ACUTE MYELOID LEUKEMIA (LMA). RESULTS OF THE ALMA/ PETHEMA COHORT IN COMPARISON WITH THE MRC RISK INDEX SCORE

Falantes, J.; (...); Ramos, F.

Meeting Abstract. 2015

Revealing the mutational landscape of acute promyelocytic leukemia

Cervera, J, Sanz, MA

Editorial Material. 10.21037/tcr.2017.02.47. 2017

Revised international prognostic scoring system for myelodysplastic syndromes.

Greenberg PL; (...); Haase D

Article. 10.1182/blood-2012-03-420489. 2012

Revision of the risk of secondary leukaemia after mitoxantrone in multiple sclerosis populations is required

Pascual, Ana M.; (...); Casanova, Bonaventura

Article. 10.1177/1352458509107015. 2009

Revisiting Co-existing Chromosomal Abnormalities in NPM1-mutated AML in Light of the Revised ELN 2022 classification.

Angenendt, Linus; (...); Schliemann, Christoph

Article. 10.1182/blood.2022018582. 2022

RIC versus MAC UCBT in adults with AML: A report from Eurocord, the ALWP and the CTIWP of the EBMT

Baron, F; (...); Nagler, A

Article. 10.18632/oncotarget.9599. 2016

Risk factors for outcomes after unrelated cord blood transplantation for adults with acute lymphoblastic leukemia: a report on behalf of Eurocord and the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation

Tucunduva L; (...); Rocha V

Article. 10.1038/bmt.2014.72. 2014

Risk of Rh (D) alloimmunisation after Rh (D) positive platelet transfusions in patients undergoing haematopoietic stem cell transplantation

Solves P; (...); Sanz MA

Letter. 10.1111/tme.12179. 2015

Risk-Adapted Treatment for Low- and Intermediate-Risk Acute Promyelocytic Leukemia

Article. 10.3816/CLML.2010.s.025. 2010

Risk-adapted treatment of acute promyelocytic leukemia based on all-trans retinoic acid and anthracycline with addition of cytarabine in consolidation therapy for high-risk patients: further improvements in treatment outcome

Sanz, Miguel A.; (...); Lowenberg, Bob

Article. 10.1182/blood-2010-01-266007. 2010

Risk-adapted treatment of acute promyelocytic leukemia with all-trans retinoic acid and anthracycline monochemotherapy: long-term outcome of the LPA 99 multicenter study by the PETHEMA Group.

Sanz MA; (...); Lowenberg B

Article. 10.1182/blood-2008-05-159632. 2008

Rituximab and Specific Therapy for Patients with Burkitt's Leukemia and Lymphoma. Results of the BURKIMAB14 Trial from the Spanish Pethema and Geltamo Groups in 80 Patients

Ribera, Josep-Maria; (...); Sancho, Juan-Manuel

Meeting Abstract. 10.1182/blood-2019-125683. 2019

Rituximab maintenance after first-line therapy with rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) for chronic lymphocytic leukemia.

Abrisqueta P; (...); Bosch F

Article. 10.1182/blood-2013-05-502773. 2013

RNA Sequencing Analysis for the Identification of a PCM1/PDGFRB Fusion Gene Responsive to Imatinib

Such, E; (...); Cervera, J

Article. 10.1159/000497348. 2019

Role of Allogeneic Stem Cell Transplantation in Preventing Relapse in Adult BCR::ABL1-like Acute Lymphoblastic Leukemia

Ribera, Jordi; (...); Ribera, Josep-Maria

Meeting Abstract. 10.1182/blood-2023-186265. 2023

Role of autologous bone marrow transplant in multiple myeloma.

Blanes M, de la Rubia J

Article. 10.1097/CCO.0b013e328358f686. 2012

Role of Hematopoietic Stem Cell Transplantation in Acute Promyelocytic Leukemia.

Sanz, Jaime, Montesinos, Pau, Sanz, Miguel A

Review. 10.3389/fonc.2021.614215. 2021

Role of Measurable Residual Disease (MRD) in Redefining Complete Response (CR) in Elderly Patients with Acute Myeloid Leukemia (AML): Results from the Pethema-Flugaza Phase III Clinical Trial

Paiva, B; (...); Montesinos, P

Meeting Abstract. 10.1182/blood-2018-99-113299. 2018

Role of microRNAs in the pathogenesis of melanoma

Murria, Rosa; (...); Botella, Rafael

Meeting Abstract. 2017

Role of Pharmacogenetics in the Treatment of Acute Myeloid Leukemia: Systematic Review and Future Perspectives.

Pinto-Merino, Alvaro; (...); Saiz-Rodriguez, Miriam

Article. 10.3390/pharmaceutics14030559. 2022

Rozanolixizumab, an Anti-FcRn Antibody: Final Results from a Phase II, Multiple-Dose Study in Patients with Primary Immune Thrombocytopenia

Robak, Tadeusz; (...); Jolles, Stephen

Meeting Abstract. 10.1182/blood-2019-129839. 2019

Rozrolimupab, a mixture of 25 recombinant human monoclonal RhD antibodies, in the treatment of primary immune thrombocytopenia.

Robak T; (...); Petersen J

Article. 10.1182/blood-2012-06-438804. 2012

RUXOLITINIB IN ACUTE AND CHRONIC GRAFT-VERSUS RECEPTOR DISEASE: LONG-TERM REAL-LIFE EXPERIENCE IN A MULTI-CENTRE STUDY IN PEDIATRIC POPULATION

Escamilla Gomez, Virginia; (...); Garcia Gutierrez, Valentin

Meeting Abstract. 2024

Sabatolimab (MBG453) Combination Treatment Regimens for Patients (Pts) with Higher-Risk Myelodysplastic Syndromes (HR-MDS): The MDS Studies in the Stimulus Immuno-Myeloid Clinical Trial Program

Zeidan, Amer M.; (...); Garcia-Manero, Guillermo

Meeting Abstract. 10.1182/blood-2021-145626. 2021

Safety and Efficacy from a Phase 1b/2 Study of IMGN632 in Combination with Azacitidine and Venetoclax for Patients with CD123-Positive Acute Myeloid Leukemia

Daver, Naval; (...); Sweet, Kendra

Meeting Abstract. 10.1182/blood-2021-146503. 2021

Safety and efficacy of talacotuzumab plus decitabine or decitabine alone in patients with acute myeloid leukemia not eligible for chemotherapy: results from a multicenter, randomized, phase 2/3 study.

Montesinos P; (...); Wei AH

Article. 10.1038/s41375-020-0773-5. 2020

Salvage regimens using conventional chemotherapy agents for relapsed/refractory adult AML patients: a systematic literature review

Review. 10.1007/s00277-018-3304-y. 2018

Salvage Therapy with Second-Generation Inhibitors for FLT3 Mutated Acute Myeloid Leukemia: A Real-World Study by the CETLAM and PETHEMA Groups

Vives, Susana; (...); PETHEMA Grp

Article. 10.3390/cancers16234028. 2024

Sclerodermatous Chronic Graft-versus-Host Disease Treated With Imatinib: A Dermatological Perspective.

Moles-Poveda, P; (...); Botella-Estrada, R

Article. 10.1016/j.ad.2017.11.003. 2018

Screening for IDH mutations in chronic myelomonocytic leukemia.

Ibañez M; (...); Sanz MA

Letter. 10.3109/10428194.2012.701295. 2013

SCREENING FOR POTENTIAL THERAPEUTIC OPPORTUNITIES FOR B-PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS WITH IKZF1 DELETIONS

Ribera, Jordi; (...); Ribera, Josep Maria

Meeting Abstract. 2020

Secondary Acute Myeloid Leukemia from a Previous Chronic Myeloproliferative Neoplasm: A Study of Grelam-Chile Concerning Chilean Patients on Behalf of AML Pethema Registry

Espinoza, Marcela; (...); Martinez-Cuadron, David

Meeting Abstract. 10.1182/blood-2023-185288. 2023

Secondary and Therapy-Related Acute Promyelocytic Leukemia. Experience of the PETHEMA Registry

Montesinos, P; (...); GATLA Cooperative Grp

Meeting Abstract. 2017

Secondary malignancies and survival outcomes after autologous stem cell transplantation for follicular lymphoma in the pre-rituximab and rituximab eras: a long-term follow-up analysis from the Spanish GELTAMO registry

Jimenez-Ubieto, A; (...); Lahuerta, JJ

Letter. 10.1038/s41409-018-0096-6. 2018

Secondary thrombotic microangiopathy and eculizumab: A reasonable therapeutic option

Roman, E; (...); Gorriz, JL

Review. 10.1016/j.nefro.2017.01.006. 2017

SEL24/MEN1703 Inhibits PIM/FLT3 Downstream Target in Acute Myeloid Leukemia (AML) Patients: Results of the Pharmacodynamics (PD) Assay and Genomic Profiling in the First-in-Human Diamond-01 Trial

Paoli, Alessandro; (...); Pellacani, Andrea

Meeting Abstract. 10.1182/blood-2021-150277. 2021

Selection and management of older patients with acute myeloid leukemia treated with glasdegib plus low-dose cytarabine: expert panel review.

Cortes JE; (...); Heuser M

Review. 10.1080/10428194.2020.1817445. 2020

Selective IgA Deficiency and Blood Component Transfusion: In Search of the Lost Evidence

Solves, Pilar; (...); de la Rubia, Javier

Article. 10.3390/hemato5020009. 2024

Sequencing of a novel HLA-B allele, B*51:153, in a Spanish individual.

Planelles D; (...); Vicario JL

Article. 10.1111/tan.12195. 2013

SEQUENCING OF THE EXOME IN THE RECALLING OR REFRACTORY AML

Simarro Claudia, Sargas; (...); Eva, Barragan

Meeting Abstract. 2021

Severity of Covid-19 Clinical Outcomes and Mortality in Multiple Myeloma Patients over Year 1 of the Pandemic

Martinez-Lopez, Joaquin; (...); San-Miguel, Jesus F.

Meeting Abstract. 10.1182/blood-2021-149192. 2021

Should we consider caplacizumab as routine treatment for acute thrombotic thrombocytopenic purpura? An expert perspective on the pros and cons.

Seguí IG; (...); de la Rubia J

Article. 10.1080/17474086.2024.2318347. 2024

Significance of increased blastic-appearing cells in bone marrow following myeloablative unrelated cord blood transplantation in adult patients.

Montesinos P; (...); Sanz GF

Article. 10.1016/j.bbmt.2011.11.008. 2012

SIGNIFICANCE OF INCREASED BONE MARROW BLASTS AFTER MYELOID ENGRAFTMENT IN ADULT PATIENTS UNDERGOING UNRELATED CORD BLOOD TRANSPLANTATION

Gascon, A.; (...); Sanz, M.

Article. 2010

Similar Outcome of Adolescents and Young Adults (AYA) and Older Adults with Newly Diagnosed Acute Lymphoblastic Leukemia (ALL) without Philadelphia Chromosome (Ph-) Included in the Pethema LAL-2019 Trial

Torrent, Anna; (...); Ribera, Josep-Maria

Meeting Abstract. 10.1182/blood-2024-207954. 2024

Simplified in-House Deep Sequencing Method of Inmunoglobulin Genes for Minimal Residual Dissease Quantification and Risk Stratification in Multiple Myeloma

Sanchez-Vega, Beatriz; (...); Martinez Lopez, Joaquin

Article. 2015

Simultaneous analysis of the expression of 14 genes with individual prognostic value in myelodysplastic syndrome patients at diagnosis: WT1 detection in peripheral blood adversely affects survival.

Santamaría C; (...); González M

Article. 10.1007/s00277-012-1538-7. 2012

SINGLE CELL-LEVEL CHARACTERIZATION OF THE IMMUNE MICROENVIRONMENT OF MULTIPLE MYELOMA IDENTIFIES CD27 NEGATIVE T LYMPHOCYTES AS TUMOR SPECIFIC

Perez, Cristina; (...); Paiva, Bruno

Meeting Abstract. 2020

Single daily dose of intravenous busulfan and melphalan as a conditioning regimen for patients with multiple myeloma undergoing autologous stem cell transplantation: a phase II trial

Blanes, Margarita; (...); Sanz, Miguel A.

Article. 10.1080/10428190802630170. 2009

Single nucleotide polymorphism array karyotyping: a diagnostic and prognostic tool in myelodysplastic syndromes with unsuccessful conventional cytogenetic testing.

Arenillas L; (...); Solé F

Article. 10.1002/gcc.22112. 2013

Single- or double-unit UCBT following RIC in adults with AL: a report from Eurocord, the ALWP and the CTIWP of the EBMT

Baron, F; (...); Nagler, A

Article. 10.1186/s13045-017-0497-9. 2017

Single umbilical cord blood with or without CD34(+) cells from a third-party donor in adults with leukemia.

Sanz, J; (...); Grp Espanol Trasplante

Article. 10.1182/bloodadvances.2017006999. 2017

Single versus tandem autologous stem-cell transplantation in patients with newly diagnosed multiple myeloma and high-risk cytogenetics: a retrospective study of the PETHEMA/Spanish Myeloma Group (GEM)

Villalba, Ana; (...); De la Rubia, Javier

Meeting Abstract. 2022

Single-Cell Characterization of Multiple Myeloma (MM) Immune Microenvironment Identifies CD27-negative T cells as Potential Tumor-Reactive Lymphocytes

Botta, C; (...); Paiva, B

Meeting Abstract. 10.1016/j.clml.2019.09.581. 2019

Single-Nucleotide Polymorphism Array-Based Karyotyping of Acute Promyelocytic Leukemia

Gómez-Seguí I; (...); Sanz MA

Article. 10.1371/journal.pone.0100245. 2014

Single-point and kinetics of peripheral residual disease by mass spectrometry to predict outcome in patients with high risk smoldering multiple myeloma included in the GEM-CESAR trial.

Puig N; (...); Mateos MV

Article. 10.3324/haematol.2024.285742. 2024

Single-unit umbilical cord blood transplantation from unrelated donors in patients with hematological malignancy using busulfan, thiotepa, fludarabine and ATG as myeloablative conditioning regimen.

Sanz J; (...); Grupo Español de Trasplante Hematopoyético y Terapia Celular (GETH)

Article. 10.1038/bmt.2012.13. 2012

SINTRA-REV CLINICAL TRIAL: PRELIMINARY ANALYSIS OF EFFICACY AND SAFETY AT WEEK 12 OF TREATMENT IN MDS DEL(5Q) AND TRANSFUSION INDEPENDENCE

Cadenas, FL; (...); Diez-Campelo, M

Meeting Abstract. 2017

Sirolimus versus cyclosporine in haploidentical stem cell transplantation with posttransplant cyclophosphamide and mycophenolate mofetil as graft-versus-host disease prophylaxis.

Hernani, Rafael; (...); Solano, Carlos

Article. 10.1002/jha2.183. 2021

Sister chromatid exchange, (SCE), High-Frequency Cells (HFCs) and SCE distribution patterns in peripheral blood lymphocytes of Spanish adult smokers compared to non-smokers

Sebastià N; (...); Montoro A

Article. 10.1016/j.fct.2014.01.011. 2014

SJOGREN-LARSSON SYNDROME IN TWO SISTERS WITH AN INTRONIC VARIANT OF ALDH3A2 GENE: CLINICAL FINDINGS

Fernandez, F.; (...); Cervera, J.

Meeting Abstract. 2019

Slit-Robo Pathway Is Clinically Relevant and May Represent a Potential Target in Acute Promyelocytic Leukemia

Weinhauser, I; (...); Rego, EM

Meeting Abstract. 10.1182/blood-2018-99-115370. 2018

Somatic gene mutation patterns and burden influence outcomes with enasidenib in relapsed/refractory IDH2-mutated AML.

Risueno, Alberto; (...); Hasan, Maroof

Article. 10.1016/j.leukres.2024.107497. 2024

Somatic Genetic and Epigenetic Architecture of Myelodysplastic Syndromes Arising from GATA2 Deficiency

Loyola, Victor Bengt Pastor; (...); Wlodarski, Marcin W.

Article. 2015

Spanish consensus statement for diagnosis and treatment of paroxysmal nocturnal haemoglobinuria

Villegas A; (...); Urbano-Ispizua Á

Editorial Material. 10.1016/j.medcli.2015.12.012. 2016

Spanish Guidelines for the use of targeted deep sequencing in myelodysplastic syndromes and chronic myelomonocytic leukaemia.

Palomo L; (...); Such E

Article. 10.1111/bjh.16175. 2020

Spanish registry of hemoglobinopathies and rare anemias (REHem-AR): demographics, complications, and management of patients with ß-thalassemia.

Bardón-Cancho EJ; (...); Cela E

Article. 10.1007/s00277-024-05694-z. 2024

Special considerations in the management of adult patients with acute leukaemias and myeloid neoplasms in the COVID-19 era: recommendations from a panel of international experts

Zeidan, AM; (...); Mascarenhas, J

Review. 10.1016/S2352-3026(20)30205-2. 2020

Spondylodiscitis caused by Candida krusei: case report and susceptibility patterns.

Pemán J; (...); Molina A.

Article. 2006

Standardising acute myeloid leukaemia classification systems: a perspective from a panel of international experts.

Shallis RM; (...); Zeidan AM

Article. 10.1016/S2352-3026(23)00159-X. 2023

STIMULUS-MDS2 design and rationale: a phase III trial with the anti-TIM-3 sabatolimab (MBG453)+azacitidine in higher risk MDS and CMML-2.

Zeidan AM; (...); Santini V

Article. 10.2217/fon-2022-1237. 2023

STUDY OF CHRONIC ANEMIA IN THE ELDERLY

Villalba, A.; (...); Sanz, M. A.

Meeting Abstract. 2017

STUDY OF MUTATIONAL PROFILE AND CORRELATION OF RESPONSE TO EX VIVO PHARMACOLOGICAL TEST, IN THE DIAGNOSTIC OF THE AML

de la Fuente, EO; (...); Diaz, RA

Meeting Abstract. 2018

STUDY OF PRE-EXISTING MUTATIONS IN HEMATOPOYETIC CELLS OF THE BONE MEDULA IN PATIENTS WITH MYELOID NEOPLASIAS RELATED TO THERAPY

Ibanez, M; (...); Sanz, G

Meeting Abstract. 2017

STUDY OF THE CELL POPULATIONS INFUSED IN THE TRANSPLANT ALOGENICO OF BROTHER HLA-IDENTICAL

Villalba, A.; (...); Sanz, M. A.

Meeting Abstract. 2017

STUDY OF THE CLINICAL RELEVANCE AND GENOMIC PROFILE OF MINIMAL RESIDUAL MULTIPLE MYELOMA DISEASE IN PATIENTS WITH STANDARD RISK AND HIGH CYTOGENETIC RISK

Goicoechea, I; (...); Paiva, B.

Meeting Abstract. 2019

STUDY OF THE EFFECTIVENESS OF IMATINIB IN CHRONIC GRAFT-VERSUS-HOST DISEASE IN A SERIES OF 19 CASES

Poveda, PM; (...); Caballer, JS

Meeting Abstract. 2017

Study of the S427G polymorphism and of MYBL2 variants in patients with acute myeloid leukemia

Dolz S; (...); Barragán E

Article. 10.3109/10428194.2015.1049167. 2016

STUDY OF TRANSCRIPTIONAL DIFFERENCES BETWEEN THE IDH2 R140 AND R172 MUTATIONS BY MEANS OF MODELING IN THE ORGANISM CAENORHABDITIS ELEGANS

Gonzalez, Romero Elisa; (...); Cervera, Jose Vicente

Meeting Abstract. 2020

Successful discontinuation of eltrombopag after complete remission in patients with primary immune thrombocytopenia

González-López TJ; (...); González-Porras JR

Article. 10.1002/ajh.23900. 2015

Summer Pruning, an Eco-Friendly Approach to Controlling Bitter Pit and Preserving Sensory Quality in Highly Vigorous Apple cv. 'Reinette du Canada'

Guerra, Marcos; (...); Antonio Casquero, Pedro

Article. 10.3390/agriculture11111081. 2021

Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study.

Rosiñol L; (...); Programa para el Estudio y la Terapéutica de las Hemopatías Malignas

Article. 10.1182/blood-2012-02-408922. 2012

SUPERIORITY OF THE BIOPSY OF BONE MARROW ON PET/TC IN THE PREDICTION OF THE FREE SURVIVAL OF PROGRESSION IN DIFFUSE LINFOMA B OF BIG CELL

Liang, THC; (...); Ortuno, F.

Meeting Abstract. 2017

Survival of hematological patients after discharge from the intensive care unit: a prospective observational study.

Bernal T; (...); Albaiceta GM

Article. 10.1186/cc13172. 2013

Survival of Patients with Acute Myeloid Leukemia According to Age in a University Hospital in Colombia

Melo, CLS; (...); Montesinos, P

Meeting Abstract. 2021

Survival of Patients with Acute Myeloid Leukemia, Taken to Hematopoietic Stem Cell Transplantation: Experience of A Center in Colombia

Melo, CLS; (...); Ortiz, MF

Meeting Abstract. 2021

Survival of Patients with Secondary Acute Myeloid Leukemia in a University Hospital in Colombia

Ortiz, MF; (...); Sossa, C

Meeting Abstract. 2021

Survival outcomes and clinical benefit in patients with acute myeloid leukemia treated with glasdegib and low-dose cytarabine according to response to therapy

Cortes, JE; (...); Heuser, M

Article. 10.1186/s13045-020-00929-8. 2020

Survival Outcomes for Patients (pts) in the QUAZAR AML-001 Trial Who Received Subsequent Therapy for Acute Myeloid Leukemia (AML) after Discontinuing Oral Azacitidine (Oral-AZA) or Placebo (PBO)

Pfeilstoecker, M.; (...); Doehner, H.

Meeting Abstract. 2023

Survival Outcomes for Patients in the QUAZAR AML-001 Trial Who Received Subsequent Therapy for Acute Myeloid Leukemia (AML) after Discontinuing Oral Azacitidine or Placebo

Ravandi, Farhad; (...); Doehner, Hartmut

Meeting Abstract. 10.1182/blood-2022-159045. 2022

Survival outcomes from the QUAZAR AML-001 trial with oral azacitidine (Oral-AZA) for patients with acute myeloid leukemia (AML) in remission by disease subtype, cytogenetic risk, and NPM1 mutation status at diagnosis (Dx)

Pfeilstoecker, Michael; (...); Menezes, Daniel

Meeting Abstract. 2022

Survival outcomes in patients with acute myeloid leukaemia who received subsequent therapy for relapse in QUAZAR AML-001.

Ravandi, Farhad; (...); Roboz, Gail J

Article. 10.1111/bjh.19202. 2023

Survival outcomes with oral azacitidine maintenance in patients with acute myeloid leukemia in remission by receipt of initial chemotherapy: subgroup analyses from the phase 3 QUAZAR AML-001 trial.

Wei AH; (...); Ravandi F

Article. 10.3324/haematol.2022.282296. 2023

Susceptibility to amphotericin B and fluconazole determined by flow cytometry. Is it the same?

Cordon, L.; (...); Sanz, M.

Article. 2011

Sustained Recovery of Uninvolved Heavy/Light Chain Pair Immunoparesis during Maintenance Discriminates Patients with Sustained Negative Minimal Residual Disease

Lakhwani, Sunil; (...); Teodoro Hernandez Garcia, Miguel

Meeting Abstract. 10.1182/blood-2023-179452. 2023

Syncope as a manifestation of mast cell activation disorder

Perales Chordá C; (...); Hernández Fernandez de Rojas D

Letter. 10.1016/j.anai.2014.11.019. 2015

Systematic Review of Pharmacogenetics of ABC and SLC Transporter Genes in Acute Myeloid Leukemia

Montesinos, Pau, Sanz, Miguel A

Review. 10.3390/pharmaceutics14040878. 2022

T Cell-Depleted Related HLA-Mismatched Peripheral Blood Stem Cell Transplantation as Salvage Therapy for Graft Failure after Single Unit Unrelated Donor Umbilical Cord Blood Transplantation

Moscardó F; (...); Sanz GF

Article. 10.1016/j.bbmt.2014.03.024. 2014

t(1;19)(q23;p13) TCF3-PBX1 May Not Be an Intermediate-Risk Subtype in Adult B-Cell Precursor Acute Lymphoblastic Leukemia Patients Treated With MRD-Oriented Protocols from the PETHEMA Group

Ribera, J; (...); Ribera, JM

Meeting Abstract. 2021

Tamibarotene in patients with acute promyelocytic leukaemia relapsing after treatment with all-trans retinoic acid and arsenic trioxide

Sanford D; (...); Cortes JE

Article. 10.1111/bjh.13607. 2015

Targeting CD38 with isatuximab and a novel CD38/CD3×CD28 trispecific T-cell engager in older patients with acute myeloid leukemia.

Martín-Sánchez E; (...); Zabaleta A

Article. 10.1182/bloodadvances.2024013212. 2024

T-cell Depleted Peripheral Blood versus Unmanipulated Bone Marrow in Matched Sibling Transplantation for Aplastic Anemia.

Chorao, Pedro; (...); Sanz, Jaime

Article. 10.1016/j.jtct.2023.01.016. 2023

T-cell-replete haploidentical transplantation versus autologous stem cell transplantation in adult acute leukemia: a matched pair analysis

Gorin NC; (...); Acute Leukemia Working Party of the European Society for Blood and Marrow Transp

Article. 10.3324/haematol.2014.111450. 2015

Testing for minimal residual disease in adults with acute lymphoblastic leukemia in Europe: a clinician survey

Pigneux, A; (...); Bruggemann, M

Article. 10.1186/s12885-018-5002-5. 2018

The addition of ofatumumab to the conditioning regimen does not improve the outcome of patients with high-risk CLL undergoing reduced intensity allogeneic haematopoietic cell transplantation: a pilot trial from the GETH and GELLC (CLL4 trial)

Montesinos, P; (...); Delgado, J

Letter. 10.1038/bmt.2016.145. 2016

The clinical benefit of instituting a prospective clinical community-acquired respiratory virus surveillance program in allogeneic hematopoietic stem cell transplantation.

Piñana J; (...); Sanz J

Article. 10.1016/j.jinf.2019.12.022. 2020

The Clinical Spectrum, Diagnosis, and Management of GATA2 Deficiency.

Santiago, Marta; (...); Cervera, Jose

Article. 10.3390/cancers15051590. 2023

THE COMBINATION OF GENOMIC ANALYSIS AND MINIMAL RESIDUAL DISEASE IMPROVES THE STRATIFICATION OF ADULT PATIENTS WITH TYPE T-LYMPHOBLASTIC LEUKEMIA (LAL-T) TREATED ACCORDING TO THE PETHEMA PROTOCOLS

Gonzalez Gil, C.; (...); Genesca Ferrer, E.

Meeting Abstract. 2021

The degree of neutropenia has a prognostic impact in low risk myelodysplastic syndrome.

Cordoba I; (...); Cañizo MC

Article. 10.1016/j.leukres.2011.10.025. 2012

The deletion of exons 3-5 of BRCA1 is the first founder rearrangement identified in breast and/or ovarian cancer Spanish families.

Palanca S; (...); Bolufer P

Article. 10.1007/s10689-012-9579-6. 2013

The differentiation syndrome in patients with acute promyelocytic leukemia: experience of the pethema group and review of the literature.

Article. 10.4084/MJHID.2011.059. 2011

The division of chronic myelomonocytic leukemia (CMML)-1 into CMML-0 and CMML-1 according to 2016 World Health Organization (WHO) classification has no impact in outcome in a large series of patients from the Spanish group of MDS

Xicoy, Blanca; (...); Sanz, Guillermo

Letter. 10.1016/j.leukres.2018.05.003. 2018

The effect of timing on community acquired respiratory virus infection mortality during the first year after allogeneic hematopoietic stem cell transplantation: a prospective epidemiological survey.

Piñana JL; (...); Navarro D

Article. 10.1038/s41409-019-0698-7. 2020

The effects of continued azacitidine treatment cycles on response in higher risk patients with myelodysplastic syndromes: an update.

Silverman, L R; (...); Beach, C L

Article. 10.3332/ecancer.2008.118. 2008

The European LeukemiaNet: achievements and perspectives

Hehlmann, Ruediger; (...); Saussele, Susanne

Article. 10.3324/haematol.2010.032979. 2011

The experience of the International Consortium on Acute Promyelocytic Leukemia in monitoring minimal residual disease in acute promyelocytic leukaemia

Lange, AP; (...); Rego, EM

Letter. 10.1111/bjh.14490. 2018

The First Real-World Evidence Prospective Registry of Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm Treated with Tagraxofusp, a CD123-Targeted Therapy, in Europe

Platzbecker, Uwe; (...); Mohty, Mohamad

Meeting Abstract. 10.1182/blood-2021-145099. 2021

The FLT3-like Gene Expression Signature Predicts Response to Quizartinib in Wild-Type FLT3 Acute Myeloid Leukemia: An Analysis of the Pethema Quiwi Trial

Mosquera Orgueira, Adrian; (...); Montesinos, Pau

Meeting Abstract. 10.1182/blood-2023-180482. 2023

The genomic profiling of high-risk smoldering myeloma patients treated with an intensive strategy unveils potential markers of resistance and progression.

Medina-Herrera A; (...); Garcia-Sanz R

Article. 10.1038/s41408-024-01053-3. 2024

The impact of graft-versus-host disease prophylaxis in reduced-intensity conditioning allogeneic stem cell transplant in acute myeloid leukemia: a study from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation

Rubio MT; (...); Mohty M

Article. 10.3324/haematol.2014.119339. 2015

The impact of GVHD on outcomes after adult single cord blood transplantation in European and Japanese populations.

Kanda, Junya; (...); Gluckman, Eliane

Article. 10.1038/s41409-021-01479-4. 2022

The Impact of GVHD on Outcomes After Adult Single Cord Blood Transplantation In European And Japanese Populations: The EUROCORD/ALWP EBMT And JSHCT/JDCHCT Collaborative Study

Kanda, J; (...); Gluckman, E

Meeting Abstract. 2021

The impact of medical education and networking on the outcome of leukemia treatment in developing countries. The experience of International Consortium on Acute Promyelocytic Leukemia (IC-APL).

Rego EM; (...); Sanz MA

Article. 10.1179/102453312X13336169155376. 2012

The Interaction Between Collagen-Activated Platelets and Erythrocytes Selectively Increases the Release of Subsets of Platelet alpha-Granules Containing Pro-Angiogenic Substances

Teresa Santos, Maria; (...); Valles, Juana

Meeting Abstract. 2014

The JAK2 V617F mutation identifies a subgroup of MDS patients with isolated deletion 5q and a proliferative bone marrow

Ingram, W.; (...); Mufti, G. J.

Article. 10.1038/sj.leu.2404215. 2006

The JAK2 V617F mutation is rare in RARS but common in RARS-T

Ceesay, M. M.; (...); Mufti, G. J.

Letter. 10.1038/sj.leu.2404373. 2006

THE LASTING RESPONSE OF ELTROMBOPAG IN PRIMARY PTI IS A PREDICTOR FOR THE PROBABILITY OF DISCONTINUING THE SUCCESS OF ELTROMBOPAG

Porras, JRG; (...); Bastida, J. M.

Meeting Abstract. 2017

The modular network structure of the mutational landscape of Acute Myeloid Leukemia

Ibanez, M; (...); Cervera, J

Article. 10.1371/journal.pone.0202926. 2018

THE MODULAR NETWORK STRUCTURE OF THE MUTATIONAL LANDSCAPE OF ACUTE MYELOID LEUKEMIA

Ibanez, M.; (...); Cervera, J.

Article. 2015

The Mutational Landscape of Acute Myeloid Leukaemia Predicts Responses and Outcomes in Elderly Patients from the PETHEMA-FLUGAZA Phase 3 Clinical Trial

Ayala, R; (...); Montesinos, P

Article. 10.3390/cancers13102458. 2021

The Mutational Landscape of Acute Promyelocytic Leukemia Reveals an Interacting Network of Co-Occurrences and Recurrent Mutations

Ibáñez, M; (...); Cervera, J.

Article. 10.1371/journal.pone.0148346. 2016

The poor prognosis of low hypodiploidy in adults with B-cell precursor acute lymphoblastic leukaemia is restricted to older adults and elderly patients

Ribera, J; (...); Ribera, JM

Article. 10.1111/bjh.15887. 2019

The potential effect of gender in combination with common genetic polymorphisms of drug-metabolizing enzymes on the risk of developing acute leukemia

Bolufer, Pascual; (...); Sanz, Miguel A.

Article. 10.3324/haematol.10752. 2007

The QUAZAR AML-001 maintenance trial: Results of a phase III international, randomized, double-blind, placebo-controlled study of oral CC-486 in patients with Acute Myeloid Leukemia (AML) in first remission

Dohner, H; (...); Roboz, GJ

Meeting Abstract. 2020

The relationship of TP53 R72P polymorphism to disease outcome and TP53 mutation in myelodysplastic syndromes

McGraw KL; (...); List AF

Article. 10.1038/bcj.2015.11. 2015

The Relevance of Minimal Residual Disease (MRD) Monitoring in Elderly Multiple Myeloma (MM) Patients

Paiva, Bruno; (...); San Miguel, Jesus

Meeting Abstract. 2015

The reliability of bone marrow cytology as response criterion in metastatic neuroblastoma.

Schumacher-Kuckelkorn R; (...); Berthold F

Article. 10.1002/pbc.28819. 2021

The Role of ADAMTS13 Activity Levels on Disease Exacerbation or Relapse in Patients with Immune-Mediated Thrombotic Thrombocytopenic Purpura: Post Hoc Analysis of the Phase 3 HERCULES and Post-HERCULES Studies

Strebel, Johanna A. Kremer Hovinga; (...); Scully, Marie

Meeting Abstract. 10.1182/blood-2022-156306. 2022

The role of bone marrow biopsy and FDG-PET/CT in identifying bone marrow infiltration in the initial diagnosis of high grade non-Hodgkin B-cell lymphoma and Hodgkin lymphoma. accuracy in a multicenter series of 372 patients

Chen-Liang TH; (...); Ortuño FJ

Article. 10.1002/ajh.24044. 2015

The transcriptomic landscape of elderly acute myeloid leukemia identifies B7H3 and BANP as a favorable signature in high-risk patients.

Villar, Sara; (...); Montesinos, Pau

Article. 10.3389/fonc.2022.1054458. 2022

Therapy-Related MDS Can be Separated into Different Risk-Groups According to Tools for Classification and Prognostication of Primary MDS

Kuendgen, A; (...); Sanz, G

Meeting Abstract. 10.1182/blood-2018-99-118215. 2018

Therapy-related myelodysplastic syndromes deserve specific diagnostic sub-classification and risk-stratification-an approach to classification of patients with t-MDS.

Kuendgen A; (...); Sanz G

Article. 10.1038/s41375-020-0917-7. 2020

Therapy-Related Myeloid Neoplasms in Patients With Acute Promyelocytic Leukemia Treated With All-Trans-Retinoic Acid and Anthracycline-Based Chemotherapy

Montesinos, Pau; (...); Sanz, Miguel

Article. 10.1200/JCO.2010.29.2268. 2010

THROMBOTIC EVENTS IN PATIENTS WITH PTI TREATED WITH THROMBOPOIETIN RECEPTOR AGONISTS. IDENTIFICATION OF PREDISPOSING FACTORS

Lozano Almela, M. L.; (...); Vicente, V.

Meeting Abstract. 2019

Time and Cost of Hospitalisation for Salvage Therapy in Adults with Philadelphia Chromosome-Negative B Cell Precursor Relapsed or Refractory Acute Lymphoblastic Leukaemia in Spain

Boluda, B; (...); Montesinos, P

Article. 10.1007/s41669-018-0098-8. 2019

Time-dependent changes in mortality and transformation risk in MDS

Pfeilstocker, M; (...); Greenberg, PL

Article. 10.1182/blood-2016-02-700054. 2016

Timing of response with venetoclax combination treatment in patients with newly diagnosed acute myeloid leukemia.

Jonas, Brian A.; (...); Ofran, Yishai

Article. 10.1002/ajh.26600. 2022

Total body irradiation versus thiotepa/busulfan-based conditioning regimens for myeloablative allogeneic stem cell transplantation in adults with acute lymphoblastic leukemia.

Mora E; (...); Sanz J

Article. 10.1038/s41409-024-02298-z. 2024

Towarda more patient-centered drug development process in clinical trials for patients with myelodysplastic syndromes/neoplasms (MDS): Practical considerations from the International Consortium for MDS (icMDS).

Efficace, Fabio; (...); Zeidan, Amer M

Article. 10.1002/hem3.69. 2024

Toxicity and efficacy of busulfan and fludarabine myeloablative conditioning for HLA-identical sibling allogeneic hematopoietic cell transplantation in AML and MDS

De La Serna, J; (...); Spanish Hematopoietic Transplant

Article. 10.1038/bmt.2016.42. 2016

TP53 State Dictates Genome Stability, Clinical Presentation and Outcomes in Myelodysplastic Syndromes

Bernard, Elsa; (...); Papaemmanuil, Elli

Meeting Abstract. 10.1182/blood-2019-129392. 2019

Transcriptional and Genomic Characterization of Measurable Residual Disease (MRD) Cells in Acute Myeloid Leukemia (AML)

Patricia Simoes, Catia; (...); Paiva, Bruno

Meeting Abstract. 10.1182/blood-2022-163159. 2022

Transcriptional and genomic characterization of measurable residual disease in acute myeloid leukaemia.

Simoes, Catia; (...); Montesinos, Pau

Letter. 10.1111/bjh.18815. 2023

TRANSCRIPTIONAL CHARACTERIZATION OF ACUTE MYELOID LEUKEMIA AT DIAGNOSIS IN THE ELDERLY PATIENT WITH IDENTIFICATION OF NEW PROGNOSTIC GROUPS

Sara, Villar; (...); Pau, Montesinos

Meeting Abstract. 2021

TRANSCRIPTOMICAL ANALYSIS AND MODELING IN C.ELEGANS OF THE IDH2 R140 R172 MUTATION

Gonzalez-Romero, E.; (...); Cervera-Zamora, J., V

Meeting Abstract. 2019

Transfusion Burden in Allogeneic Hematopoietic Stem Cell Transplantation over Time: Experience from a Single Institution.

Solves, Pilar; (...); Sanz, Jaime

Article. 10.3390/jcm12103467. 2023

Transfusion Management and Immunohematologic Complications in Liver Transplantation: Experience of a Single Institution

Solves P; (...); Sanz MÁ

Article. 10.1159/000370260. 2015

Transfusion management in multiple myeloma patients receiving daratumumab: Experience of a single tertiary care centre.

Solves P; (...); Carpio N

Article. 10.1016/j.transci.2019.09.011. 2020

Transfusion of ABO non-identical platelets does not influence the clinical outcome of patients undergoing autologous haematopoietic stem cell transplantation

Solves P; (...); Sanz MA

Article. 10.2450/2015.0195-14. 2015

TRANSFUSIONAL REQUIREMENTS OF PATIENTS UNDERGOING TRANSPLANTATION OF HAEMATOPOIETIC PROGENITORS OF DIFFERENT SOURCES

Blanco, JA; (...); Alonso, MAS

Meeting Abstract. 2018

TRANSLOCATIONS IN THERAPY-RELATED MYELODYSPLASTIC SYNDROMES: REVIEW OF 69 PATIENTS FROM THE SPANISH SMD GROUP DATABASE WITH AN EVALUABLE KARYOTYPE

Grau, Javier; (...); Granada, Isabel

Meeting Abstract. 2020

Transmembrane electrochemistry of erythrocytes: Direct electrochemical test for detecting hemolysis in whole blood

Domenech-Carbo, A; (...); Cebrian-Torrejon, G

Article. 10.1016/j.snb.2015.12.001. 2016

Treatment of acute promyelocytic leukemia in older patients: recommendations of an International Society of Geriatric Oncology (SIOG) task force.

Klepin HD; (...); Cordoba R

Review. 10.1016/j.jgo.2020.03.019. 2020

Treatment of acute promyelocytic leukemia.

Sanz, Miguel A

Article. 2006

Treatment of Frail Older Adults and Elderly Patients With Philadelphia Chromosome-negative Acute Lymphoblastic Leukemia: Results of a Prospective Trial With Minimal Chemotherapy

Ribera, JM; (...); Spanish Soc Hematology

Article. 10.1016/j.clml.2020.03.011. 2020

Treatment of High-Risk Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia in Adolescents and Adults According to Early Cytologic Response and Minimal Residual Disease After Consolidation Assessed by Flow Cytometry: Final Results of the PETHEMA ALL-AR-03 Trial

Ribera JM; (...); Feliu E

Article. 10.1200/JCO.2013.52.2425. 2014

Treatment of invasive fungal disease using anidulafungin alone or in combination for hematologic patients with concomitant hepatic or renal impairment

Montesinos P; (...); Sanz MÁ

Article. 10.1016/j.riam.2014.10.003. 2015

Treatment of invasive fungal infections in high risk hematological patients. The outcome with liposomal amphotericin B is not negatively affected by prior administration of mold-active azoles.

De la Serna J; (...); Vallejo C

Article. 2013

Treatment of multiple myeloma in the elderly: realities and hopes

De La Rubia, Javier, Sanz, Miguel A.

Review. 10.3109/10428194.2010.530361. 2011

Treatment of newly diagnosed acute promyelocytic leukemia (APL): a comparison of French-Belgian-Swiss and PETHEMA results

Ades, Lionel; (...); Fenaux, Pierre

Article. 10.1182/blood-2007-07-099978. 2008

Treatment of young patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia using increased dose of imatinib and deintensified chemotherapy before allogeneic stem cell transplantation.

Ribera JM; (...); Hernández-Rivas JM

Article. 10.1111/j.1365-2141.2012.09240.x. 2012

Treatment Outcomes in Unfit Patients with Newly Acute Myeloid Leukemia According to IDH1 Mutational Status: Real World Evidence from the Pethema Epidemiologic Registry

Martinez-Cuadron, David; (...); Montesinos, Pau

Meeting Abstract. 10.1182/blood-2023-189800. 2023

Treatment patterns and outcomes in real-world transplant-ineligible patients newly diagnosed with multiple myeloma

Cejalvo, MJ; (...); de la Rubia, J

Article. 10.1007/s00277-021-04529-5. 2021

Treatment patterns and outcomes in secondary acute myeloid leukemia arising after hypomethylating agents: PETHEMA registry study.

Lloret-Madrid, Pilar; (...); Montesinos, Pau

Article. 10.1002/cncr.35696. 2025

Treatment patterns and outcomes of 2310 patients with secondary acute myeloid leukemia: a PETHEMA registry study.

Martínez-Cuadrón D; (...); Montesinos P

Article. 10.1182/bloodadvances.2021005335. 2022

Treatment Patterns and Overall Survival in Patients with Intermediate-Risk MDS: A Retrospective Analysis in the Spanish MDS Registry

Diez-Campelo, Maria; (...); Valcarcel, David

Meeting Abstract. 10.1182/blood-2021-146019. 2021

Tumor lysis syndrome in patients with acute myeloid leukemia: identification of risk factors and development of a predictive model

Article. 10.3324/haematol.11575. 2007

Twenty-three novel BRCA1 and BRCA2 sequence alterations in breast and/or ovarian cancer families of Eastern Spain.

Esteban Cardeñosa, E.; (...); Martínez de Dueñas, E.

Article. 2008

TYK2 Variants in B-Acute Lymphoblastic Leukaemia.

Turrubiartes-Martínez E; (...); Fernández-Ruiz E

Article. 10.3390/genes11121434. 2020

Tyrosine kinase inhibitors for acute myeloid leukemia: A step toward disease control?